

**BEST AVAILABLE COPY**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number  
**WO 02/102999 A1**(51) International Patent Classification<sup>7</sup>: C12N 7/04, 15/34

Scott [AU/AU]; 13 Disraeli Grove, Pascoe Vale, VIC 3044 (AU).

(21) International Application Number: PCT/AU02/00787

(74) Agent: OBERIN, Colin; Allens Arthur Robinson Patent &amp; Trade Marks Attorneys, Stock Exchange Centre, 530 Collins Street, Melbourne, VIC 3000 (AU).

(22) International Filing Date: 14 June 2002 (14.06.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PR 5674

14 June 2001 (14.06.2001) AU

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): THE UNIVERSITY OF MELBOURNE [AU/AU]; Dept. of Veterinary Science, Grattan Street, Parkville, VIC 3052 (AU).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

**Published:**

(75) Inventors/Applicants (for US only): BROWNING, Glenn, Francis [AU/AU]; 78 Eglinton Street, Moonee Ponds, VIC 3039 (AU). PETERS, Michelle, Alma [AU/AU]; 63 Cardigan Street, Carlton, VIC 3053 (AU). TIVENDALE, Kelly, Ann [AU/AU]; 16 Goff Street, Beaconsfield, VIC 3807 (AU). SCOTT, Peter, Christopher [AU/AU]; 16 Learmonth Street, Moonee Ponds, VIC 3039 (AU). BROWN, Hayley, Kay [AU/AU]; 8 Ferguson Street, Mitcham, VIC 3132 (AU). CRABB, Brendan,

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**WO 02/102999 A1**

(54) Title: ATTENUATED CIRCOVIRUS

(57) Abstract: An isolated attenuated circovirus having a mutation in viral nucleic acid encoding viral protein 2 (VP2). The attenuated circovirus is particularly suitable for use in conferring immunity in an animal, particularly birds.

**ATTENUATED CIRCOVIRUS****Technical Field**

The present invention relates to attenuated viruses, viral vaccine compositions, particularly attenuated circoviruses in the form of chicken anaemia virus.

**5    Background Art**

Chicken anaemia virus (CAV) is a member of the Circoviridae family. The Circoviridae include a number of plant and animal viruses that are characterised by the possession of a single stranded, negative-sense, circular DNA genome. There is minimal similarity in the genomic sequence and organisation between CAV and the other 10 characterised animal circoviruses: Psittacine Beak and Feather Disease Virus (PBFDV), Pigeon Circovirus and Porcine Circoviruses (PCV) 1 and 2. TT viruses (TTV) have recently been identified in human hosts and other species as a heterogeneous cluster of single stranded, negative-sense, circular DNA viruses. Sequence analysis of this group of viruses has demonstrated greatest overall homology to CAV and others have recently 15 proposed the classification of the TTV, SANBAN, YONBAN, TLMV (TTV Like Mini Viruses) and CAV viruses as the Paracircoviridae, however, the phylogeny remains an area of active revision. The highest sequence homology to CAV is seen in the non-coding region and between open reading frame (ORF2) of TTV and VP2 of CAV. The high level of sequence conservation between CAV and TTV suggests VP2 may play a critical role in 20 viral infection and pathogenesis.

CAV encodes only three proteins, with overlapping ORFs in three frames. ORF3 encodes the major 45-52 kDa capsid protein VP1, ORF2 encodes the 11-13 kDa VP3 that has demonstrated apoptotic activity in transformed cell lines, and ORF1 encodes a 28 kDa non-structural protein VP2 with unknown function. VP2 is expressed at barely detectable 25 levels during infection, but has been shown to be essential for viral infection and replication in cells. The low level of expression of VP2 is consistent with a non-structural, regulatory protein involved in viral replication and infection.

CAV pathogenesis is characterised by immunosuppression and pancytopenia arising from panmyelophthisis and thymocyte depletion. Immunosuppression results in 30 increased rates of morbidity and mortality associated with coinfections and vaccination failure in CAV infected chicks. CAV infection is directly cytotoxic to two distinct T-cell

populations of the thymus and spleen. Thymic infection involves immature lymphoblastic precursors, whereas splenic infection is of mature T-lymphocytes that are highly activated. There is a second indirect component of immunosuppression found in uninfected immune effector cells. Reductions in macrophage and APC effector functions and B cell antigenic responses have been documented. Limited cytokine profiles from infected cells are suggestive of a basis for generalised indirect immunosuppression. There is a reduction in interleukin 2 (IL-2), interferon gamma (IFN $\gamma$ ), lymphocyte stimulation index, IL-1, T-cell growth factor activity and Fc receptor levels in lymphocytes of infected birds. The molecular basis for viral modulation of cytokine profiles and indirect immunosuppression is unknown.

Preliminary comparisons of the CAV VP2 sequence to sequences available in the Genbank database suggested similarity to a number of eukaryotic receptor PTPases (R-PTPase alpha). Database searches identified the human placental, rat, mouse and chicken R-PTPase alpha precursors as homologous to the CAV VP2 sequence. Reversible protein phosphorylation is universal in the regulation of cellular processes, including metabolism, gene regulation, cell cycle control, cytoskeletal organisation and cell adhesion. The PTPase family is highly diverse and includes the eukaryotic receptor-like transmembrane proteins and soluble cytosolic proteins, as well as bacterial PTPases, such as the YopH PTPase from pathogenic *Yersinia*, and a viral PTPase VH1 found in Vaccinia virus, a member of the Poxviridae. During Vaccinia virus infection the VH1 protein blocks interferon  $\gamma$  signalling thereby evading the immune response to virus infection. The role of the VH1 PTPase in infection, although currently the only viral PTPase with a characterised *in vivo* function, does highlight the potential for virus encoded PTPases to be involved in mechanisms of immune evasion and virus persistence.

Commercial poultry producers require a chicken anaemia virus (CAV) vaccine that will reduce the economic losses incurred through both clinical and subclinical infections. The elimination of subclinical disease in adult birds associated with CAV infection requires overcoming immunosuppression due to infection. CAV infection is of greatest economic significance in broiler flocks. Both clinical and subclinical infections impact on commercial broiler performance and profitability. Whilst clinical infection produces a more marked reduction in performance parameters, subclinical infection is responsible for a greater degree of financial loss as it is of higher incidence. There is a strong need for a

WO 02/102999

PCT/AU02/00787

vaccine suitable for pullets, broilers and breeders. Such a vaccine may be administered to birds at the point of lay and therefore must be safe in the event of vertical transmission to embryos.

The development of a CAV vaccine has international applications. Chicken  
5 anaemia virus (CAV) has a worldwide distribution based on serological surveillance, and is endemic in both SPF and commercial chicken flocks, with the exception of Australian SPF flocks. Countries from which CAV isolates have been characterised and their complete genome sequences published include Germany, UK, USA, Japan, Australia, and the Netherlands. All isolates are classified within a single serotype based on cross  
10 reactivity in immunofluorescence and neutralisation tests utilising polyclonal antiserum. Genome sequence conservation is a key feature of all CAV isolates. All field isolates demonstrate equivalent pathogenicity in experimental infection and any variation in the morbidity and severity of disease with CAV exposure is attributed to a range of interacting, epidemiological factors. Viral dose is the key determinant of the severity of CAV induced  
15 disease in the field. It is expected that live attenuated vaccines developed from any one isolate will be protective in poultry flocks internationally.

An attenuated CAV strain should be infectious whilst having reduced pathogenicity. Clinical disease is best characterised in the literature in birds infected at 1 day old. Clinical disease in chicks infected at 1 day of age is characterised by weakness,  
20 depression, stunting and anaemia. By 7 days post infection, there is a transient but severe, peracute anaemia due to destruction of erythroblastoid cells and immunodeficiency due to depletion of cortical lymphocytes. Severe bone marrow hypoplasia, thymic and lymphoid atrophy and thrombocytopaenia are apparent at 14-21 days post infection. Petechial and ecchymotic haemorrhages develop due to a primary coagulopathy. Immunosuppression is  
25 a significant feature of CAV induced disease and secondary infections are common. CAV affected birds have an increased incidence of malignant oedema, gangrenous dermatitis, colibacillosis and pulmonary aspergillosis. The recovery phase extends from 14-35 days post infection. Erythrocytopoiesis precedes granulocytopoiesis during recovery. At 16 days post infection there are a high proportion of circulating immature erythrocytes,  
30 thrombocytes and granulocytes, and the haematocrit is completely restored by 28 days post infection. The thymus is repopulated by the third wave of migrating lymphocytes at 21 days.

WO 02/102999

PCT/AU02/00787

4

CAV affected birds develop a severe anaemia of myelophthisis. The haematocrit is less than 27%, and typically between 9-23% (normally in chicks 7-14 days of age it is 32-37.5%). Cyanosis is evident in the non-feathered integument and on mucosal membranes. There is a leukopaenia attributable to a heterocytopaenia and lymphopaenia. Prolonged clotting times are associated with petechial and ecchymotic haemorrhages observed over the integument, skeletal muscle, mucosa of the proventriculus and rarely the pericardium.

The bone marrow appears yellow to white and watery in texture due to panmyelophthisis and compensatory adipocyte hyperplasia. This is most obvious in the proximal femoral medullary cavity.

10 The thymus undergoes severe atrophy. Affected thymuses have a quantifiable reduction in weight and a diameter of 2-4 mm. They appear red-brown instead of grey due to a reduction in parenchymal lymphocyte populations, hyperplasia of reticular cells and hyperaemia of the tissue.

15 There is a generalised depletion of lymphoid follicular components of all tissues. The bursa of Fabricius undergoes transient, moderate atrophy but is not swollen or oedematous. Bursal atrophy can be mild to unapparent in clinically affected chicks.

The liver, kidneys and spleen are diffusely discoloured and swollen at 14 days post infection.

20 Focal, dermal haemorrhagic lesions are most prominent on the wings, but also involve the head, rump, sides of thorax and abdomen, thighs, legs and feet. The lesions progress to large ulcers with a serosanguinous extravasation due to ischaemic necrosis of the overlying dermis. A purulent exudate develops in association with secondary infections. The lesions are prone to complicating abrasive and mutilation injury in the environment of the commercial broiler rearing unit.

25 An experimental model for CAV pathogenesis is required for the assessment of attenuation. Such a model does not need to represent the full spectrum of pathology observed in field infection but must demonstrate attenuation under conditions that produce most severe pathology. Yolk sac inoculation of 7 day embryos with high doses of virus is the most stringent model available. This model best approximates the field situation in which naïve breeder birds at the point of lay are exposed to CAV and transmit virus transovarially. Chicks infected by vertical transmission have the highest rates of morbidity (100%) and mortality (10-70%) and the pathology is of greatest severity. Extensive studies

of the pathology of embryos experimentally infected at 7 days by yolk sac inoculation have not been reported in the literature.

Chickens of all ages are susceptible to CAV infection, however there is an age-specific resistance to the development of disease in chickens older than 14 days. Embryos 5 and 1 day old chicks have the highest disease susceptibility. Age resistance may relate to the developing capacity of the bird to produce a serum neutralising humoral response. Co-infection with synergistic avian pathogens such as IBDV will eliminate age-related resistance and will result in outbreaks of acute severe disease in older birds.

The majority of commercial breeder flocks have been exposed to CAV and have 10 long lasting neutralising humoral immunity. Antibody persists for at least 20 weeks after seroconversion. Serological surveys of breeder flocks typically demonstrate 97.5-100% of birds remain seropositive over an extended period post infection. Maternal antibody is important in protection against clinical disease in chickens up to 2 weeks of age, and persists until 3 weeks of age. The decay of maternal antibody follows a linear relationship 15 and has a half life of approximately 1 week. Low levels of maternal antibody are effective in preventing clinical disease with infection. The majority of hatchlings derived from immune breeder flocks are infected horizontally following the waning of maternal antibody, develop subclinical disease and seroconvert between 8-12 weeks post infection. In an exposed flock, approximately 10 % of breeders will be seronegative at any point post 20 exposure. A minor proportion of chickens are infected vertically and excrete high titres of virus acting as the source of horizontal infection for other hatchlings. There may be between 16 and 25 % birds sub-clinically affected in the progeny of immune breeder flocks. Vaccination will therefore improve performance even in flocks with endemic CAV and persistent neutralising humoral immunity.

25 The present inventors have developed live attenuated CAV and CAV DNA capable for use in vaccines suitable for the inoculation of pullets, broiler and breeder flocks, based on the identification of the function of the VP2 as a novel protein tyrosine phosphatase and the identification of regions of its sequence required for full function.

#### Disclosure of Invention

30 In a first aspect, the present invention provides an isolated attenuated circovirus having a mutation in viral nucleic acid encoding viral protein 2 (VP2).

Preferably, the circovirus is Chicken anaemia virus (CAV), a TT virus (TTV) or other similar virus. More preferably, the circovirus is Chicken anaemia virus (CAV). The definition of circovirus is intended to include CAV and any other virus having a single stranded, negative-sense, circular DNA genome and expressing a protein having the 5 functionally equivalent activity as CAV VP2 protein.

The selection of sites for mutation is best based on concurrent investigations of viral function. The present inventors have found that CAV VP2 is a good target for attenuation through mutagenesis as the possibility exists to alter virulence whilst retaining infectivity and immunogenicity. The establishment of a precise biochemical function for 10 CAV VP2 as a PTPase, as part of the current invention, greatly facilitates the process of rational attenuation and provides a focal point for the mutagenesis strategy. Mutations can be designed to modify the role of the PTPase in infection based on the understanding of their effect on PTPase catalysis *in vitro*. It is predicted that CAV VP2 is a multifunctional protein with an essential non-structural role in virus infection and replication. As the 15 protein is non-structural, it is improbable that mutations will alter epitopes essential to immunogenicity. As the lymphocyte is the target cell of CAV infection, it is probable that virulence is inversely correlated with immunogenicity, provided adequate virus replication is achieved for antigenic stimulation. Mutations which reduce virulence and the immunosuppressive influence of virus infection may therefore enhance the immunogenic 20 properties of the virus relative to wild type virus.

In one preferred form, a mutation is present in the region of nucleic acid encoding the key residues in the signature motif of VP2. Such mutations should modify the role of the PTPase during viral infection. More preferably, sites targeted for mutagenesis within CAV VP2 are 86, 95, 97, 101, 103, and 169. Residue 86 is normally C and was mutated to 25 S (mut C 86 S), and the other demonstrative mutations were mut C 95 S, mut C 97 S, mut R 101 G and mut H 103 Y. The mutations mut C 95 S and mut C 97 S remove the cysteine residues predicted to be essential to PTPase activity and to be the catalytic cysteines involved in the formation of the cysteinyl-phosphate intermediate formed during catalysis. The mutation mut R 101 G removes the basic, charged residues predicted to be essential to 30 PTPase activity and to be involved in the coordination of the phosphotyrosine substrate to the catalytic cysteine residues. Residues 103 and 86 flank the predicted signature motif and are highly conserved across TT and CAV viruses.

WO 02/102999

PCT/AU02/00787

In another preferred form, a mutation is present in the region of nucleic acid encoding two predicted regions of amphipathic  $\alpha$ -helix from residues 128 to 143 and amphipathic  $\beta$ -sheet from residues 151 to 158 in CAV VP2. Other regions suitable include nucleic residues 80 to 110, 128 to 143, 151 to 158 and 160 to 170 in CAV VP2.

5 Preferably, CAV constructs are selected from mut C 86 R, mut C 95 S, mut C 97 S, mut R 101 G, mut H 103 Y, mut R 129 G, mut Q 131 P, mut R/K/K 150/151/152 G/A/A, mut D/E 161/162 G/G, mut L 163 P, mut D 169 G, mut K 102 E, mut E 186 G and combinations thereof.

10 The CAV found to be particularly suitable candidates for a vaccine include mut C 86 R, mut R 101 G, mut K 102 D, mut H 103 Y, mut R 129 G, mut N 131 P, mut R/K/K 150/151/152 G/A/A, mut D/E 161/162 G/G, mut L 163 P, mut D 169 G, mut K 102 E and mut E 186 G.

15 Preferably, CAV constructs are selected from sequence no's 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, or 27.

20 As the genome structure of TTV is similar to CAV, the attenuation information obtained by the present inventors on CAV would be applicable to TTV. This has been further supported by the demonstration by the present inventors that the ORF2 of TLMV has protein tyrosine phosphatase activity. Thus, from the extensive information obtained by the present inventors on CAV, it would be expected that attenuated TTV (or other similar circoviruses) could be formed by introducing mutations at the corresponding or similar ORF2 coding regions of TTV or other ciroviruses.

In a second aspect, the present invention provides a circovirus vaccine composition comprising an attenuated circovirus according to the first aspect of the present invention together with an acceptable carrier or diluent.

25 In one preferred form, the virus is CAV and the animal is a bird, preferably a chicken.

In another preferred form, the virus is TTV and the animal is a mammal, preferably a human.

30 The vaccine composition may be formulated to contain a carrier or diluent and one or more of the attenuated viruses of the invention. Suitable pharmaceutically acceptable

carriers facilitate administration of the viruses but are physiologically inert and/or non-harmful to the recipient. Carriers may be selected by one of skill in the art. Suitable carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextrin, agar, pectin, peanut oil, olive oil, sesame oil, and water. Additionally, the carrier or diluent may 5 include a material which delays release of the virus, such as glycerol monostearate or glycerol distearate alone or with a wax. In addition, slow release polymer formulations can be used.

Optionally, the vaccine composition may further contain preservatives, chemical stabilizers, other antigenic proteins, and conventional pharmaceutical ingredients. Suitable 10 ingredients which may be used in a vaccine composition in conjunction with the viruses include, for example, casamino acids, sucrose, gelatin, phenol red, N-Z amine, monopotassium diphosphate, lactose, lactalbumin hydrolysate, and dried milk. Typically, stabilizers, adjuvants, and preservatives are optimized to determine the best formulation for efficacy in the target animal or human. Suitable preservatives include chlorobutanol, 15 potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol.

A vaccine composition of this invention is most preferably produced without an adjuvant. Where necessary, one or more of the above described vaccine components may be admixed or adsorbed with a conventional adjuvant. The adjuvant is used as a non-specific irritant to attract leukocytes or enhance an immune response. Such adjuvants 20 include, among others, mineral oil and water, aluminum hydroxide, Amphigen, Avridine, L121/squalene, D-lactide-polylactide/glycoside, pluronic polyols, muramyl dipeptide, killed Bordetella, saponins, and Quil A.

Alternatively, or in addition to the virus of the invention, other agents useful in 25 treating viral infection, such as immunostimulatory agents, are expected to be useful in reducing and eliminating disease symptoms, particularly in humans. The development of vaccine or therapeutic compositions containing these agents is within the skill of one of skilled in the art in view of the teaching of this invention.

According to the method according to the second aspect of the invention, an animal 30 or human may be vaccinated against circovirus infection by administering an effective amount of a vaccine composition described above. An effective amount is defined as that

WO 02/102999

PCT/AU02/00787

amount of circovirus vaccine capable of inducing protection in the recipient against circovirus infection. The vaccine may be administered by any suitable route. Such a composition may be administered parenterally, preferably intramuscularly or subcutaneously. However, it may also be formulated to be administered by any other 5 suitable route, including intranasal, oral, intravaginal, subcutaneous or intradermal, or *in ovo* route.

Suitable effective amounts of the circovirus of this invention can be determined by one of skill in the art based upon the level of immune response desired. Such a composition may be administered once, and/or a booster may also be administered. 10 However, suitable dosage adjustments may be made by the attending veterinarian or physician depending upon the age, sex, weight and general health of the animal or human subject. Typically, dosage range for the vaccine is in the order of 1-100 million TCID<sub>50</sub>. Preferably, the dosage is around 1000 TCID<sub>50</sub>.

Similarly, suitable doses of the vaccine composition of the invention can be readily 15 determined by one of skill in the art. The dosage can be adjusted depending upon the animal species being treated, i.e. its weight, age, and general health.

In a third aspect, the present invention provides a method of conferring immunity in an animal against a circovirus infection, the method comprising administration to the animal of a vaccine composition according to the second aspect of the present invention.

20 In one preferred form, the virus is CAV and the animal is a bird, preferably a chicken.

In another preferred form, the virus is TTV and the animal is a mammal, preferably a human.

The vaccine may be administered by any suitable route including via an intranasal, 25 oral, intravaginal, subcutaneous or intradermal, or *in ovo* route.

For bird such as chickens, the preferred route of administration is by mucosal administration, aerosol administration or via drinking water.

The administered vaccine composition may also be used to prevent clinical signs of circovirus infection.

WO 02/102999

PCT/AU02/00787

10

The administered vaccine composition may also be used to induce an immunological response in the animal against a circovirus.

In a fourth aspect, the present invention provides an isolated nucleic acid molecule derived or obtained from a circovirus genome, the nucleic acid molecule including at least 5 a portion of a coding region for viral protein 2 (VP2) having a mutation therein.

Preferably, the circovirus is Chicken anaemia virus (CAV), a TT virus (TTV) or other similar virus. More preferably, the circovirus is Chicken anaemia virus (CAV). The definition of circovirus is intended to include CAV and any other virus having a single stranded, negative-sense, circular DNA genome and expressing a protein having the 10 functionally equivalent activity as CAV VP2 protein.

Preferably, the isolated nucleic acid molecule includes the complete circovirus genome incorporating mutations in either the VP2 translational initiation regions, the PTPase motifs or the acidic alpha helical regions or the basic beta sheet regions.

Preferably, the isolated nucleic acid molecule is selected from sequence no's 1, 3, 5, 15 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, or 27.

In a fifth aspect, the present invention provides a circovirus vaccine composition comprising an isolated nucleic acid molecule according to the fourth aspect of the present invention together with an acceptable carrier or diluent.

In one preferred form, the virus is CAV and the animal is a bird, preferably a 20 chicken.

In another preferred form, the virus is TTV and the animal is a mammal, preferably a human.

In a sixth aspect, the present invention provides a method of conferring immunity in an animal against a circovirus infection, the method comprising administering to the 25 animal a vaccine composition according to the fifth aspect of the present invention.

In a seventh aspect, the present invention provides an isolated viral protein 2 (VP2) having PTPase activity obtained from a circovirus.

Preferably, the circovirus is Chicken anaemia virus (CAV), a TT virus (TTV) or other similar virus. More preferably, the circovirus is Chicken anaemia virus (CAV). The

WO 02/102999

PCT/AU02/00787

11

definition of circovirus is intended to include CAV and any other virus having a single stranded, negative-sense, circular DNA genome and expressing a protein having the functionally equivalent activity as CAV VP2 protein.

Preferably, the isolated VP2 is modified to have altered PTPase activity.

5 Preferably, the isolated VP2 molecule includes the amino acid sequences selected from sequence no's 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or 28.

In an eighth aspect, the present invention provides use of an attenuated circovirus according to the first aspect of the present invention in the manufacture of a vaccine for conferring immunity in an animal against a circovirus infection.

10 In a ninth aspect, the present invention provides use of an isolated nucleic acid molecule according to the fourth aspect of the present invention in the manufacture of a vaccine for conferring immunity in an animal against a circovirus infection.

In a tenth aspect, the present invention provides a method for producing a circovirus vaccine according to the second aspect of the invention comprising:

- 15 (a) inoculating an isolated nucleic acid molecule derived or obtained from a circovirus genome into the yolk sac of an ambryonated egg, wherein the nucleic acid molecule includes at least a portion of a coding region for viral protein 2 (VP2) having a mutation therein;
- (b) allowing circovirus to replicate from the isolated nucleic acid; and
- 20 (c) harvesting the circovirus from the egg.

Preferably, the circovirus is Chicken anaemia virus (CAV), a TT virus (TTV) or other similar virus. More preferably, the circovirus is Chicken anaemia virus (CAV). The definition of circovirus is intended to include CAV and any other virus having a single stranded, negative-sense, circular DNA genome and expressing a protein having a functionally equivalent activity as CAV VP2 protein.

Preferably, the isolated nucleic acid molecule includes the complete circovirus genome incorporating mutations in either the VP2 translation initiation regions, the PTPase motifs or the acidic alpha helical regions or the basic beta sheet regions.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.

In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following drawings and examples.

#### Brief Description of the Drawings

15 Figure 1 shows Chou-Fasman plots of two predicted regions of amphipathic  $\alpha$ -helix from residues 128 to 143 and amphipathic  $\beta$ -sheet from residues 151 to 158 of VP2.

Figure 2 shows transfection of mut C86 R into MSB1 cells.

Figure 3 shows transfection of mut C 95 S into MSB1 cells.

Figure 4 shows transfection of mut C 97 S into MSB1 cells.

20 Figure 5 shows transfection of mut R 101 G into MSB1 cells.

Figure 6 shows transfection of mut H103 Y into MSB1 cells.

Figure 7 shows transfection of mut R129 G into MSB1 cells.

Figure 8 shows transfection of mut Q 131 P into MSB1 cells.

Figure 9 shows transfection of mut R/K/K 150/151/152 G/A/A into MSB1 cells.

25 Figure 10 shows transfection of mut D/E 161/162 G/G into MSB1 cells.

Figure 11 shows transfection of mut L 163 P into MSB1 cells.

Figure 12 shows transfection of mut D169 G into MSB1 cells.

Figure 13 shows R-PTPase homologues aligned to the CAV VP2 amino acid sequence using the ECLUSTALW software (WebANGIS) and displayed graphically using the Seqvu software (Garvin Institute). Row 1: chicken protein-tyrosine phosphatase alpha (Z32749), residues 302-306, homology score 30%. Row 2: human R-PTPase alpha (PP18433), residues 301-353, homology score 32%. Row 3: rat R-PTPase alpha (Q03348), residues 295-347, homology score 32%. Row 4: mouse R-PTPase alpha (P18052), residues 328-380, homology score 32%. Row 5: human R-PTPase alpha (17011300A). Row 6: human placental protein-tyrosine phosphatase (CAA38065), residues 292-345, homology score 32%. Row 7: CAV VP2.

Figure 14 shows alignment of CAV VP2 amino acid sequence and SANBAN TTV sequence using the ECLUSTALW software (WebANGIS) and displayed graphically using the Seqvu software (Garvin Institute). The Genbank accession numbers for the TT viruses are shown.

Figure 15 shows an electrophoresis separation of glutathione-S-transferase (GST) fusion proteins on a 12.5% polyacrylamide gel and visualisation with Coomassie blue staining. Lane 1, Broad range molecular weight standards (Biorad); lane 2, 2.6 µg CAV VP2-GST fusion; lane 3, 3.0 µg GST.

Figure 16 shows a western blot probed with a mouse polyclonal antiserum raised against the COOH-terminal region of VP2. Lane 1, Broad range molecular weight standards (Biorad); lane 2, 3.0 µg GST; lane 3, 2.6 µg CAV VP2-GST fusion.

Figure 17 shows a western blot probed with a rabbit polyclonal antiserum raised against GST. Lane 1, molecular weight standards; lane 2, 3.0 µg GST; lane 3, 2.6 µg chicken anaemia virus VP2-GST fusion.

Figure 18 shows a time course study of phosphate release from ENDY(Pi)INASL as catalysed by VP2-GST or a GST control preparation. Reactions were carried out with 15 nmol substrate. Activity [V] was measured in nmol of phosphate released for each timepoint.

Figure 19 shows PTPase activity of VP2-GST and GST control proteins in the PTPase assay. Reactions were carried out with 10 nmol substrate and for 1 min. Initial activity [ $V_0$ ] was measured in nmol phosphate released for each substrate concentration. The standard error of the mean for each substrate concentration tested was less than 0.101.

Figure 20 shows TLMV VP2 PTPase activity relative to CAV VP2 activity.

**Mode(s) for Carrying Out the Invention**

**EXPERIMENTAL PROCEDURES**

**I. CAV Vaccine**

**5 Analysis of CAV genome and design of sites for mutagenesis**

Studies described later (EXPERIMENTAL PROCEDURES – VP2) have established PTPase activity and predicted key residues in the signature motif have been identified by comparison to known PTPase signature motifs. These residues have formed the basis for the design of a mutagenesis strategy in an infectious full genome clone of CAV. Mutations can be designed to modify the role of the PTPase during infection based on an understanding of their effect on PTPase catalysis *in vitro*. Sites targeted for mutagenesis within CAV VP2 to demonstrate the applicability of this strategy were 86, 95, 97, 101, and 103. Residue 86 is normally C and was mutated to S (mut C 86 S), and the other demonstrative mutations were mut C 95 S, mut C 97 S, mut R 101 G, and mut H 103 Y. The mutations mut C 95 S and mut C 97 S remove the cysteine residues predicted to be essential to PTPase activity and to be the catalytic cysteines involved in the formation of the cysteinyl-phosphate intermediate formed during catalysis. The mutations mut R 101 G removes the basic, charged residues predicted to be essential to PTPase activity and to be involved in the coordination of the phosphotyrosine substrate to the catalytic cysteine residues. Residues 103 and 86 flank the predicted signature motif and are highly conserved across TT and CAV viruses.

VP2 protein structural predictions were made using software available through the ANGIS interface (WebANGIS, Australian National Genomic Information Service). A region of high degree secondary structure was identified towards the carboxyl-terminal end of VP2. Chou-Fasman plots of the region predict an acidic region consisting of  $\alpha$ -helix, followed by a basic region consisting of  $\alpha$ -helix and  $\beta$ -sheet, then a second acidic region of  $\alpha$ -helix. The secondary structure is further subdivided by a series of proline residues. There are two predicted regions of amphipathic  $\alpha$ -helix from residues 128 to 143 and amphipathic  $\beta$ -sheet from residues 151 to 158 (Figure 1). It is predicted that the high degree of secondary structure correlates to a functional protein domain. The predictions for secondary structure allow the introduction of mutations designed to disrupt the

WO 02/102999

PCT/AU02/00787

15

structural organisation of the region thereby modifying the function of this region. To demonstrate the effect of mutation within the region of predicted basic amphipathic alpha-helix mut R 129 G and mut R/K/K 150/151/152 G/A/A have been constructed to neutralise the polar basic charge distribution in the secondary structure. The mut Q 131 P has also 5 been introduced into the alpha helix in this region to break the helix. An identical approach was employed to disrupt the region of acidic alpha helix with the introduction of mut L 163 P. In the region of acidic alpha helix mut D/E 161/162 G/G and mut D 169 G constructs were made with the objective of neutralising the acidic charge distribution. The mutated nucleic sequences of the CAV genome and VP2 amino acid sequences are listed in 10 sequences no's 1 to 28.

#### Primer design

The CAU269/7 Australian isolate of CAV was used in all experiments. For each introduced mutation, paired, overlapping oligonucleotides were synthesised complementary to both strands of the CAV VP2 sequence. The oligonucleotide pairs were 15 designed to incorporate nucleotide substitutions encoding the amino acid alterations. The CAV genome encodes 3 genes in 3 different overlapping open reading frames. The regions of CAV VP2 targeted for mutagenesis overlap ORF2 and ORF3, which are frameshifted relative to VP2 by one and two base pairs respectively. None of the introduced mutations change the amino acid sequences encoded by ORF2 and ORF3. 20 Table 1 outlines primers used in the introduction of mutations to CAV VP2.

WO 02/102999

PCT/AU02/00787

16

Table 1. Primers incorporating base changes encoding directed mutations within CAV VP2 sequence. The numbering of mutations is based on VP2 amino acid sequence. Mutated residues are indicated.

5

mutation introduced into CAV VP2	+ sense oligonucleotide	- sense oligonucleotide
mut C 86 R	ctgcgcgaaCgctcg gttcccacgctaag	aacgcgcgacGttcg cagccacacacgca
mut C 95 S	cgcataaggatcAgcaact gcg	cgcagtgcTgatcta gcgtg
mut C 97 S	atctgcaacAgcggac aattc	attgtccgcTgtgcag atcttag
mut R 101 G	ctgcggacaattcGga aaacactgg	cagtgttttcCgaatt gtccgcag
mut H 103 Y	cagaaaaTactggttc aagaatgtgccggac	gaaaccagtAtttct gaattgtccgcag
mut R 129 G	ctgcgaccctcGgag tacaggg	ccctgtactcCgaggg gtcgaggatcgc
mut Q131 P	cgcgtacCggtaagc gagctaaaag	cgcgtaccccGgtactc ggagg
mut R/K/K 150/151/152 G/A/A	ccgaacGgcGCgGCg gtgtataag	atacaccGCcGCgcCg ttcggggtc
mut D/E 161/162 G/G	taagatggcaagGcg Ggctcgacacc	tgcgagcCcgCcttgc catc
mut L 163 P	gacgagcCcgcagacc gagag	ggcccttcggctcg Ggctcgtc
mut D 169 G	gagaggccgGttttac gccttcag	gcgtaaaaCcgccctc tcggtc
mut K 102 E	ctgcggacaattcagaGa acactggttc	gaaaccagtgttCtct gaattgtccgcag
mut E 186 G	gcgcacttcgacgGaga tataaatttc	tttatatctCcgtcgaag tcgc

### Overlap Extension PCR Mutagenesis

Mutations were introduced into CAV VP2 sequence by overlap extension PCR. The following method applies to the mutagenesis of all mutant constructs unless otherwise stated. The PCR template was a full genome clone of CAV (*pCAU269/7*) in the plasmid 5 vector pGEX-4Z (Promega). Template DNA was prepared from *E. coli* DH5 $\alpha$  possessing the *pCAU269/7* clone cultured at 37°C on Luria-Bertani agar (LA) with 50  $\mu$ g/mL ampicillin selection. A plasmid preparation was made using a Qiagen kit according to the manufacturer's instructions (Qiagen). The mutagenesis PCR was carried out in two stages. The first stage consisted of a set of 2 PCR reactions: one from an upstream flanking primer 10 to the -sense mutagenesis primer, and one from a downstream flanking primer to the + sense mutagenesis primer. In the second stage of mutagenesis PCR products from the first pair of reactions acted as template in an oversew PCR reaction utilising the flanking primers. The PCR product generated is bounded by the flanking sequences and incorporates in both strands the mutations introduced into the template in the first stage of 15 PCR.

The upstream flanking primer CAV.1 - 5' CTATCGAATTCCGAGTGGTTACTAT 3' and downstream flanking primer CAV.10 - 5' TGCTCACGTATGTCAGGTT 3' were used in the oversew PCR for the construction of mut C 95 S and mut C 97 S. In the first stage, a 100  $\mu$ L reaction mixture was prepared containing 300  $\mu$ M each of dATP, dCTP, dGTP and 20 dTTP, 2 mM MgSO<sub>4</sub>, 200  $\mu$ M of each primer, 10  $\mu$ L of 10x Platinum *Pfu* *Taq* DNA polymerase buffer, 2 U of Platinum *Pfu* *Taq* DNA polymerase (Promega), and 1  $\mu$ L of template DNA. The PCR reaction was incubated at 95°C for 2 min, followed by 30 cycles at 95°C for 40 s, 60°C for 60 s then 68°C for 40 s, and a final incubation at 68°C for 5 min. First stage template was removed by digestion with *Dpn*I restriction endonuclease (Life 25 Technologies). The PCR products were analysed by agarose (1%) gel electrophoresis and the bands corresponding to the stage one products were excised and purified by Qiaex II (Qiagen) gel extraction according to the manufacturer's instructions. For the oversew PCR, a 100  $\mu$ L reaction mixture was prepared containing 300  $\mu$ M each of dATP, dCTP, dGTP and dTTP, 2 mM MgSO<sub>4</sub>, 200  $\mu$ M of each primer, 10  $\mu$ L of 10x Hifidelity *Taq* 30 DNA polymerase buffer, 2 U of Hifidelity *Taq* DNA polymerase (Promega), and 1  $\mu$ L of template DNA. The PCR reaction was incubated at 95°C for 2 min, followed by 1 cycle at

95°C for 40 s, 57°C for 90 s then 68°C for 40 s, then 15 cycles at 95°C for 40 s, 57°C for 60 s then 68°C for 40 s, and a final incubation at 68°C for 5 min.

Methods for mutagenesis of all other mutants except for mut C 86 R and mut H 103 Y were as described for mut C 95 S and mut C 97 S, except the upstream flanking primer 5 was primer CAV.2- 5' GCGGAGCCGCGCAGGGCAA 3' and the downstream flanking primer was CAV.10. In the second stage oversew PCR the reactions were incubated at 96°C for 2 min, followed by 15 cycles at 96°C for 40 s, 58°C for 60 s then 72°C for 60 s, and a final incubation at 72°C for 5 min.

A range of PCR conditions were tried unsuccessfully in an attempt to PCR oversew 10 the mutagenesis products for mut C 86 R and mut H 103 Y. Mut C 86 R and mut H 103 Y were therefore generated by full-circle, overlap extension mutagenesis in a single PCR reaction. A 100 µL reaction mixture was set up as described previously, however using the relevant mutagenesis primers only. The PCR reaction was incubated at 96°C for 2 min, followed by 1 cycle at 96°C for 40 s, 55°C for 60 s then 68°C for 5 min, then 40 cycles at 15 96°C for 40 s, 60°C for 60 s then 68°C for 5 min, and a final incubation at 68°C for 5 min. Template DNA was removed by digestion with *Dpn*I restriction endonuclease and the PCR product was purified by standard phenol, phenol-chloroform and phenol-chloroform-isoamyl extraction and ethanol precipitation.

#### Cloning of mutant constructs

20 The following method applied to the cloning of all mutant constructs unless otherwise stated. The PCR products containing the mutant sequences were subcloned into the CAV infectious clone in the plasmid vector pGEX-4Z, *pCAU269/7*. The PCR products were digested with *Stu*I and *Bsm*I restriction endonuclease and analysed by agarose (1%) gel electrophoresis. A band of 357 bp was excised and purified by Qiaex II (Qiagen) gel 25 extraction according to the manufacturer's instructions. *pCAU269/7* was similarly digested with *Stu*I and *Bsm*I restriction endonucleases to remove the region of 357 bp to be replaced with the mutant sequence and the band of 4687 bp was purified from a 1% agarose gel. The PCR product was then ligated into the digested CAV-pGEX-4T-2 (Promega) backbone following standard protocols. *E. coli* DH5 $\alpha$  was transformed by 30 electroporation with the ligated plasmid and cultured at 37°C on Luria-Bertani agar (LA) containing ampicillin at 50 µg/mL. Plasmid was purified from selected clones using a

WO 02/102999

PCT/AU02/00787

19

Qiagen kit according to the manufacturer's instructions (Qiagen). Clones were screened for the presence of insert by PCR using the forward primer CAV.2 and reverse primer CAV.10. The cloned DNA was sequenced using a Taq Dye Deoxy Terminator Cycle Sequencing kit (Perkin Elmer), using primers CAV.2 and CAV.10.

- 5 Methods for the construction of mut C 86 R and mut H 103 Y proceeded as described, except for the following variations. The purified stage 2 PCR product was cloned initially into the pGEM-4T-2 vector (Promega) according to the manufacturer's instructions, and then digested with *Stu*I and *Bsm*I restriction endonucleases and subcloned into *pCAU269/7* as described previously. The mut C 86 R and mut H 103 Y PCR
- 10 products, following digestion with *Dpn*I restriction endonuclease, were ligated following standard protocols, and transformed by electroporation into *E. coli* DH5 $\alpha$  and cultured at 37°C on Luria-Bertani agar (LA) containing ampicillin at 50  $\mu$ g/mL. Clones containing the mutant sequence were then screened and selected as described above.

#### Transfection of mutated viral genomes into MSB1 cells

- 15 The clone control *pCAU269/7*, control pEGFP-C2 and constructs mut C 86 R, mut C 95 S, mut C 97 S, mut R 101 G, mut H 103 Y, mut R 129 G, mut N 131 P, mut R/K/K 150/151/152 G/A/A, mut D/E 161/162 G/G, mut L 163 P, mut D 169 G and mut E 186 G were transfected into cell culture. CAV DNA for transfection was prepared using a Qiagen plasmid purification kit. All constructs were digested with *Eco*RI restriction endonuclease
- 20 to release the genomic insert, electrophoresed on a 1% agarose gel and the 2298 bp bands were excised from the gel and purified using the Qiaex II gel plasmid purification kit according to the manufacturer's instructions. The purified CAV DNA was resuspended in sterile 10 mM Tris (pH 8 at 25°C). The transfection control DNA pEGFP-C2 containing the green fluorescent protein (GFP) downstream from a CMV promoter was prepared as
- 25 undigested plasmid.

- The Marek's disease virus transformed lymphocytic MDCC-MSB1 cell line was used in all experiments. The cells were cultured in RPMI 1640 medium (Sigma Chemical Company, St. Louis, Missouri, U.S.A.) supplemented with 2 mM glutamine (Sigma), 2 mM pyruvate (Sigma), 0.2 % NaHCO<sub>3</sub>, 50  $\mu$ g / mL ampicillin (CSL), 50  $\mu$ g / mL gentamicin (CSL) and 10 % foetal calf serum (Flow Laboratories) (heat inactivated at 52°C) (complete media referred to as RF10), at 37° C in 5 % CO<sub>2</sub>. The culture was passaged into fresh medium 24 hours prior to transfection to synchronise the stage of cell

cycle. The cells were washed twice in FCS-free RPMI, resuspended at a final concentration of  $10^7$  cells/mL and an aliquot of 700  $\mu$ L was transferred with 10  $\mu$ g of the relevant DNA to a microfuge tube on ice for each sample. Transfection was achieved through electrointernalisation with a pulse of long duration and low voltage in a 0.4 cm gap 5 electroporation cuvette in a Gene Pulser apparatus (Bio Rad). A pulse was delivered at 400 v, 900  $\mu$ F,  $\infty$  resistance and extension capacitance. The cells were incubated at room temperature for 5 minutes, then resuspended in 5 mL of prewarmed growth medium. Transfection efficiency was assessed 48 hours later by determining the percentage of cells positive for GFP expression in the control transfection.

10 **Assessment of replication competency and infectivity of mutant CAV constructs**

The capacity of mutant viruses for infection and replication in cell culture was assessed from MDCC-MSB1 cells transfected with mutant viral constructs. Cultures were serially passaged at a 1/10 dilution at 48 hourly intervals for 10 passages. Samples (48 hourly) were assessed for infectivity by percentage of cells expressing VP3. VP3 15 expression was detected by an immunofluorescence assay. Infected cells were washed twice and resuspended in 200  $\mu$ L of phosphate buffered saline (PBS) pH 7.4 and applied to a multiwell slide. The preparations were washed between all incubations with PBS buffer containing 0.1% BSA and 0.05% Tween 20. Cells were fixed in ice cold 90% methanol for 5 minutes and the preparation was blocked for 1 hour with a solution of 5% BSA/PBST 20 at 37°C in a humidified chamber. The primary antibody was an anti-VP3 mouse monoclonal antibody (TropBio) diluted 1/200 in 0.1% BSA / PBST and incubated for 1 hour at 37°C in a humidified chamber. The secondary antibody was an anti-mouse sheep 25 monoclonal antibody conjugated to fluorescein isothiocyanate (Dako) diluted 1/100 in 0.1% BSA/PBST and incubated for 1 hour. The percentages of fluorescent cells against passage number were quantified relative to control MSB1 background fluorescence.

Preparations of mutant virus were made from the earliest passage of transfected culture that demonstrated at least 50% infection with CAV. The culture was frozen and thawed three times and then clarified by centrifugation at 6000 g for 10 min. MDCC-MSB1 cells were then reinjected with the virus preparation. Preparation of virus by this 30 method and reinfection of culture was repeated for at least three viral passages in each case. Recovery of replication competent virus was demonstrated by immunofluorescence assay (as described above), PCR of infected lysate followed by Southern blot with a CAV

specific probe, and Western blot of infected lysate. A cellular DNA preparation was purified from MDCC-MSB1 cells 48 h after infection with mutant CAV by proteinase K and sodium dodecyl sulphate (SDS) lysis and phenol/chloroform extraction, according to the method of Meehan, B. M., Todd, D., Creelan, J. L., Earle, J. A., Hoey, E. M. and McNulty, M. S. (1992). Characterization of viral DNAs from cells infected with chicken anaemia agent: sequence analysis of the cloned replicative form and transfection capabilities of cloned genome fragments. *Arch Virol* 124, 301-319. The mutant sequence was then amplified using the CAV.2 and CAV.10 primer set and the corresponding PCR reaction conditions described above. The PCR product was electrophoresed on a 1% agarose gel and transferred to Hybond-N (Amersham) nylon membrane using capillary transfer (Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989). *Molecular Cloning, A Laboratory Manual*, (ed. C. Nolan). New York: Cold Spring Harbor Laboratory Press). Following the transfer the membrane was rinsed for 10 min in 6xSSC buffer and exposed to ultraviolet light on a transilluminator for 10 min. A radiolabelled CAV specific probe was made from the CAV genomic clone DNA using random hexamer priming of DNA synthesis with a commercial kit according to the manufacturer's instructions (Boehringer Mannheim). The membrane was soaked in a prehybridisation buffer of 5xSSC, 5x Denhart's solution, 100 µg/mL denatured salmon sperm DNA and 0.5% SDS, to which was added the prepared radiolabelled probe. The probe was hybridised to the blotted DNA overnight at 50°C. The blot was washed three times for 20 min with 2xSSC and 0.1% SDS at 68°C and a radiographic film was exposed to the blot for 4 h at -70°C.

Western blots were made of a lysate of  $10^3$  MDCC-MSB1 cells infected with mutant CAV. Proteins were electrophoresed in 12.5% sodium dodecyl sulphate (SDS) polyacrylamide gels and stained with Coomassie brilliant blue (Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227, 680-685). Proteins were electrotransferred onto a polyvinylidifluoride membrane (PVDF: Immobilon, Millipore). Western blots were probed with a mouse monoclonal antibody raised against CAV VP3 (TropBio) diluted 1/2000 in 0.1% BSA/PBST and incubated for 1 h, followed by a secondary sheep anti-mouse horseradish peroxidase (HRP) conjugate diluted 1/2000, and developed with chemiluminescence substrate (Amersham Pharmacia).

**Demonstration of an *in vitro* phenotype for mutant CAV viruses**

The growth characteristics and cytopathogenicity of mutant viruses was investigated. CAV mutant viruses were plate titrated using as a control virus generated from *pCAU269/7*. Titration was performed in an 8x12 multiwell tray (Nunc) in 200 µL culture volumes at  $5 \times 10^5$  MSB1 cells /mL. Serial 10 fold dilutions of virus stock were set up with 6 duplicates, and ranged from final dilution factors of 0.05 through to  $0.5 \times 10^{-10}$ . At intervals of 48 hours, infected cells were serially passaged into fresh medium at a dilution of 1 in 4. Each well was scored for evidence of a cytopathogenic effect (CPE). Indications of CPE are enlarged swollen cells, nuclear vacuolation and chromatin assemblies, cell fragmentation and alkalisation of the media. The culture was serially passaged until there was no difference detected between successive passages in the endpoint or lowest dilution at which CPE was observed in 50% of the wells. The observation of CPE was confirmed by immunofluorescence assays of the endpoint dilution. The titre was calculated as the tissue culture infective dose for 50% infectivity (TCID<sub>50</sub> /mL) using the Karber method. Typically 5-7 passages were necessary to establish the endpoint.

The titres of viral stocks obtained by plate titration were confirmed by Fluorescence Activated Cell Sorting (FACS) relative to the parental virus stock as the standard. A ten fold dilution series from  $10^0$  to  $10^{-4}$  was made of the viral stock in 0.5 mL volumes of RPMI. The viral dilutions were then adsorbed onto  $4 \times 10^6$  MSB1-MDCC cells and resuspended in 4 mL of RF10 in a 6 well culture tray. After 48 h of infection, 2 mL of cells were pelleted by centrifugation at 1500 g for 5 min. The infected cells were prepared for immunofluorescence staining by fixing, permeabilisation and blocking of non-specific surface reactivity. All washes were with 5 mL volumes of 1% FCS and 1 mM sodium azide (NaN<sub>3</sub>) in PBS. Centrifugation steps between buffer stages were performed at 1500 g for 5 min. The cells were fixed by incubation for 45 min at 4°C in 1 mL of 3% ultrapure formaldehyde in PBS and 1 mM NaN<sub>3</sub>. Fixed cells were then washed twice in 5 mL of 0.1 M glycine and 1 mM NaN<sub>3</sub>, then permeabilised for 5 sec by resuspension in 0.5 mL of 0.1% Triton-X100 and 1 mM NaN<sub>3</sub> in PBS, followed by dilution in 4.5 mL of wash buffer and two subsequent wash steps. Following permeabilisation, the cells were handled on ice at all steps. Non-specific reactivity was blocked by a 15 min incubation at 4°C in 10% FCS and 1 mM NaN<sub>3</sub> in PBS, followed by two wash steps. The primary antibody was 50

WO 02/102999

PCT/AU02/00787

$\mu$ l of an anti-VP3 mouse monoclonal antibody (TropBio) diluted 1/50 in wash buffer and cells were incubated in this for 45 min at 4°C. The secondary antibody was an anti-mouse sheep monoclonal antibody conjugated to FITC (Dako) again diluted 1/50 in wash buffer and cells were incubated in this for 45 min at 4°C. Immunostained cells were stored for up 5 to 16 h in 200  $\mu$ l of 1% ultrapure formaldehyde and 1 mM NaN<sub>3</sub> in PBS.

*pCAU269/7* viral stocks, which had been plate titrated on three previous occasions, were used as standards for each FACS analysis. Data acquisition and analysis was performed with the Cellquest software. Cytometer instrument settings are given in Table 2.

10 **Table 2. Cytometer instrument settings**

parameter	detector	voltage	A gain	mode
P1	FSC	E01	1.81	linear
P2	SSC	366	1.00	linear
P3	FL1	469	1.00	logarithmic

The gated lymphocyte population was displayed as a histogram with the dependent variable fluorescence intensity. Two distinct normally distributed cell populations were seen; a low fluorescence intensity peak due to background staining and autofluorescence, 15 and a second specific high fluorescence intensity peak. A marker was visually set to include the cells staining with high intensity, specifically for CAV VP3, and to contain <0.05% of cells in the negative control uninfected sample. A standard curve of virus dilution against cell count in the marker region was constructed from the viral stocks. The curves were established independently on three separate occasions. Relative dilutions of 20 test viral stocks were established by calculating the transposition of the FACS curve from a concurrent standard curve.

*In vitro* cytopathology was assessed by phase contrast microscopy and by staining of fixed cells with a monoclonal antibody specific for VP3 as described above. Cells were counterstained for 2 min in Hoescht stain. Immunofluorescent staining (IFA) was also 25 performed with a mouse polyclonal antiserum raised against the C-terminal region of VP2, at a dilution of 1/100, and a secondary anti-mouse sheep polyclonal antibody conjugated to FITC (Dako) again diluted 1/100 in 0.1% BSA/PBST.

**Challenge model in embryonated eggs**

A challenge model was developed in embryonated eggs in order to assess infectivity and *in vivo* phenotype of mutant CAV. The model was initially used to verify equivalence between virus generated from transfection of *pCAU269/7* DNA (clone virus) and the parental CAV strain CAU269/7 virus (parental virus). Yolk sac inoculation of 7 day old embryos with parental virus, *pCAU269/7* and mock MSB1 inocula was repeated on 3 separate occasions. The viruses mut C 86 R, , mut R 101 G, mut H 103 Y, mut R 129 G, mut N 131 P, mut R/K/K 150/151/152 G/A/A, mut D/E 161/162 G/G, mut L 163 P, mut D 169 G and mut E 186 G were then tested in the model compared with clone virus and uninfected MSB1 cell control inocula. The mutant challenge experiments were repeated on two separate occasions.

**Inoculation of embryonated eggs**

Viral stocks for inoculation were prepared from 400 mL of MDCC-MSB1 infected culture in a method adapted from Todd, D., Mackie, D. P., Mawhinney, K. A., Conner, T. J., McNeilly, F. and McNulty, M. S (1990). Development of an enzyme-linked immunosorbent assay to detect serum antibody to chicken anemia agent. *Avian Dis* 34, 359-363. Briefly, 400 mL of culture was sonicated at low frequency in an ice bath, SDS was added to 0.5% and the lysate was incubated for 30 min at 37°C. Cellular debris was removed by pelleting at 10 000 g for 30 min. Virus was then purified by ultracentrifugation at 80 000 g for 3 h at 15°C. Viral pellets were washed in RPMI media and pelleted again at 80 000 g for 3 h. Viral stocks were titrated following the method described above and resuspended at a final titre of  $10^{4.5}$  TCID<sub>50</sub>/mL.

Fertile Specific Pathogen Free (SPF) eggs were obtained from SPAFAS Australia Pty. Ltd., James Rd (PO Box 641), Woodend VIC 3442, Australia. The eggs were incubated in a Multiplo Brooder incubator with 300 egg capacity and manual turning. A 0.5 mL virus inoculum, or 10<sup>4</sup> TCID<sub>50</sub>, was inoculated into the yolk sac of 7 day embryonated eggs using a 24 gauge needle.

**Assessment of infectivity and *in vivo* phenotype for mutant viruses**

Infectivity was assessed by the detection of viral protein VP3 by immunofluorescence in cells isolated from bone marrow and from thymus, spleen and bursa. Squash preparations were made from bone marrow removed from the femoral medullary cavity. The immunofluorescence assay, described above for cell culture, was

WO 02/102999

PCT/AU02/00787

25

used to detect CAV VP3 in bone marrow. *In vivo* phenotype was assessed by body weight, lymphoid organ weights and lesion scoring of gross pathology in embryos at 21 days. Weights were measured for the whole embryos and the dissected thymus, spleen and bursa of Fabricius. Packed cell volume (PCV) was measured in blood obtained by venipuncture 5 from the vitteline vein or cardiac puncture. Gross pathology was assessed using a standardised system of lesion scoring for target organs of CAV infection.

#### **Lesion scores**

A grading system was established to allow consistent classification of lesion severity associated with CAV infection. Lesions within the thymus, bone marrow, spleen, 10 bursa of Fabricius and incidence of haemorrhage were all scored on a scale of 1 to 4. From these a cumulative lesion score was derived for the overall severity of pathology with scores for the thymus and bone marrow doubled as they are the key target organs for infection. In all cases a score of 1 indicates no pathology. Tables 3-8 outline the scoring system used for gross pathology.

**Table 3. Thymus score**

<b>Graded points</b>	<b>classification</b>	<b>description</b>
4	severe	~80-100 % loss of lobar parenchyma, +/- severe haemorrhage, +/- severe serosanguinous exudate
3	moderate	~50-80 % loss of lobar parenchyma, +/- moderate haemorrhage, +/- moderate serosanguinous exudate
2	mild	minor ~10-50 % loss of lobar parenchyma, OR mild haemorrhage, OR mild serosanguinous exudate

**Table 4 Bone marrow score**

<b>Graded points</b>	<b>classification</b>	<b>description</b>
4	severe	~80-100 % virtually complete loss of marrow, very pale
3	moderate	~30-50 % focal loss of marrow, moderately pale
2	mild	marrow slightly paler than normal OR acutely lytic and haemorrhagic

**5 Table 5. Spleen score**

<b>Graded points</b>	<b>classification</b>	<b>description</b>
4	severe	~70-90 % reduction in size, very pale, +/- subcapsular haemorrhage
3	moderate	~30-50 % reduction in size, moderately pale, +/- subcapsular haemorrhage
2	mild	<30 % reduction in size, OR slightly pale, OR mild subcapsular haemorrhage

**Table 6. Bursa of Fabricius score**

<b>Graded points</b>	<b>classification</b>	<b>description</b>
3	severe	~50 % reduction in size, collapsed folds
2	mild	~30 % reduction in size

**Table 7. Haemorrhage score**

<b>Graded points</b>	<b>classification</b>	<b>description</b>
3	severe	extensive petechial haemorrhage in subcutaneous tissues and fascial planes OR mesentery OR organs, OR blood visibly watery on venipuncture
2	moderate to mild	low grade petechiation present over thighs OR flanks OR wing tips only

5 **Table 8. Total cumulative lesion score**

<b>Graded points</b>	<b>classification</b>
19-13	severe CAV lesions
13-8	moderate CAV lesions
8-2	mild CAV lesions

## RESULTS

### I. CAV Vaccine

#### Construction of CAV with mutant genotypes

- 10 The constructs mut C 86 R, mut C 95 S, mut C 97 S, mut R 101 G, mut H 103 Y, mut R 129 G, mut Q 131 P, mut R/K/K 150/151/152 G/A/A, mut D/E 161/162 G/G, mut L 163 P, mut D 169 G and mut E 186 G were made by PCR mutagenesis and subcloning into a full genome CAV clone pCAU269/7. The presence of the mutations in each construct was confirmed by sequencing the final construct twice in both directions across the mutation site. Viruses with mutant genotypes were generated from the transfection of the
- 15

construct into cell culture. The transfection efficiency was assessed by the number of cells expressing GFP following transfection with control pEGFP plasmid. Transfection efficiency was variable and between 1 and 40 % of cells were found to be positive for GFP expression 48 hrs after transfection. pCAU269/7 transfection resulted in an initial phase 5 of transient expression of CAV VP3 as observed by IFA. Transient expression does not necessarily represent active viral replication. A variable number of passages were required before an exponential increase in cell numbers positive for control VP3 expression was evident by IFA. Serial passaging was performed with 1/10 dilutions. Therefore, the exponential increases in cell numbers positive for CAV VP3 represented active viral 10 replication and infection rather than simply maintenance of transfected DNA constructs. All CAV VP2 mutant constructs assayed were found to be infectious and able to replicate to some extent *in vitro* when assessed in parallel to the pCAU269/7 and mock controls (Figures 2 to 12). For each construct, the presence of replication competent virus independent of cell associations was confirmed by lysis and clarification of the transfected 15 culture followed by culture reinfection. This process was serially repeated over four passages. The presence of virus was confirmed by western blotting to detect CAV VP3, by Southern blotting using a CAV specific probe and by PCR of culture digested with *Dpn*I restriction endonuclease to remove any residual transfected DNA. The mutant genotypes were confirmed by sequencing of the PCR product from lysate.

20 Although replication competent virus was generated from all mutant constructs, the mut C 95 S and mut C 97 S viruses produced maximal log viral titres (TCID<sub>50</sub>/mL) of 1.5 and 1.7 respectively, despite repeated attempts to optimise culture conditions. These viral titres were considered too low for inoculation of embryos and the mut C 95 S and mut C 97 S viruses were not investigated further. Log viral titres (TCID<sub>50</sub>/mL) of 4.5 were obtained 25 for mut C 86 R, mut R 101 G, mut H 103 Y, mut R 129 G, mut N 131 P, mut R/K/K 150/151/152 G/A/A, mut D/E 161/162 G/G, mut L 163 P, mut D 169 G and mut E 186 G constructs when prepared over 4 passages in a final volume of 400 mL of infected culture, concentrated by ultracentrifugation and resuspended at equivalent titres (Table 9). The titres were considered adequate for inoculation of embryos and 0.5 mL of the stock or 10<sup>4.2</sup> 30 TCID<sub>50</sub> was used.

**Table 9. Titres for concentrated viral stocks used for inoculation of embryos.**  
**Titres were established by plate titration and by FACS by correlation with a clone virus standard. Stocks were assessed by PCR and sequencing to confirm the mutant genotype. FACS titre estimated accuracy of +/- 10<sup>0.5</sup> TCID<sub>50</sub>/mL .**

mutant	log FACS titre TCID <sub>50</sub> / mL	log plate titre TCID <sub>50</sub> / mL	PCR on stock	Sequencing of stock for mutation
pCAU269/7	4.5	4.5	positive	correct
mut C 86 R	4.5	4.5	positive	correct
mut C 95 S	1.5	1.5	positive	correct
mut C 97 S	1.5	1.7	positive	correct
mut R 101 G	4.5	4.5	positive	correct
mut H 103 Y	4.5	4.5	positive	correct
mut R 129 G	4.5	4.5	positive	correct
mut L 131 P	4.5	4.8	positive	correct
mutR/K/K150/ 151/152G/A/A	4.5	4.1	positive	correct
mutD/E 161/162G/G	4.5	4.5	positive	correct
mut163	4.5	4.5	positive	correct
mut D 169 G	4.5	3.9	positive	correct
mut E 186 G	Not done	4.5	positive	correct

5

#### Infection model in embryonated eggs

A series of infection experiments were performed. Experiments 1 and 2 established equivalent infectivity and virulence between the parental virus and virus generated from the cloned construct, pCAU269/7 (clone virus). All birds in both the parental and clone virus treatment groups had lesions within the thymus, bone marrow, spleen and haemorrhage categorised as severe CAV pathology. There was no significant difference in thymus, bone marrow, spleen, haemorrhage and cumulative lesion scores for the two

10

groups as determined by a Mann Whitney test. Both groups were significantly different from the uninfected group in all cases with the exception of the bone marrow scores for the clone group. Severe pathology associated with wild type virus infection (parental or clone virus) can be summarised as follows: mild to moderate petechiation was found in the

5 fascial and subcutaneous tissues in all chicks or embryos. The spleen was reduced between 50-80% in size and in general appeared abnormally pale and had subcapsular haemorrhages. In all birds the reduction in the size of all thymic lobes was graded as severe, and in the majority the appearance was of either haemorrhage into the lobes or a subcapsular, gelatinous, serosanguinous exudate in the lobes, consistent with acute

10 cytolysis. There was a reduction in bone marrow content, and either a pale fatty appearance to the marrow or severe acute haemorrhage and lysis. In a minority of birds the bursa of Fabricius was reduced in size and the capsule and parenchymal folds appeared grossly collapsed.

Experiments 3-12 involved infection with mutant viruses and clone virus and uninfected

15 controls. Statistical analyses of lesion scores, body weights, lymphoid organ weights compared to body weights and the size of lymphocyte populations in the thymus, Bursa of Fabricius and spleen in embryos infected mutant viruses or wild type virus and uninfected controls are outlined in Tables 10-17. In summary, lesion scores were significantly less in embryos infected with the mutant viruses than in those infected with the wild type virus,

20 and in most cases lesions were significantly less severe in most of the lymphoid organs (Table 10). Similarly a significant difference was found in body weight, in thymus/bodyweight and spleen/bodyweight ratios, and in most cases bursa/bodyweight ratio between embryos infected with mutant viruses and those infected with cloned wild type CAU269/7 (Table 11).

WO 02/102999

PCT/AU02/00787

31

**Table 10. Lesion scores in the lymphoid tissues, haemorrhage scores and cumulative scores, in embryos infected with CAV.**

Treatment group <sup>1</sup>	Median lesion scores <sup>2</sup>												Cumulative scores										
	Thymus				Spleen				Bursa				Bone marrow				Haemorrhage						
	S	R	n	P <sub>1</sub>	S	R	n	P <sub>1</sub>	S	R	n	P <sub>1</sub>	S	R	n	P <sub>1</sub>	S	R	n	P <sub>1</sub>			
CAU2697	3	1.4	24	NA ***	3	1.4	14	NA ***	1	1.3	24	NA ‡	3	1.4	24	NA ***	2	1.4	24	NA ***	13 3-18 14 NA ***		
Mut C36R	2	1.4	23	*** ***	2	1.4	23	*** ***	1	1.2	24	‡	2	1.4	13	*** ***	1	1.2	23	*** ‡	6 2-8 13 *** ***		
Mut R101G	1	1.3	11	*** ***	2	1.2	11	*** ***	1	1.2	11	‡	2	1.2	11	*** ***	2	1.2	11	*** ***	5 3-8 13 *** ***		
Mut H103Y	2	1.4	22	*** ***	1	1.3	22	*** ***	1	1.3	14	‡	2	1.4	13	*** ***	1	1.2	22	*** ‡	6 1-17 13 *** ***		
Mut R129G	3	1.4	20	*** ***	1	1.3	18	*** ***	1	1.2	18	‡	1	1.2	10	*** ‡	1	1.2	19	*** *	4 2-9 10 *** ***		
Mut Q131P	2	1.4	14	*** ***	2	1.4	14	*	1	1.2	14	‡	2	1.2	7	*** ***	1	1.2	14	*	6 2-8 6 *** ***		
Mut R/K150/I51/I52G/A/A	2	1.3	19	*** ***	1	1.3	19	*** ***	1	1.2	18	‡	2	1.4	9	*	2	1.3	19	‡ ***	7 1-14 9 *** ***		
Mut D/E16/I62G/G	3	1.3	5	*	1	1.2	5	**	‡	1	1.2	5	‡	1	1.2	5	** ‡	1	1.1	5	*	6 1-7 5 *** ***	
Mut L163P	2	1.5	20	*** ***	1	1.4	20	*** ***	1	1.2	20	‡	2	1.3	10	*	**	1	1.3	20	** ‡	9 1-12 10 *** ***	
Mut D169G	3	2-4	10	‡	***	3	1.4	10	‡	***	1	1.2	10	‡	2	1.4	10	‡ ***	2	1.3	10	‡ ***	9 6-13 10 *
Mut E186G	2	1-2	6	***	1	1-2	6	**	‡	1	1-2	6	‡	1	1-2	6	** ‡	1	1-2	6	** ‡	3 2-5 6 *** ***	
Uninfected	1	1-1	17	*** NA	1	1-1	17	*** NA	1	1-1	17	‡	1	1-1	28	*** NA	1	1-1	18	*** NA	1 1-1 17 *** NA		

<sup>1</sup> virus inoculated into E7 embryos<sup>2</sup> median lesion scores<sup>3</sup> median score<sup>4</sup> group size<sup>5</sup> range<sup>6</sup> P value for Mann Whitney test between CAU2697 and<sup>7</sup> P value for Mann Whitney test between control negative and treatment group<sup>8</sup> P value for Mann Whitney test between control negative and treatment group<sup>9</sup> P value significant at 0.05 level<sup>10</sup> P value significant at 0.01 level<sup>11</sup> P value significant at 0.001 level<sup>12</sup> P value not significant at 0.05 level

WO 02/102999

PCT/AU02/00787

32

Table 11. Bodyweight, thymus:bodyweight, spleen:bodyweight, and bursa:bodyweight ratios for embryos infected with CAV.

Treatment Group <sup>5</sup>	Bodyweight <sup>6</sup>						Thymus : bodyweight						Spleen : bodyweight						Bursa : bodyweight									
	$\mu$			SEM	n	P <sub>1</sub>	P <sub>2</sub>	$\mu$			SD	n	P <sub>1</sub>	P <sub>2</sub>	$\mu$			SD	n	P <sub>1</sub>	P <sub>2</sub>	$\mu$			SD	n	P <sub>1</sub>	P <sub>2</sub>
	CAU269/7	24.8	1.9	24	NA	***		5.75	2.4	9	NA	***	0.21	0.06	9	NA	***	0.64	0.30	9	NA	***	0.64	0.30	9	NA	***	
Mut C86R	34.60	1.4	20	***	‡		9.85	3.3	23	***	‡	0.34	0.1	23	**	‡	0.91	0.40	23	*	**							
Mut R101G	37.95	1.9	8	***	‡		10.54	2.0	7	***	‡	0.37	0.07	7	***	‡	1.01	0.24	7	**	‡							
Mut H103Y	35.02	1.5	10	***	‡		9.94	3.5	22	***	‡	0.33	0.13	22	**	‡	0.78	0.26	22	‡	***							
Mut R129G	34.13	1.8	14	**	‡		10.68	3.5	19	***	‡	0.39	0.12	19	***	‡	1.03	0.35	19	**	‡							
Mut Q131P	36.95	1.6	10	***	‡		9.38	3.4	13	**	‡	0.39	0.2	13	**	‡	1.08	0.69	13	*	‡							
Mut R/K/K150/I51/I52G/A/A	31.33	1.8	16	**	‡		10.11	2.4	18	***	‡	0.32	0.1	18	**	‡	0.82	0.36	18	‡	**							
Mut D/E/161/162G/G	34.38	3.8	5	*	‡		11.35	3.4	5	***	‡	0.39	0.05	5	***	‡	0.78	0.36	5	*								
Mut L163P	32.21	1.5	18	*	‡		10.18	3.4	20	***	‡	0.42	0.1	20	***	‡	1.01	0.37	20	**	‡							
Mut D169G	33.10	3.5	10	*	‡		9.15	2.5	9	**	‡	0.28	0.1	9	*	*	1.40	1.10	9	*	‡							
Mut E186G	42.94	0.8	6	***	‡		10.03	2.7	6	**	‡	0.36	0.1	6	***	‡	1.06	0.14	6	**	‡							
Uninfected	37.12	2.4	11	***	NA		10.99	4.2	16	***	NA	0.39	0.1	16	***	NA	1.23	0.52	16	**	NA							

<sup>1</sup> virus inoculated into E7 embryos<sup>5</sup>  $\mu$  mean weight<sup>6</sup>(g), or, mean organ weight(mg): bodyweight(g)

SEM standard error of the mean

SD standard deviation

n number in treatment group

<sup>6</sup> P<sub>1</sub> P value for t-test between CAU269/7 and treatment group<sup>7</sup> P<sub>2</sub> P value for t-test between control negative and treatment group

\* P value significant at 0.05 level

\*\* P value significant at 0.01 level

\*\*\* P value significant at 0.001 level

† P value not significant at 0.05 level

WO 02/102999

PCT/AU02/00787

**Examination of lymphocyte populations**

The effect of virus infection on lymphocyte populations in major lymphoid organs was assessed. The thymus, spleen and bursa were dissected from the embryos and placed into chilled sterile PBS wash buffer containing 1% BSA and 1 mM NaN3. The tissue was 5 roughly macerated and filtered through a 50 mm pore nylon mesh. The filter was flushed with chilled PBS wash buffer and the tissue homogenate was collected and mixed thoroughly. The weight of residual tissue on the filter was compared to the original filter weight. Extracted cells were pelleted at 2000 g for 7 min and resuspended in 4 ml of PBS wash buffer. The cell suspension was purified by centrifugation for 5 min at 1000 g over a 10 Ficoll-Paque (Amersham Pharmacia Biotech) gradient and the collected cells were washed twice in PBS wash buffer. Triplicate Coulter counter and haemocytometer readings were taken.

15 Examination of the size of the lymphocyte populations in the thymus, spleen and bursa by (Table 12) established that all mutants caused significantly less depletion of lymphocyte populations than the virulent wild type virus.

**Fluorescence activated cell sorting (FACS) of lymphocyte populations**

The concentrations were optimised for mAbs mouse anti-chicken TCR1 (Southern Biotechnology), mouse anti-chicken TCR2 (Southern Biotechnology), mouse anti-chicken TCR3 (Southern biotechnology), mouse anti-chicken CD4-FITC conjugate (Southern Biotechnology), mouse anti-chicken CD8-FITC conjugate (Southern Biotechnology) and mouse anti-chicken AvBu-1 (supplied by Dr. Fred Davidson, Compton Laboratories, UK). Two White Leghorn Chickens (SPAFAS) were euthanased by immersion in a CO<sub>2</sub> chamber and the spleens, thymuses and bursae were removed at post mortem and placed into PBS. Pooled leukocytes were purified as described above. To determine optimal 20 concentrations of the antibodies used for FACS analysis, the mouse anti-chicken TCR1 mAb was assessed at dilutions of 1/100, 1/1000 and 1/5000. The mouse anti-chicken TCR2 mAb was assessed at dilutions of 1/50, 1/100 and 1/1000. The mAbs mouse anti-chicken TCR3 and mouse anti-chicken AvBu-1 were assessed at dilutions of 1/20, 1/50 25 and 1/100. The mouse anti-chicken CD4-FITC conjugate and mouse anti-chicken CD8-FITC conjugate mAbs were titred at dilutions of 1/20, 1/50, 1/100, 1/200 and 1/500. Optimal dilutions were decided based on the highest antibody dilution at which there was 30

WO 02/102999

PCT/AU02/00787

34

clearest definition of background and signal staining on FACS analysis, and also peak intensity for specific staining.

Lymphocyte populations isolated from the thymus and spleen of each embryo were analysed for the proportion of cells positive on FACS analysis for the TCR1, TCR2, 5 TCR3, CD4 and CD8 cell surface markers using a double staining protocol. For each embryo eight staining treatments were performed on duplicate samples of  $10^6$  lymphocytes. In the first staining step, cells were incubated for 30 min at 4°C with either mouse anti-chicken TCR1 mAb at a 1/1000 dilution in PBS wash buffer, or mouse anti-chicken TCR2 mAb at a 1/100 dilution, or mouse anti-chicken TCR3 mAb at a 1/100 10 dilution, or all 3 mAbs in combination. The cells were washed and then incubated with the secondary rabbit anti-mouse-phycoerythrin (PE) conjugate (Sigma Aldrich) at a 1/1500 dilution for 30 min at 4°C, then blocked by incubation with 10% normal mouse serum (Sigma Aldrich) in PBS for 30 min at 4 °C. In the third staining step each set of 4 15 treatments was incubated for 30 min at 4 °C with either mouse anti-chicken CD4-FITC conjugate at a 1/100 dilution, or mouse anti-chicken CD8-FITC conjugate at a 1/100 dilution.

Lymphocyte samples from the thymus, spleen and bursa of a selection of the experimental chicks were stained and analysed for the B-cell marker avian Bu-1 (AvBu-1). Samples of 10<sup>6</sup> lymphocytes were incubated with the mAb mouse anti-chicken AvBu-1 at 20 a 1/200 dilution followed by the secondary rabbit anti-mouse-PE conjugate mAb at a 1/1500 dilution for 30 min at 4 °C.

Proportions of double positive and single positive cells were analysed using a cytofluorometer.

Data was analysed using Cellquest software (Becton Dickinson). Sample 25 populations of 10E8 cells were graphed on density plots, with intensity of FITC staining displayed on the X-axis and intensity PE staining displayed on the Y-axis. Quadrants established from plots of control cells were used to delineate positively and negatively stained populations. The absolute size and proportion of the total lymphocyte pool was calculated for the lymphocyte subsets.

30 Analysis of different lymphocyte subsets in the thymus, spleen and bursa using fluorescence activated cell sorting established that the mutant viruses caused significantly

WO 02/102999

PCT/AU02/00787

35

less depression in the numbers of CD4+TCR-, CD4+TCR1+, CD4+TCR2+, and in some cases CD4+TCR3+, thymocytes (Table 13), significantly less depression in the numbers of CD8+TCR-, and in some cases CD8+TCR1+, CD8+TCR2+ and CD8+TCR3+, thymocytes (Table 14). In general the mutants also caused less depression in these subsets 5 of splenocytes (Tables 15 and 16). In some cases, the mutants also had significantly less effect on B lymphocyte populations than the wild type virus (Table 17). These findings establish that the mutation of VP2 significantly decreases the immunosuppressive effects of CAV.

**Table 12. Lymphocyte populations from the thymus, spleen and bursa of E21 embryos infected with wild type and VP2 mutant CAU269/7.**

Treatment group <sup>¶</sup>	Mean lymphocyte populations ( $\times 10^6$ ) <sup>#</sup>												
	Thymus						Spleen						
	$\mu$	SEM	n	$P_1$	$P_2$	$\mu$	SEM	n	$P_1$	$P_2$	$\mu$	SEM	
CAU269/7	760	22	9	**	NA	27	2	9	‡	NA	13	2	9
Mut C86R	4002	78	10	‡	**	27	4	10	‡	*	49	10	10
Mut R101G	1969	42	7	‡	**	93	22	7	**	**	355	30	7
Mut H103Y	4374	61	9	‡	***	102	41	9	‡	*	751	24	9
Mut R129G	6080	28	7	‡	*	155	64	7	*	*	118	6	7
Mut Q131P	3735	85	5	‡	***	36	2	5	‡	‡	73	3	5
Mut R/K/R150/151/152G/A/A	2452	74	5	‡	**	105	23	5	**	***	120	9	5
Mut D/E161/162G/G	5664	370	7	‡	*	110	34	7	*	**	60	2	7
Mut L163P	1838	22	7	‡	**	163	5	7	**	***	107	3	7
Mut D169G	4678	173	9	‡	*	248	8	9	**	***	341	82	9
Mut E186G	1938	94	10	*	***	80	2	10	‡	*	105	2	10
Uninfected	3824	11	7	NA	**	31	2	7	NA	‡	62	1	7

<sup>¶</sup> virus inoculated into E7 embryos  
<sup>#</sup> population size measured by coulter counter

$\mu$  mean

SEM standard error of the mean

n sample size

$P_1$  P value for t-test between uninfected and treatment group  
 $P_2$  P value for t-test between CAU269/7 and treatment group

\* P value significant at 0.05 level

\*\* P value significant at 0.01 level

\*\*\* P value significant at 0.001 level

‡ P value not significant at 0.05 level

WO 02/102999

PCT/AU02/00787

37

Table 13. CD4<sup>+</sup> thymocyte populations from E21 embryos infected with VP2 mutant and wild type CAU269/7.

Treatment group <sup>1</sup>	Mean CD4 <sup>+</sup> thymocyte populations ( $\times 10^6$ ) <sup>2</sup>																			
	TCR <sup>-</sup>				TCR1 <sup>+</sup>				TCR2 <sup>+</sup>				TCR3 <sup>+</sup>							
	$\mu$	SEM	n	P <sub>1</sub>	$\mu$	SEM	n	P <sub>1</sub>	$\mu$	SEM	n	P <sub>1</sub>	$\mu$	SEM	n	P <sub>1</sub>	P <sub>2</sub>			
CAU269/7	133	29	19	***	NA	7	2	7	**	NA	35	24	7	**	NA	29	15	7	NA	*
Mut C86R	728	251	18	†	**	110	28	10	†	**	222	85	11	*	*	66	33	10	†	**
Mut R101G	4008	1362	11	**	***	121	23	8	†	***	355	151	7	†	*	167	80	7	†	*
Mut H103Y	1985	21	22	†	*	202	48	8	†	**	332	64	8	†	***	295	75	8	†	**
Mut R129G	9529	1839	20	***	***	323	134	7	†	***	2060	577	7	*	**	1311	418	7	*	***
Mut Q131P	2747	366	18	***	***	87	32	6	†	**	143	45	6	*	*	99	50	6	†	†
Mut R/K/K	885	184	15	†	***	89	31	5	†	***	177	70	5	*	*	214	82	5	†	**
150/151/152G/A/A																				
Mut D/E 161/162G/G	524	170	12	†	**	105	66	5	†	*	1291	114	5	†	*	869	77	5	†	†
Mut L163P	8392	1546	8	***	***	75	16	7	†	***	544	277	7	†	*	501	238	7	†	*
Mut D169G	3204	1027	18	***	***	248	153	5	†	***	1315	530	5	†	**	639	287	7	†	***
Mut E186G	8495	900	8	***	***	195	32	8	*	***	2911	926	8	**	**	1427	492	8	*	**
Uninfected	977	178	19	NA	***	98	35	7	NA	**	692	213	7	NA	**	409	165	7	*	NA

<sup>1</sup> Virus inoculated into E7 embryos  
<sup>2</sup> populations immunostained and analysed by FACS $\mu$  mean  
SEM standard error of the mean  
n sample size $P_1$  P value for t-test between uninfected and treatment group  
 $P_2$  P value for t-test between CAU269/7 and treatment group  
\* P value significant at 0.05 level  
\*\* P value significant at 0.01 level  
\*\*\* P value significant at 0.001 level  
† P value not significant at 0.05 level

WO 02/102999

PCT/AU02/00787

Table 14. CD8<sup>+</sup> thymocyte populations from E21 embryos infected with VP2 mutant and wild type CAU269/7.

Treatment group <sup>1</sup>	Mean CD8 <sup>+</sup> thymocyte populations ( $\times 10^6$ ) <sup>#</sup>																			
	TCR <sup>-</sup>				TCR1 <sup>+</sup>				TCR2 <sup>+</sup>											
$\mu$	SEM	n	P <sub>1</sub>	$P_2$	$\mu$	SEM	n	P <sub>1</sub>	$P_2$	$\mu$	SEM	n	P <sub>1</sub>	$P_2$						
CAU269/7	190	49	19	***	NA	15	4	7	**	NA	28	22	7	***	NA	20	15	7	NA	*
Mut C86R	560	49	18	†	*	34	8	10	‡	***	259	72	11	†	**	147	33	10	†	*
Mut R101G	5127	1237	11	*	***	461	249	8	†	*	60	9	7	***	†	255	80	7	†	*
Mut H103Y	2016	174	22	*	***	229	33	8	*	***	115	64	8	†	†	313	75	8	†	**
Mut R129G	12893	2153	20	**	***	503	148	7	**	**	172	50	7	†	**	691	418	7	†	*
Mut Q131P	2830	479	18	***	***	66	35	6	†	†	64	32	6	†	***	61	50	6	*	**
Mut R/K/K	595	101	15	**	***	174	111	5	†	*	49	18	5	†	***	258	82	5	†	**
150/151/152G/A/A																				
Mut D/E 161/162G/G	816	153	12	†	***	188	115	5	†	†	258	103	5	†	†	1704	77	5	†	†
Mut L163P	8356	80	8	**	***	121	28	7	†	***	150	41	7	†	**	619	238	7	†	**
Mut D169G	4162	1027	18	***	***	189	64	5	†	**	96	34	5	†	*	333	287	7	†	*
Mut E186G	10172	1203	8	***	***	230	18	8	**	***	505	116	8	**	***	1919	492	8	†	†
Uninfected	1370	288	19	NA	***	118	93	7	NA	**	159	14	7	NA	***	93	25	7	*	NA

<sup>1</sup> virus inoculated into E7 embryos  
<sup>#</sup> populations immunostained and analysed by FACS

 $\mu$  mean

SEM standard error of the mean

n sample size

P<sub>1</sub> P value for t-test between uninfected and treatment group  
P<sub>2</sub> P value for t-test between CAU269/7 and treatment group

\* P value significant at 0.05 level

\*\* P value significant at 0.01 level

\*\*\* P value significant at 0.001 level

† P value not significant at 0.05 level

**Table 15. CD4<sup>+</sup> splenocyte populations from E21 embryos infected with VP2 mutant and wild type CAU269/7.**

Treatment group <sup>¶</sup>	Mean CD4 <sup>+</sup> splenocyte populations ( $\times 10^6$ ) <sup>#</sup>														
	TCR <sup>-</sup>				TCR1 <sup>+</sup>				TCR2 <sup>+</sup>						
$\mu$	SEM	n	P <sub>1</sub>	P <sub>2</sub>	$\mu$	SEM	n	P <sub>1</sub>	P <sub>2</sub>	$\mu$	SEM	n	P <sub>1</sub>	P <sub>2</sub>	
CAU269/7	2	1	24	***	NA	11	6	*	NA	78	48	8	*	NA	
Mut C86R	3	2	31	***	†	519	30	11	†	*	307	101	11	*	417
Mut R101G	20	8	11	†	**	17	6	8	†	*	32	1	7	*	117
Mut H103Y	56	25	27	†	*	122	6	8	*	*	7058	291	7	*	11192
Mut R129G	6	1	5	*	***	210	190	7	†	*	142	119	7	†	97
mut Q131P	23	8	18	†	***	385	17	6	†	*	155	71	5	†	93
mut R/K/K	14	5	15	†	***	2319	13	5	†	*	2223	55	5	***	3860
150/151/152G/A/A															
Mut D/E 161/162G/G	40	9	12	†	***	13	4	5	†	***	16	8	5	†	13
Mut L163P	24	12	10	†	*	121	83	7	†	*	64	28	6	*	57
Mut D169G	241	14	29	†	†	4363	3	10	†	*	3226	273	10	†	3071
Mut E186G	7	1	10	**	**	200	10	8	†	†	40	1	8	†	50
Uninfected	17	4	19	NA	***	98	35	7	NA	**	771	42	8	NA	*

<sup>¶</sup> virus inoculated into E7 embryos<sup>#</sup> populations immunostained and analysed by FACS $\mu$  mean

SEM standard error of the mean

n sample size

P<sub>1</sub> P value for t-test between uninfected and treatment group<sup>†</sup> P<sub>2</sub> P value for t-test between CAU269/7 and treatment group

\* P value significant at 0.05 level

\*\* P value significant at 0.01 level

\*\*\* P value significant at 0.001 level

† P value not significant at 0.05

WO 02/102999

PCT/AU02/00787

40

Table 16. CD8<sup>+</sup> splenocyte populations from E21 embryos infected with VP2 mutant and wild type CAU269/7.

Treatment group <sup>a</sup>	Mean CD8 <sup>+</sup> splenocyte populations (x10 <sup>3</sup> ) <sup>b</sup>																			
	TCR-				TCR1 <sup>+</sup>				TCR2 <sup>+</sup>				TCR3 <sup>+</sup>							
	μ	SEM	n	P <sub>1</sub>	μ	SEM	n	P <sub>1</sub>	μ	SEM	n	P <sub>1</sub>	μ	SEM	n	P <sub>1</sub>	P <sub>2</sub>			
CAU269/7	6	2	24	*	NA	45	24	8	**	NA	152	11	8	*	NA	99	7	8	**	NA
Mut C86R	5	2	32	*	***	289	10	11	†	*	755	28	11	†	*	967	73	8	†	*
Mut R101G	16	7	10	†	*	23	7	8	*	***	16	4	7	*	**	25	9	7	*	***
Mut H103Y	63	4	27	†	†	1870	95	9	*	*	6417	28	9	*	*	7805	28	9	**	***
Mut R129G	136	9	9	*	**	128	107	7	†	†	45	18	7	*	***	62	35	7	*	***
Mut Q131P	28	1	18	†	**	503	41	6	†	†	621	32	6	†	*	954	57	5	†	*
Mut R/K/K	8	3	15	†	†	2246	64	5	**	***	1312	383	5	*	***	1410	36	5	**	***
150/151/152G/A/A																				
Mut D/E	39	6	10	†	***	20	5	5	**	***	13	3	5	**	***	23	11	5	*	***
161/162G/G																				
Mut L163P	22	5	11	†	**	38	13	7	**	***	32	6	8	†	†	54	24	6	*	***
Mut D169G	141	7	30	†	*	1922	69	10	†	*	1538	96	10	†	*	801	55	10	†	*
Mut E186G	5	2	10	†	†	40	10	8	†	**	40	10	8	†	†	70	20	8	†	***
Uninfected	20	24	10	NA	*	412	14	7	NA	**	508	11	8	NA	*	295	15	8	NA	**

virus inoculated into E7 embryos populations immunostained and analysed by FACS

populations with no statistics and analysed by ANCOVA

standard error of the mean sample size

$P$  value for t-test between uninfected and treatment group

**P<sub>2</sub>** P value for t-test between C4U269/7 and treatment group virus inoculated into E7 embryos

\* P value significant at 0.05 level

**Table 2** Mean and standard error of the mean P value significant at 0.01 level

SEM standard error of the mean  
sample size

WO 02/102999

PCT/AU02/00787

41

**Table 17. B lymphocyte populations from the thymus, spleen and bursa of E21 embryos infected with wild type and VP2 mutant CAU269/7.**

Treatment group <sup>1</sup>	Mean Av Bu <sup>+</sup> lymphocyte populations ( $\times 10^6$ ) <sup>a</sup>														
	Thymus						Spleen								
	$\mu$	SEM	n	P <sub>1</sub>	P <sub>2</sub>	$\mu$	SEM	n	P <sub>1</sub>	P <sub>2</sub>	$\mu$	SEM	n	P <sub>1</sub>	P <sub>2</sub>
CAU269/7	44	20	3	*	NA	9.5	0.3	3	***	NA	0.7	0.3	3	*	NA
Mut C86R	213	40	9	†	*	2.5	0.5	9	†	**	2.9	0.7	9	†	**
Mut R101G	120	39	7	†	†	8.3	0.3	7	†	†	53	1.8	7	†	*
Mut H103Y	77	16	9	†	†	7.7	1.4	9	†	†	45	2.4	9	†	†
Mut R129G	116	45	8	†	†	2.9	1.5	8	†	†	24	1.2	8	†	†
Mut R/K/K150/151/152G/A/A	556	219	5	†	*	14	3.4	5	†	*	45	7.3	5	*	**
Mut D/E161/162G/G	198	155	5	†	†	24	0.9	5	†	*	17	1	5	†	†
Mut L163P	191	92	8	†	†	6.4	0.2	8	†	†	13	0.6	8	†	*
Mut D169G	103	32	9	†	*	19	0.8	9	†	†	64	2.5	9	†	†
Mut E186G	118	13	10	†	**	3.3	0.8	10	***	***	8.9	0.	8	*	*
Uninfected	119	76	2	NA	*	6.5	0.3	2	NA	***	29	1.9	2	NA	*

<sup>1</sup> virus inoculated into E7 embryos  
<sup>a</sup> populations immunostained and analysed by FACS

$\mu$  mean  
 SEM standard error of the mean

n sample size

P<sub>1</sub> P value for t-test between uninfected and treatment

P<sub>2</sub> P value for t-test between CAU269/7 and treatment

\* P value significant at 0.05 level  
 \*\* P value significant at 0.01 level

\*\*\* P value significant at 0.001 level  
 † P value not significant at 0.05 level

WO 02/102999

PCT/AU02/00787

## II. Mutation of the Translational Initiation Signals of CAV VP2

### Construction of CAV genomes containing mutations about the VP2 ATG codon

All CAV DNA sequences were originally derived from plasmid pCAU269/7. Overlapping PCR extension was used to generate DNA sequences containing the desired 5 nucleotide changes. An *Apal/BstBI* DNA fragment of CAV genome was amplified by means of PCR using synthetic oligonucleotide pairs (CAV1/CAV20, CAV19/CAV11, CAV1/CAV22, CAV21/CAV11), see Table 18.

**Table 18. PCR primers.**

Oligonucleotide	Sequence (5'-3')	Context	Coding change
CAV 19	cggccgggAggatgcacggaaacg g	-3 position -> A	No aa change
CAV 20	gtgcattccTcccgaccgccttcgt	-3 position -> A	No aa change
CAV 21	cggccgggtggatgGacggaaacgg	+4 position -> G	His->Arg in VP2 (aa#2)
CAV 22	gtCcatccacccggaccgccttcgt	+4 position -> G	His->Arg in VP2 (aa#2)
CAV 1	ctatcgaattcccgagtggttactat	Forward	N/A
CAV 11	agctcgcttgcacatttacagtcttatac	Reverse	N/A

N/A – not applicable

10 Oligonucleotide pairs, CAV1/CAV20, CAV19/CAV11, CAV1/CAV22 and CAV21/CAV11 containing desired nucleotide changes, were used in separate 1<sup>st</sup> round PCR amplifications (25 cycles) to generate products of 347 bp, 495 bp, 347 bp and 495 bp, respectively. Products were analysed by gel electrophoresis to verify size and quantity and subsequently diluted to 25 ng/µL before being used (either the CAV1/CAV20 product with 15 the CAV19/CAV11 product, or the CAV1/CAV21 product with the CAV22/CAV11 product) to seed two 2<sup>nd</sup> round PCR amplifications (20 cycles) in which only oligonucleotide pair CAV1/CAV11 was utilised. The products generated from this overlapping extension PCR were identical to fragment CAV1/CAV11 except for the

WO 02/102999

PCT/AU02/00787

incorporation of the desired nucleotide changes (either the replacement of a T with and A in the -3 position for pCAU283-3, or the replacement of a C with a G in the +4 position for pCAU283+4) about the VP2 ATG codon. The overlapping extension products were digested with *Apa*I/*Bst*BI and 153 bp fragments spanning the VP2 ATG codon were isolated and ligated separately with plasmid pCAU269/7 digested with the same enzymes. The resulting constructs were designated pCAU283-3 and pCAU283+4 and were analysed by restriction enzyme digestions and sequencing to confirm the newly introduced sequences.

#### Sequence analysis

10 DNA sequences were determined by the dideoxy chain termination method using BigDye Terminator sequencing chemistry (ABI Prism) with combination of vector specific (T7 and SP6) and CAV sequence specific synthetic primers (CAV 12, 2, 10, 3, 9, 4, 7, 5).

#### DNA preparation and transfection

15 Viral DNAs were prepared for transfection by digesting 10 µg of endotoxin-free plasmid DNA, purified by Triton X-100, with *Eco*RI to release the CAV genome insert. Restriction products were extracted with phenol-chloroform, ethanol precipitated and resuspended at a concentration of 1 µg/µL. Aliquots were examined by agarose gel electrophoresis to verify release of insert and efficiency of recovery.

20 MSB1 cells were washed 3 times and resuspended in warmed RPMI-1640 without supplements to a final concentration of  $4 \times 10^6$  in 700 µL. Cells were transfected by electroporation in 0.4 cm-gap cuvettes (BioRad) at 400V and 375µF. Pulsed cells were incubated at room temperature (RT) for 5 mins before being transferred to 6-well tissue culture trays containing 3 mL of prewarmed RF10 and incubated at 37°C in 5% CO<sub>2</sub>. Transfection efficiency (CMV-GFP expression - pEGFPC2, Clonetech) in control wells 25 was estimated 24 hours post transfection. The transfected cells were observed for cytopathic effect (cpe) and sampled for expression of VP3 as determined by fluorescence staining.

**Indirect immunofluorescence assay**

Cells were washed twice and resuspended in phosphate-buffered-saline and plated at approximately 30-50,000 cells/well on 12-well slides, air dried and fixed with ice-cold acetone:methanol (90:10). Slides were blocked with 5% BSA in PBS/0.05% Tween 20 before reacting them with the mouse derived CAV VP3-specific monoclonal antibody JCU/CAV/1C1 (JCU TropBio, Townsville, Queensland) for 60 mins in a humidi-chamber at 37°C, and fluorescein isothiocyanate-conjugated rabbit anti-mouse immunoglobulin G antibody under the same conditions. Following a third wash, slides were mounted with VectaShield and viewed by fluorescence microscopy.

**10 RESULTS****Construction of CAV genomes containing mutations around the VP2 ATG codon**

Plasmid pCAU269/7 can be used for the production of viable infectious CAV particles. In this study, the present inventors examined whether the mutated CAV-DNA genomes, pCAU283-3 and pCAU283+4, could also produce replication-efficient virus. To that end, MDCC-MSB1 cells were transfected with these modified CAV genomes in parallel with wt CAV DNA (pCAU269/7).

**Analysis of differences in the replication rate of mutated CAV versus wt CAV**

In establishing the replication competency of the mutated genomes, the synthesis of the CAV protein VP3 was tracked in transfected MDCC-MSB1 cells. At 40 hours post transfection, a sample of the transfected cultures was analysed by indirect immunofluorescence with mAB JCU/CAV/1C1 against VP3. In parallel, samples of transfected cultures were passaged (1:10) into fresh culture medium.

The transfected CAV mutants showed a similar percentage of cells expressing VP3 as wild type (wt) CAV genome 40 hours following transfection. In VP3-expressing cells, cytopathic effects observed were characterised by the appearance of enlarged, misshapen cells and were consistent with that of other reported CAV isolates. Total cell degeneration of these cells was apparent within 96 hours of infection.

There was no apparent difference in cellular localisation or fluorescence intensity of VP3 staining in the wt or mutant genomes, as determined by fluorescence microscopy. At several time points after transfection, further samples of passaged transfected cultures

WO 02/102999

PCT/AU02/00787

45

were examined for the production of viable infectious CAV particles. Within six days, no VP3-positive cells could be found in MDCC-MSB1 cultures transfected with mutant genomes pCAU283-3 or pCAU283+4. Furthermore, medium taken from cultures transfected with these genomes did not produce cytopathic effects when passaged onto  
5 fresh MDCC-MSB1 cells.

These results suggest that the mutant DNAs exhibit severely reduced cytopathogenicity in MDCC-MSB1 cells relative to wt pCAU269/7 and only transiently express CAV proteins following transfection. Such mutant virus genomes can be used for DNA vaccination in chickens as they will not result in the generation of replicative virus,  
10 but will be able to transiently express viral proteins.

### III. Viral Protein 2

Viral protein 2 (VP2) of the immunosuppressive circovirus Chicken Anaemia Virus (CAV) has been shown to be essential to viral infectivity and replication, however its function has not yet been established. The CAV VP2 amino acid sequence has significant  
15 homology to a number of eukaryotic receptor, protein-tyrosine phosphatase alpha proteins, as well as to a cluster of TT viruses within the SANBAN group. The ORF encoding VP2 was amplified by PCR and cloned into the bacterial expression vector pGEX4T-2. VP2-GST fusion protein was expressed and purified by affinity chromatography. Purified VP2-GST was assayed for protein tyrosine phosphatase (PTPase) activity using the generalised  
20 peptide substrate ENDY(Pi)INASL, with free phosphate detected using the malachite green colorimetric assay. VP2-GST exhibited protein tyrosine phosphatase activity with a  $V_{max}$  of 14 280 U/mg.min and a  $K_m$  of 16.95  $\mu$ M. Optimal activity was observed at pH 6-7 and activity was specifically inhibited by 0.01 mM orthovanadate. A unique signature motif is proposed for CAV VP2 PTP: ICNCGQFRK encoded by amino acid residues 94 to  
25 102.

### EXPERIMENTAL PROCEDURES – VP2

#### Sequence analysis

Protein sequences with homology to CAV VP2 were identified by searches of the Genbank database using the BLASTX software (Basic Local Alignment Search Tool) via  
30 the NCBI interface. Sequences identified by this method were then aligned to the CAV sequence using EclustalW (WebANGIS, Australian National Genomic Information Service).

**Molecular Cloning of CAV viral protein 2 and TLMV ORF2**

The CAU269/7 Australian isolate of CAV was used in all experiments. CAV ORF1 (VP2) was amplified by polymerase chain reaction (PCR) from the double stranded replicative form of the CAV genome. A cellular DNA preparation was purified from CAV 5 infected MDCC-MSB1 cells 48 h after infection by proteinase K and sodium dodecyl sulphate (SDS) lysis and phenol/chloroform extraction, using the method of Meehan, B. M., Todd, D., Creelan, J. L., Earle, J. A., Hoey, E.M. and McNulty, M. S. (1992). Characterization of viral DNAs from cells infected with chicken anaemia agent: sequence analysis of the cloned replicative form and transfection capabilities of cloned genome 10 fragments. *Arch Virol* 124, 301-319. Oligonucleotide forward primer CAV.1 – 5' CGGTCCGGATCCATGCACGGAAACGGCGGACAAC 3' and reverse primer CAV.2 – 5' GGTTTGGATTCTCACACTATACGTACCGGGGC 3' were synthesised to incorporate *Bam*HI and *Eco*RI restriction endonuclease sites within the respective 5' ends. A 100 µL reaction mixture was prepared containing 300 µM each of dATP, dCTP, dGTP 15 and dTTP, 2 mM MgCl<sub>2</sub>, 200 µM of each primer, 10 µL of 10x *Taq* DNA polymerase buffer, 2 U of *Taq* DNA polymerase (Promega), and 2 µL of template DNA. The PCR reaction was incubated at 95°C for 2 min, followed by 40 cycles at 96°C for 40 s, 60°C for 40 s and 72°C for 40 s, with a final incubation at 72°C for 5 min. The PCR products were analysed by agarose (1%) gel electrophoresis and a band of 677 bp was excised and 20 purified using a Qiaex II (Qiagen) gel extraction kit according to the manufacturer's instructions, digested with *Bam*HI and *Eco*RI and ligated to appropriately digested pGEX-4T-2 (Promega). The *E. coli* strain DH5 $\alpha$  was transformed by electroporation with the ligated plasmid and cultured at 37°C on Luria-Bertani agar (LA) containing ampicillin at 50 µg/mL. The cloned DNA was sequenced using a *Taq* Dye Deoxy Terminator Cycle 25 Sequencing kit (Perkin Elmer) using commercial sequencing primers specific for PGEX-4T-2.

Purified nested PCR product from primers M-1360 to M-1363 (258 bp-886 bp) of TLMV strain CBD231 was kindly supplied by Shunji Mishiro (Takahashi *et al*, 2000). TLMV ORF2 was amplified by PCR from the M-1360 to M-1363 template.

30 Oligonucleotide forward primer TLMV.1 – 5' TTGGATCCATGAGCAGCTTCTAACACCATC 3' and reverse primer TLMV.2 – 5' GGCGAATTCTTACCCATCGTCTTCGAAATC 3' were synthesised to incorporate

unique *Bam*HI and *Eco*RI restriction enzyme sites within the 5' ends respectively. A 50 µL reaction mixture was prepared containing 300 µM each of dATP, dCTP, dGTP and dTTP, 2 mM MgCl<sub>2</sub>, 200 µM of each primer, 5 µL of 10x *Taq* DNA polymerase buffer, 1 U of *Taq* DNA polymerase (Promega), and 1 µL of template DNA. The PCR reaction 5 was incubated at 96°C for 2 min, followed by 40 cycles at 96°C for 40 s, 56°C for 40 s, then 72°C for 40 s, and a final incubation at 72°C for 5 min. Purification, digestion and cloning of the 295bp PCR product into the pGEM-T plasmid vector (Promega) proceeded as described above for CAV viral protein 2. The insert was subsequently subcloned into 10 the pGEX-4T-2 plasmid vector and the sequence and frame of the insert was verified by sequencing.

#### Protein expression and purification

CAV VP2 was produced as a C-terminal fusion with glutathione *S*-transferase. Briefly, 1 L cultures of *E. coli* DH5α possessing the CAV VP2 pGEX-4T-2 construct were cultured in Luria-Bertani broth containing ampicillin at 50 µg/mL. Expression was 15 induced by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM when the culture reached an optical density of 0.6 at 600 nm, and the culture incubated an additional hour prior to harvest. Bacteria were recovered by centrifugation at 6000 g for 30 min and the pellets washed twice in phosphate buffered saline (PBS). The cells were resuspended in 25 mL of PBS containing 0.3 M EDTA, 200 mg lysozyme, and 20 100 µg of phenyl methyl sulfonyl fluoride (Sigma)/mL and lysed by 10 second bursts of sonication at low frequency. The lysate was solubilised in 0.1% Triton X-100, incubated a further 10 min at 4°C, and the cellular debris removed by centrifugation at 10 000 g for 30 min. The fusion protein was affinity purified using glutathione sepharose resin (Promega) following the manufacturer's protocol. The eluate was extensively dialysed against a 25 buffer containing 137 mM NaCl, 2.7 mM KCl and 25 mM Tris HCl (TBS) pH 7.4.

Negative control glutathione-*S*-transferase was purified from *E. coli* DH5α transformed with pGEX-4T-2 following the same method as was used to purify the GST-VP2 fusion.

Purified protein was separated by electrophoresis in 12.5% SDS-polyacrylamide 30 gels and stained with Coomassie brilliant blue (Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227, 680-

- 685). Proteins were electrotransferred to a polyvinyldifluoride membrane (PVDF: Immobilon Millipore). Western blots of GST-VP2 and GST were probed with rabbit polyclonal antiserum raised against GST, at a dilution of 1/500, followed by a secondary swine anti-rabbit HRP conjugate (Dako) diluted 1/1000, and developed with Sigma Fast 5 3,3'-diaminobenzidine substrate (DAB, Sigma) according to the manufacturer's instructions. A second western blot was probed with pooled immune chicken serum, followed by rabbit anti-chicken-HRP conjugate at a dilution of 1/500, and developed with DAB substrate. Protein concentration was quantified using the Bradford Assay (BioRad) with a bovine serum albumin (BSA) (Sigma) standard.
- 10 TLMV ORF2 was purified from *E. coli* DH5 $\alpha$  transformed with the TLMV ORF2 pGEX 4T-2 clone following the same method as was used to purify the GST-VP2 fusion. However protein expression was induced for only 30 min.

#### Synthesis of peptide substrate

The generalised protein tyrosine phosphatase substrate described by Daum, G., Solca, F., Diltz, C. D., Zhao, Z., Cool, D.E. and Fischer, E.H. (1993). A general peptide substrate for protein tyrosine phosphatases. *Anal Biochem* 211, 50-54, was used in all enzyme assays. The phosphopeptide sequence was H-Glu-Asn-Asp-Tyr(PO<sub>3</sub>H<sub>2</sub>)-Ile-Asn-Ala-Ser-Leu-OH. Briefly, the nonapeptide was assembled manually in the solid phase using Fmoc chemistry. All chemicals for use in peptide synthesis were of analytical grade.

20 Fluorenylmethoxycarbonyl (Fmoc) protected amino acid residues (Auspep, Melbourne, Australia) were used for synthesis. The residues used were Fmoc-L-Leu-OH, Fmoc-L-Ser(tBu)-OH, Fmoc-L-Ala-OH, Fmoc-L-Asn(Trt)-OH, Fmoc-L-Ile-OH, Fmoc-L-Tyr(MDSPE), Fmoc-L-Asp(OtBu)-OH, Fmoc-L-Asn(Trt)-OH and Fmoc-L-Glu(OtBu)-OH. The support resin PAC-PEG-PS (Perspective Biosystems, capacity 0.18 mmol/g) was 25 used for the synthesis. The amino acids were activated by incubation with equimolar quantities of *O*-benzotriazole-N,N,N',N' -tetra methyl-uronium-hexafluorophosphate (HBTU)) (Auspep) and 1-hydroxybenzotriazole (HOt) (Auspep) and two equivalents of diisopropylethylamine (DIPEA) (Auspep). The coupling reaction was carried out for 60 min followed by the trinitrobenzene sulfonic acid test. The Fmoc groups were removed 30 after each coupling reaction by washing in 2.5 % 1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU). For the coupling of residues 4 to 9 each cycle was repeated twice. The side chain protective groups were removed and the peptide was cleaved from the resin by treatment

with 88% trifluoroacetic acid (TFA), 5% phenol and 2% tri-isopropylsilane (Aldrich, Milwaukee, WI) in water. The crude peptide was precipitated in cold diethyl ether prior to purification by reverse-phase High Performance Liquid Chromatography (RP-HPLC) over a Vydac C4 semipreparative column in 0.1% trifluoroacetic acid and eluted with a 2% /min 5 gradient of acetonitrile. The identity of the peptide was confirmed by mass spectroscopy.

#### Protein tyrosine phosphatase assay

All protein tyrosine phosphatase reactions were adapted from the method of Tonks, N K., diltz, C D. and Fischer, E. H (1991). Purification and assay of CD45: an integral membrane protein-tyrosine phosphatase. *Methods Enzymol* 201, 442-451. The following 10 reaction conditions apply for all assays unless otherwise stated. An assay buffer (AB) was prepared with 50 mM Tris (pH 7 at 25°C), 1 mM EDTA, 50 mM 2-mercaptoethanol and 1 % (w/v) BSA. A second buffer (TB) was prepared with 50 mM Tris (pH 7 at 25°C) and 0.01% w/v Brij 35 (Sigma). All reactions were carried out in 200 µl volumes in a microtitre plate. A 1 mM solution of phosphopeptide substrate was made in AB buffer. 15 Fifteen nanomoles of substrate was added to each of 14 triplicate reaction mixtures of 1:1 AB and TB buffers. The reactions were started by the addition of 9 µg of either VP2-GST or GST. Reactions were incubated with shaking at room temperature for 0, 1, 2, 3, 4, 5 or 10 minutes, and terminated by the addition of malachite green reagent. All assays were repeated on at least three occasions and the average activity was plotted for each time 20 point. Activity was adjusted by a factor of 0.52 to account for the contribution to mass of the 24 kDa GST fusion tag and expressed as nmol of catalysed substrate per microgram of enzyme.

#### Malachite green detection of soluble phosphate

The release of free phosphate into solution was detected by the malachite green 25 colorimetric assay. Briefly, stock malachite green solution was made by the slow addition of 60 mL of concentrated sulfuric acid to 300 mL of water followed by cooling to room temperature, and then 0.44 g of malachite green (Fisher Scientific) was added. Immediately before use the colorimetric reagent was made from 10 mL of stock malachite green, 3%(w/v)  $(\text{NH}_4)_3\text{MoO}_3$  (Sigma) and 0.15% Tween 20 (Sigma). 30 Fifty microlitres of the colorimetric reagent was added to the 200 µl reaction volume in a microtitre plate and allowed to equilibrate for 20 minutes at room temperature.

WO 02/102999

PCT/AU02/00787

50

Absorbance was read at 620 nm and phosphate release was calibrated against a phosphate standard curve.

A phosphate standard curve was prepared for phosphate values of 0, 2.5, 5, 7.5, 10, 15, 20, 25, 30, 40 and 45 nmol. Phosphate solutions were prepared in buffer at a 1:1 ratio of AB and TB buffer, and 200 µl added to each of three wells in a microtitre plate. For each concentration 50 µl of the colorimetric reagent was added and allowed to equilibrate for 20 minutes at room temperature. Absorbance was then measured at 620 nm.

#### **Enzyme kinetic and inhibition studies**

Substrate was added to triplicate reaction mixtures at 0, 2.5, 5, 7.5, 10, 15, 20, 25, 30 and 40 nmol. Incubations were for 1 min, and all other reaction conditions were as described above. For each substrate concentration activity was measured in at least 6 replicate reactions and the standard error of the mean activity calculated for each value.  $V_{max}$  and  $K_m$  estimates were derived by linear regression analysis from a double reciprocal plot and the standard error and P-value calculated for the constant  $1/V_{max}$  and the coefficient  $K_m/V_{max}$  from the plot.

Stock 1 mM  $\text{Na}_3\text{VO}_3 \cdot 10\text{H}_2\text{O}$  was made in distilled water and adjusted to pH 10 with sulphuric acid. Once dissolved, stock  $\text{Na}_3\text{VO}_3 \cdot 10\text{H}_2\text{O}$  was added to AB and TB buffer at a ratio of 1:1:1 and adjusted to pH 7. Inhibition studies were conducted with 0.1 mM, 0.01 mM and 0.001 mM of sodium orthovanadate. All other reaction conditions were as described above. Assays were with 10 nmol substrate and 9 µg CAV VP2-GST and were in triplicate for each concentration of inhibitor.

#### **Enzyme pH optimum**

TriPLICATE reactions were set up at pH 4, pH 5, pH 6, pH 7, pH 8 and pH 9. Assays were with 10 nmol substrate and 9 µg CAV VP2-GST and all other reaction conditions were as described above. Prior to addition of the malachite green reagent the pH was neutralised to pH 7 with either sulphuric acid or sodium hydroxide.

#### **TLMV VP2 GST fusion assay**

The TLMV-GST protein was assayed following the reaction conditions described for CAV VP2. Reactions were repeated 4 times.

## **30 RESULTS – VP2**

#### **Sequence analysis**

A database search for protein sequences with homology to CAV VP2 identified a number of receptor protein tyrosine phosphatase alpha (R-PTPase) proteins of human, rat, mouse and chicken origin. CAV VP2 homology was to the WPD loop flanking the P-loop in all R-PTPase homologues. The WPD loop is involved in PTPase activity. The P-loop 5 contains the catalytic site and signature motif. Similarity between CAV VP2 and the R-PTPase homologues was in the range of 30-32%. The R-PTPase homologues and CAV VP2 amino acid sequences have been aligned in Figure 13.

A second cluster of sequences was identified from the Genbank database as highly homologous to CAV VP2. The SANBAN group of TT viruses possess significant 10 homology to CAV VP2. In all SANBAN viral sequences, the region of homology extends from residues 54-80 of the amino acid sequence encoded by the putative ORF1. Homology was to the same region of the protein as for the PTPase homologues, however, the pattern of homologous residues varied. Homology between CAV VP2 and the SANBAN viral sequences was 48%. The alignment of CAV VP2 sequence with 15 SANBAN viruses is illustrated in Figure 14.

#### **Protein expression and purification**

CAV ORF1 was amplified from the CAU269/7 Australian isolate of CAV. The CAU269/7 isolate was equivalent in pathogenicity and infectivity to other described isolates of CAV. The PCR product was cloned into the pGEX 4T-2 vector and CAV VP2 20 protein was produced as a recombinant fusion protein with glutathione-S-transferase in a bacterial expression system. The size and identity of the protein was verified by electrophoresis in 12.5% SDS PAGE, followed by Coomassie brilliant blue staining and Western blotting (Figures 15 to 17). A band of 58 kDa molecular weight corresponding to the CAV VP2-GST fusion protein was identified by SDS-PAGE from affinity purified 25 eluate. The protein band reacted specifically with antiserum raised against the GST tag and also with pooled hyperimmune chicken serum. The dialysed protein was readily soluble in TBS buffer and was used directly in PTPase assays. Protein concentration was determined by the Bradford assay against a BSA standard curve.

#### **Synthesis of peptide substrate**

Peptide substrate was synthesised on a solid support using standard Fmoc 30 chemistry. Following the addition of the phosphotyrosine residue, all subsequent cycles were duplicated to counter potential steric hindrance to coupling by the large phosphate

group. A single peak consistent with pure phosphopeptide was seen on analytical RP-HPLC, and the formula weight was confirmed as 1116.3 by mass spectroscopy.

#### Protein tyrosine phosphatase assays

- A standard curve of absorbance at 620 nm as a function of phosphate concentration  
5 was established for the assay conditions. The sensitivity of the malachite green colorimetric detection was 2.5 nmol phosphate and the relationship between log[Pi] and absorbance at 620 nm was linear over the range of 0 to 45 nmol of phosphate. Concentrations of phosphate greater than 45 nmol resulted in a phosphomolybdate precipitation thereby eliminating the linearity of the relationship.  
10 VP2-GST fusion protein was clearly shown to have protein tyrosine phosphatase activity. The time course for phosphate release by CAV VP2-GST relative to control GST protein is shown in Figure 18. Based on the linear region of the curve from the time course study, in all subsequent reactions  $V_o$  was measured at 1 min. VP2-GST displayed Michaelis-Menten kinetics and the relationship between  $V_o$  and [S] was  $1/[V_o] =$   
15  $(1.292).1/[S] + 0.060$ . The plots of activity of VP2-GST and GST control proteins are illustrated in Figure 19. The Lineweaver-Burk double reciprocal plot for VP2-GST is shown in Figure 20. From the Lineweaver-Burk plot,  $1/V_{max}$  was found by linear regression to be 0.060 (standard deviation = 0.0137,  $P < 0.0001$ ) and  $K_m / V_{max}$  was found to be 1.292 (standard deviation = 0.1085,  $P < 0.0001$ ). Based on these results,  $V_{max}$  was  
20 estimated to be 14 280 U/mg min and  $K_m$  to be 16.95  $\mu\text{M}$ . All assays were repeated three times using 2 different preparations of VP2-GST protein and each substrate concentration was repeated at least 4 times.

#### Effect of reaction pH and orthovanadate inhibition on tyrosine phosphatase activity

- Protein tyrosine phosphatase activity was measured at varying reaction pH (Table  
25 19). The optimal VP2-GST PTPase activity was found to be in the range of pH 6 – pH 7. The inhibitory effect of sodium orthovanadate on VP2-GST PTPase activity is shown in Table 20. Orthovanadate concentrations of 0.001, 0.01 and 0.1 mM completely inhibited PTPase activity by VP2-GST.

WO 02/102999

PCT/AU02/00787

**Table 19: Effect of reaction pH on CAV VP2-GST PTPase activity.**

pH	S (nmol)	mean V <sub>o</sub> (nmol)	SD
4	10	1.746	0.007
5	10	1.474	0.018
6	10	5.636	0.156
7	10	5.612	0.041
8	10	1.829	0.049
9	10	0.000	0.000

**Table 20. The effect of sodium orthovanadate inhibition on the kinetics of VP2-GST PTPase activity.**

[orthovanadate] mMol	[S] nmol	V <sub>o</sub>
-	10	5.612
0.001	10	0.002
0.01	10	0.000
0.1	10	0.000

5

**PTPase Activity of TLMV ORF2 Product**

PTPase activity was demonstrated for TLMV ORF2-GST fusion protein relative to a control CAV VP2-GST assay. The steady state activity was equivalent to that demonstrated for CAV VP2 (Figure 20).

10 **III. VP2**

One aim of this study was to investigate whether CAV VP2 was a novel viral PTPase. This investigation primarily stemmed from the finding of homology between CAV VP2 and a number of PTPases, and the proposal of a PTPase signature motif within the VP2 sequence. PTPases are characterised by the minimal PTPASE signature motif CXXXXXR and by the catalysis of dephosphorylation using a cysteinyl-phosphate enzyme intermediate. The surrounding domains of the protein are involved in the regulation of enzyme activity and in substrate specificity. The profile of VP2 as a non-structural protein, expressed at very low levels but essential to infectivity, and a highly conserved protein

between CAV and TT viruses, is consistent with an essential regulatory protein such as a PTPase.

This work is the first to define a function for VP2, and has established that VP2 is a novel PTPase. These enzymes (PTPases) are defined by their capacity to remove phosphate specifically from phosphotyrosine residues in phosphoprotein substrates. PTPases have been found to vary in their specific activity for different complex protein substrates. The generalised peptide substrate ENDY(Pi)INASL used in these assays has been previously described. A wide range of PTPases utilise this substrate allowing comparison of kinetic parameters. The time course and kinetic studies clearly demonstrate that CAV VP2 has protein tyrosine phosphatase activity. A number of other descriptive features have been defined for the PTPase family. As a family, these enzymes are resistant to inhibition of activity by EDTA and display a neutral pH optimum within the range of pH 5.5-7. Studies with CAV VP2 found that the inclusion of EDTA in the assay buffer was essential to activity, and the activity was optimal for pH 6-7. These results are consistent with those described for the family as a whole.

PTPases catalyse the removal of phosphate from phosphotyrosine via a cysteinyl-phosphate intermediate formed with the active cysteine in the catalytic cleft. The mechanism of catalysis is unique to the PTPase family, as is inhibition of activity by low concentrations of orthovanadate. The compound orthovanadate is a structural analogue of phosphate and as such competitively inhibits the cysteinyl-phosphate intermediate. Members of the PTPase family have been shown to vary in the concentration of orthovanadate required for inhibition. CAV VP2 activity was maximally inhibited by orthovanadate concentrations as low as 0.001 mM.

Under the assay conditions described, CAV VP2 had a  $V_{max}$  of 14 280 U/mg.min and a  $K_m$  of 16.95  $\mu$ M. CAV VP2 activity is intermediate between that characteristic of high and low molecular mass (Mr) PTPases. The low Mr PTPases tend to have high specific activity. An example is PTP1B which has a  $V_{max}$  of 20 000 U/mg min. The high Mr PTPs have lower specific activities in general, although the activity is dependent on substrate specificities. For example CD45 from human spleen has a  $V_{max}$  of 1 000 U/mg.min.

The crystallographic structure and catalytic mechanisms of some protein tyrosine phosphatases (PTPases) have been studied in detail. From the studies of high Mr PTPases

the consensus signature motif has been defined as (I/V)HCXAGXGR(S/T). The cysteine residue is critical in binding the phosphate and the arginine coordinates the phosphotyrosine in the catalytic cleft. A minimal signature motif has been defined for the PTPase superfamily as CXXXXXR. This definition is based on a subgroup of low Mr  
5 PTPs that lack overall sequence homology to the conserved PTPase domain but contain this minimal signature motif. The low Mr PTPs are also characterised by activity over a wide range of pH. The proposed catalytic motif in CAV VP2 is ICNCQFRK, encoded by amino acid residues 94 to 102. The proposed CAV VP2 signature motif diverges from the highly conserved consensus motif seen in high Mr PTPases. However, CAV VP2 has  
10 sequence homology to the high Mr PTPases over an extended region that is not seen for the low Mr PTPs. In addition kinetic properties such as pH optimum are characteristic of the subgroup of high Mr PTPs.

Database homology searches identified a number of eukaryotic receptor PTPases (R-PTPases) with identity scores of 30-32% to CAV VP2 over an extended region of  
15 approximately 53 amino acids, including the proposed signature motif. This group of R-PTPases have significant homology to each other. Paradoxically, the sequence homology between CAV VP2 and the eukaryotic PTPases is to a region upstream from the defined catalytic motif of the eukaryotic proteins. The protein domains of eukaryotic PTPases have been shown to be modular in organisation, and in many PTPases two tandem  
20 conserved catalytic domains have been identified, only one of which is functional. The significant homology between the active VP2 catalytic fold and the protein fold flanking the eukaryotic motif of identical function may indicate functional redundancy in the eukaryotic proteins. Redundancy within PTPases may exist not only as entire domains as previously understood, but also at the level of secondary structure within protein folds.

25 Of additional interest is the finding of significant homology over the same region between CAV VP2 and the SANBAN subgroup of TT viruses. TT viruses have recently been identified from human hosts as a heterogeneous cluster of single stranded, negative-sense, circular DNA viruses. Sequence analysis of this group of viruses has demonstrated greatest overall homology to CAV. The highest sequence homology to CAV is seen in the  
30 non-coding region and between ORF2 of TTV viruses and CAV VP2. All TTV, SANBAN, YONBAN and TLMV viruses (TTV Like Mini Viruses) have in common with CAV the sequence WX<sub>7</sub>HX<sub>3</sub>CXCX<sub>5</sub>H in ORF2. This homologous sequence corresponds

to the 5' end of the predicted PTPase signature motif. However the homology between the SANBAN isolates and CAV VP2 is more extensive and includes the entire sequence of the proposed signature motif. Others have recently proposed the classification of the TTV, SANBAN, YONBAN, TLMV and CAV viruses as the Paracircoviridae. The current 5 designation of ORFs in TT viruses is based on sequence analysis alone, as these viruses have not yet been grown in culture or the viral protein expression profiles characterised.

The results shown above clearly identify TLMV ORF2 as a second novel viral PTPase. The demonstration of PTPase activity by TLMV ORF2 is indicative of a common viral strategy for infection and replication between CAV and the TT viruses. The finding 10 is consistent with the close similarity found in genome organisation and the sequence homology between TTV and CAV.

Protein tyrosine phosphatases are known to function in the regulation of mitogenesis, gene transcription, signal transduction, cell-cell interactions, cellular differentiation and in cytokine responses of lymphocytes. CAV infection of T-lymphocyte 15 and haemocytoblast populations of chickens up to 21 days of age leads to profound immunosuppression and anaemia. VP2 PTPase activity during infection may represent a virulence mechanism through viral induced regulatory changes in infected lymphocyte populations. All previous accounts of virus encoded regulatory proteins have involved viruses with large genome sizes and extensive coding capacity. It has been suggested that 20 these viruses can maintain cell regulatory proteins in addition to critical viral structural and replicative proteins. This includes the previously described VH1 PTPase from Vaccinia virus. The present finding is therefore unusual in that CAV has an extremely small genome size (2.3 kb) and only three viral proteins expressed from overlapping reading frames. CAV is therefore highly dependent on host function for completion of its 25 replication cycle, and it is possible that a capacity to regulate the lymphocyte cell cycle may be a critical viral function. To the best of our knowledge, CAV VP2 PTPase is only the second viral PTPase to be described, and is the only PTPase described in a virus of this type.

**IV. DNA inoculation of embryos with single and double-stranded CAV genome****Introduction**

- The standard method used for the generation of infectious virus from CAV genome by the transfection of double-stranded DNA into MDCC-MSB1 cells was described by
- 5 Noteborn, M.H., de Boer, G.F., van Roozelaar, D.J., Karreman, C., Kranenburg, O., Vos, J. G., Jeurissen, S. H., Hoeben, R.C., Zantema, A. and Koch, G. (1991). Characterisation of cloned chicken anaemia virus DNA that contains all elements for the infectious replication cycle. *J Virol* **65**, 3131-3139. Alternative methodologies for the generation of CAV virions from genome have not been investigated, and there are no published reports of the
- 10 inoculation of naked genomes of any virus into chick yolk sac. A capacity to generate infectious virus *in ovo* from naked DNA genome would permit the production of vaccines without an intermediate transfection step in MDCC-MSB1 cells. This methodology would have the potential to enhance biosecurity, as the transformed MDCC-MSB1 cell line contains latent Marek's Disease Virus genome, and cell passage carries the risk of
- 15 inadvertent contamination of vaccine virus.
- Chicken Anaemia Virus, in common with other members of the *Circoviridae*, has a circular, single-stranded, negative-sense DNA genome enclosed within a non-enveloped capsid. The normal infectious cycle of the virus has been investigated and viral replication proceeds through a double-stranded, replicative intermediate. Double-stranded, replicative forms of 2.3 kbp, 1.3 kbp and 0.8 kbp, and open circular and closed circular forms, have
- 20 been identified in MDCC-MSB1 cells infected with CAV. The order in which the double-stranded replicative intermediate, the transcript, and the encapsidated single-stranded genome are synthesised, is not known. It has been demonstrated that infectious virus could be readily recovered from MDCC-MSB1 cells transfected with the double-stranded form
- 25 of the genome alone. Therefore the 2319 bp cloned CAV DNA sequence contains all the genetic information required for the generation of infectious virus within the host-cell. The recovery of replication-competent virus from the transfection of single-stranded DNA genome has not been investigated. For virus replication to proceed from the transfection of single-stranded DNA genome it would require a double-stranded replicative form to be
- 30 synthesised from cytoplasmic single-stranded genome.

The objective of this study was to investigate whether virus replication can proceed from the transfection of MDCC-MSB1 cells with different CAV genomic constructs. The

capacity for viral replication to proceed from either the single-stranded or double-stranded forms of the genome, from either linear or circular forms, and from either positive or negative sense strands, was investigated. A further objective was to investigate whether virus replication can proceed *in vivo* after inoculation of these DNA constructs into the 5 yolk sac, and to investigate the relative efficiency of the different genomic constructs, in generating infectious virus after inoculation into the yolk sac.

#### **Bi-directional cloning of the CAV genome into M13.t130 bacteriophage**

In order to obtain positive-sense and negative-sense single-stranded CAV genome, the genome was subcloned from the pGEX-4Z plasmid vector into the M13.t130 bacteriophage. The construction of the pCAU269/7 genomic clone in the pGEX-4Z vector has been described by Brown, H.K., Browning, G. F., Scott, P. C. and Crabb, B. S. (2000). Full-length infectious clone of a pathogenic Australian isolate of chicken anaemia virus. *Aust Vet J* 78, 637-640. The CAU269/7 genome was bidirectionally subcloned from the pGEX-4Z plasmid vector into the M13.t130 bacteriophage. The orientation of the genomic 10 insert within the M13.t130 bacteriophage vector was determined from the analysis of the *Pst*I digestion pattern. Bands of approximately 8.9 kbp and 0.6 kbp were seen after *Pst*I digestion of an M13.t130 clone containing CAV genome inserted with the positive-sense 15 strand oriented 5' to 3' (designated CAV.M13.pos). Bands of approximately 7.8 kbp and 1.8 kbp were seen after *Pst*I digestion of an M13.t130 clone containing CAV genome inserted with the negative sense strand oriented 5' to 3' (designated CAV.M13.neg). The 20 orientation of the CAV genomic sequence in these clones was further confirmed by sequencing in both directions using primers that hybridised to sequences flanking the cloning site.

#### **Transfection of MDCC-MSB1 cells with CAV genomic constructs**

The efficacy of virus growth after transfection of different CAV genomic constructs into MDCC-MSB1 was assessed. Single-stranded and double-stranded forms of the CAV genome were prepared. Double-stranded CAV DNA was prepared from a culture of the pCAU269/7 plasmid. A band of the correct size from the CAV genome released 25 from the pCAU269/7 clone by *Eco*RI digestion, was purified by 1% gel electrophoresis and circularised by ligation. Bands of the correct size were purified by 1% gel electrophoresis 30 for single-stranded, CAV DNA prepared from cultures of the bacteriophage clones

WO 02/102999

PCT/AU02/00787

59

- CAV.M13.pos and CAV.M13.neg. The presence of only single-stranded DNA in the preparation was confirmed by digestion of all DNA by Mung Bean nuclease which specifically digests single-stranded DNA. Primers which hybridised to sequences flanking the cloning sites were annealed to both the single-stranded CAV.M13.pos and
- 5 CAV.M13.neg preparations, and then digested with *EcoRI*. The DNA was circularised by ligation, and then quantified by spectroscopy.
- The regeneration of virus after transfection with these DNA constructs was assessed by immunofluorescence over sequential cell culture passages, and cell-free virus was prepared from cell lysates. Virus was recovered after transfection with the following
- 10 genomic DNA constructs :
- (i) circularised, positive-sense, single-stranded, CAV DNA, prepared from the CAVM13.pos clone;
- (ii) linear, positive-sense, single-stranded, CAV DNA, prepared from the CAVM13.pos clone;
- 15 (iii) circularised, negative-sense, single-stranded CAV DNA, prepared from the CAVM13.neg clone;
- (iv) linear, negative-sense, single-stranded CAV DNA, prepared from the CAVM13.neg clone; and
- (v) double-stranded, circularised CAV DNA, derived from *EcoR1* digestion of
- 20 *pCAU269/7*.

No virus was recovered after transfection with control plasmid DNA. Transfection efficiency for double-stranded DNA was 10% as assessed by the proportion of fluorescent cells at 48h following transfection with pEGFP plasmid.

Transfection with all single-stranded constructs resulted in a markedly higher proportion of infected cells than transfection with the double-stranded DNA construct .

25 There was at least 50% infection of MDCC-MSB1 cells by the second culture passage after transfection with all forms of single-stranded genome. However, 50% infectivity was not seen until the fourth passage after transfection with double-stranded CAV genome. There were no differences seen in the proportion of cells infected after transfection between

positive or negative-sense single-stranded genomes, nor between linear and circularised genomes.

#### DNA inoculation in embryos

- The efficacy of virus growth after inoculation *in ovo* of different CAV genomic constructs was assessed. The different CAV genomic constructs were inoculated into the yolk sac of groups of five 7 day embryos (E7). The titres of virus in clarified homogenates of whole E18 chick embryos were determined by inoculation of MDCC-MSB1 cell cultures (Table 21). Virus was recovered from homogenised E18 embryos inoculated with the following genomic DNA constructs (Table 21):
- (i) circularised, positive-sense, single-stranded, CAV DNA, prepared from the CAVM13.pos clone;
- (ii) linear, positive-sense, single-stranded, CAV DNA, prepared from the CAVM13.pos clone;
- (iii) circularised, negative-sense, single-stranded CAV DNA, prepared from the CAVM13.neg clone;
- (iv) linear, negative-sense, single-stranded CAV DNA, prepared from the CAVM13.neg clone; and
- (v) double-stranded, circularised CAV DNA, derived from *EcoR*1 digestion of *pCAU269/7*.
- No virus was recovered from homogenised E18 embryos inoculated with control plasmid DNA (Table 21). The efficiency of virus growth from the inoculation of positive, circularised single-stranded genome was very low, with virus recovered from only one out of 5 embryos (Table 21). The greatest efficiency of virus growth was seen from the inoculation of circularised, negative-sense single-stranded genome, which is the form of genome present in the virion. The mean titre for circularised, negative-sense, single-stranded genome was significantly greater at the 0.001 level, than the mean titre for double-stranded genome inoculation.

The findings from this study were further confirmed by inoculation of the yolk sac of eggs after 6 days of incubation with cloned mutant viral genomes still contained within the plasmid vector. The three mutant genomes were mut C86R, mut H103Y and mut

Q131P. At 16 days of incubation chorioallantoic membranes and bone marrow smears were prepared from the embryos and stained with immunofluorescent antibody against CAV-VP3. In all inoculated eggs there was evidence of viral replication as demonstrable by specific staining for VP3.

5    **V. DNA inoculation of embryos with single and double-stranded CAV genome**

In this study a new methodology was developed for the growth of CAV *in ovo* after inoculation of E6 or E7 embryos with naked DNA genome. This is the first study to demonstrate for CAV that virus growth *in vivo* can proceed from the inoculation of DNA, and the first description of the inoculation of naked viral genome into the yolk sac for any 10 avian viral pathogen.

This study has demonstrated the efficacy of DNA inoculation into the yolk sac for the cultivation of CAV. Delivery of CAV DNA into the yolk sac of embryos or by other *in ovo* routes can be used as a route of vaccination.

This methodology represents a significant advance in biosecurity due to the 15 capacity to generate infectious virus from manipulated genome in a cell-free system. The cultivation of virus by the transfection of the manipulated genome into MDCC-MSB1 cells exposes potential vaccine inoculate to components of the cell culture system which may pose biosecurity risks. The capacity to generate virus from DNA genome inoculated into the embryonic yolk sac is therefore significant to the enhancement of biosecurity. The titre 20 of  $10^5$  to  $10^6$  TCID<sub>50</sub> typically obtained for cultivation of CAV in MDCC-MSB1 cell culture is restrictively low. Amplification of titre could be possible through further cycles of yolk sac inoculation.

The efficacy of yolk sac inoculation was greatest for the single-stranded, negative-sense circularised genome (Table 21). High titres of infectious virus were recovered from 25 the inoculation of single-stranded, negative-sense, circularised genome and moderate titres from yolk sac inoculation of double-stranded, circularised genome (Table 21). The titre obtained from the inoculation of embryos with single-stranded, negative-sense, circularised genome was 3 log higher than for double-stranded genome (Table 21). There was a significant difference in the titres obtained from the inoculation of circularised versus 30 linear negative-sense genome. Viral titres obtained from the inoculation of either negative-sense linear genome, positive-sense circularised genome or positive-sense linear genome were low. Given that no differences were observed in the efficacy of transfection in

WO 02/102999

PCT/AU02/00787

62

MDCC-MSB1 cells between the different forms of single-stranded DNA constructs , the differences in efficacy after yolk sac inoculation are probably attributable to influences upstream from processing of the viral genome once it is in the cytoplasm. DNA constructs inoculated extracellularly into the yolk sac must persist in the yolk without degradation, 5 and enter into host target cells for viral replication to commence. The difference observed between positive-sense and negative-sense constructs therefore most probably relates to the stability of the construct following yolk sac inoculation, and its capacity for uptake into the target cells. The folding and confirmation of the negative-sense, circularised strand may determine this difference.

10 Infectious virus can be generated from single-stranded genome after transfection of MDCC-MSB1 cells . There were no differences observed between positive and negative-sense strands, nor between circularised and linear constructs. This is most probably because the circular, double-stranded replicative intermediate can be synthesised from either the positive or the negative-sense strand once it is in the cytoplasm. Transfection of 15 single-stranded, negative-sense genome resulted in a higher infectivity at earlier passages than transfection of double-stranded genome .

Methods for the transfection of double-stranded CAV genome into MDCC-MSB1 cells have been described by Noteborn, M.H., de Boer, G.F., van Roozelaar, D. J., Jeurissen, S. H., Hoeben, R. C., Zantema, A. and Koch, G. (1991). Characterization of 20 cloned chicken anemia virus DNA that contains all elements for the infectious replication cycle. *J Virol* **65**, 3131-3139, and this technique has been replicated in many published studies. Using this technique, the DNA genome can be readily manipulated *in vitro*, and the alterations precisely defined, prior to generation of virions in cell culture. The transfection of single-stranded constructs may increase the efficacy of this process. A 25 method providing enhanced transfection efficiency would be particularly beneficial for the cultivation of mutant strains with altered growth characteristics, such as extended latent periods or low burst size. Primer mutagenesis in the M13 bacteriophage cloning system involves only a single mutagenesis step for the generation of single-stranded mutant genome, and is therefore a quicker and more simple technique. The M13 bacteriophage 30 vector is therefore a suitable alternative system to plasmid propagation for the manipulation of CAV genome.

WO 02/102999

PCT/AU02/00787

63

Further studies showed that use of cloned genome, in a plasmid vector, were also able to be inoculated into the yolk sac of emryonated eggs as a method for generating infectious virus. Thus this process may be used for recovery of mutant genomes and also for production of vaccines. It also showed that direct inoculation of cloned genomes of 5 CAV mutants into eggs may be used as a method of vaccination, especially given the demonstration that the mutant viruses are attenuated for chick embryos.

WO 02/102999

PCT/AU02/00787

64

**Table 21 Mean titres of CAV in E18 embryos following yolk sac inoculation with different genomic constructs.**

DNA inoculum	Mean titre <sup>¶</sup>	SD	P-value <sup>#</sup>
<b>control negative</b>	0	0	NA
ds <sup>a</sup>	2.9	0.6	***
(-ve) <sup>b</sup> ss <sup>c</sup> circ <sup>d</sup>	5.5	0.7	***
(-ve) ss lin <sup>e</sup>	1.3	0.9	**
(+ve) <sup>f</sup> ss circ	0.6	0.9	‡
(+ve) ss lin	1.6	0.3	***

<sup>¶</sup> Mean titre as  $\log_{10}$ TCID<sub>50</sub>/embryo

5 SD standard deviation

# P-value t-test between control negative and treatment

<sup>a</sup> double-stranded

<sup>b</sup> negative-sense

<sup>c</sup> single-stranded

10 <sup>d</sup> circularised genome

<sup>e</sup> linear genome

<sup>f</sup> positive-sense

NA not applicable

\* P-value significant at 0.05 level

15 \*\* P-value significant at 0.01 level

\*\*\* P-value significant at 0.001 level

‡ P-value not significant at 0.05 level

WO 02/102999

PCT/AU02/00787

65

**VI. Assessment of selected mutant CAV viruses for attenuation and for induction of protective immunity in day old chicks**

**Aim**

- To assess safety of selected CAV mutants in day old chicks and assess protective  
 5 immunity induced by inoculation of day old chicks with CAV mutants.

**Method**

There were six experimental groups:

Group	Treatment day 1	Treatment day 21
1	Media	Media
2	Media	Wild type CAV
3	Wild type CAV	Wild type CAV
4	Mutant 169	Wild type CAV
5	Mutant 101	Wild type CAV
6	Mutant 161/162	Wild type CAV

- Each experimental group consisted of 10 birds, and each group was housed in a  
 10 separate positive pressure fibreglass isolator with all entry and exit air filtered by high efficiency particle air filters and all food and water sterilised before introduction into the isolators. All chicks were individually identified by wing bands.

Half the chicks were euthanased at day 14 and removed for assessment of safety of the mutants. The remaining chicks remained in the isolators for a further 21 days.

- 15 The birds were inoculated subcutaneously with 0.5 mL of CAV containing  $10^4$  median tissue culture infective doses of virus or with 0.5 mL of a lysate of uninfected MSB1 cells.

- At day 14, 5 birds in each group were euthanased by exposure to halothane. At post mortem, body weights were taken and all lymphoid organs, bone marrow, liver,  
 20 spleen and dermus (for evidence of haemorrhage) examined for gross pathology. The thymic chain was dissected out and weighed.

WO 02/102999

PCT/AU02/00787

At day 21, the remaining birds in each group were inoculated subcutaneously with 0.5 mL of CAV containing  $10^4$  median tissue culture infective doses of virus or with 0.5 mL of a lysate of uninfected MSB1 cells.

At day 35, the remaining birds were euthanased by exposure to halothane. At post 5 mortem body weights were taken and all lymphoid organs, bone marrow, liver, spleen and dermus (for evidence of haemorrhage) examined/photographed for gross pathology. The thymic chain was dissected out and weighed.

### **Results and Discussion**

There was no evidence that birds infected with virus had lower body weights than 10 uninfected birds at day 14 and no evidence that there was any difference in body weight between any of the groups at day 35.

At day 14 there was no evidence of a difference in thymic weight or thymus/body weight ratio between birds infected with the mutant viruses 101 and 161/162 and uninfected birds. However, the thymic weight and thymus/body weight ratio of birds 15 infected with wild type virulent virus were significantly lower than those of uninfected birds. The thymic weight and thymus/body weight ratio of birds infected with mutant 169 were not significantly different from uninfected birds or birds infected with wild type virulent virus.

### **Results at Day 14**

Group	Treatment day 1	Thymus Weight (g)	Thymus/Body Weight Ratio (mg/g)
1	Uninfected	$1.3 \pm 0.3^a$	$8.8 \pm 1.6^a$
2	Uninfected	$1.1 \pm 0.3^{ab}$	$8.4 \pm 1.6^a$
3	Wild type CAV	$0.8 \pm 0.3^b$	$4.9 \pm 2.0^b$
4	Mutant 169	$1.1 \pm 0.3^{ab}$	$7.1 \pm 2.1^{ab}$
5	Mutant 101	$1.3 \pm 0.4^a$	$8.9 \pm 2.3^a$
6	Mutant 161/162	$1.3 \pm 0.3^a$	$8.3 \pm 1.5^a$

WO 02/102999

PCT/AU02/00787

Values in the same column with the same superscript letter are not significantly different

These results show that mutant viruses that were attenuated for chick embryos were also attenuated for day old chicks, with the attenuation of mutant 169 somewhat intermediate compared to that of mutants 101 and 161/162

##### 5 Protection experiment

At day 35 there was no evidence of a difference in thymic weight or thymus/body weight ratio between birds vaccinated with mutant virus 169 and then challenged with wild type virulent CAV at 21 days, birds that had not been infected, and birds that had been inoculated at 1 day old with wild type virulent CAV and then challenged with wild type virulent CAV at 21 days. However, the thymic weight and thymus/body weight ratio of birds that had not been exposed to CAV at 1 day of age but were then infected with wild type virulent virus at 21 days of age were significantly lower than these groups. Birds that had been vaccinated with mutants 101 or 161/162 and then challenged with wild type virulent virus had intermediate levels of protection.

##### 15 Results at Day 35

Group	Treatment day 1	Treatment day 21	Thymus Weight	Thymus/Body
			(g)	Weight Ratio (mg/g)
1	Uninfected	Uninfected	4.1 ± 0.8 <sup>a</sup>	9.5 ± 1.4 <sup>a</sup>
2	Uninfected	Wild type CAV	1.3 ± 0.3 <sup>b</sup>	3.3 ± 0.9 <sup>b</sup>
3	Wild type CAV	Wild type CAV	5.1 ± 1.2 <sup>a</sup>	10.5 ± 1.9 <sup>a</sup>
4	Mutant 169	Wild type CAV	3.5 ± 0.4 <sup>a</sup>	9.0 ± 0.8 <sup>a</sup>
5	Mutant 101	Wild type CAV	2.2 ± 0.4 <sup>c</sup>	5.0 ± 1.4 <sup>b</sup>
6	Mutant 161/162	Wild type CAV	2.0 ± 1.0 <sup>bc</sup>	5.2 ± 2.1 <sup>b</sup>

Values in the same column with the same superscript letter are not significantly different

These results show that vaccination with mutant viruses was able to protect chickens against the effects of CAV infection.

Thus, the mutant CAV viruses were not only attenuated, but were also capable of inducing protective immunity in 1 day old chickens.

## DISCUSSION

### I. CAV Vaccine

- 5       The present inventors have developed CAV live attenuated and DNA vaccines suitable for the inoculation of pullets, broiler and breeder flocks. A number of stages were involved in this process including:
- establishing an *in vitro* cell culture system for the analysis and growth of virus;
  - analysing virus for appropriate sites for mutagenesis and investigation of viral
- 10      function;
- site-directed mutagenesis utilising PCR on a full genome clone;
  - transfection of mutant viruses in a cell culture system and assessment for infectivity, cytopathogenic effects and specific changes in viral function;
  - testing mutant viruses as potential vaccine candidates in a challenge model using
- 15      SPF chick embryos; and
- assessing phenotype and *in vivo* infectivity of mutant viruses in the challenge model.

The results from pathogenicity testing in chick embryos clearly demonstrated that mutation of VP2 in the key regions of structure and function identified was able to be used 20 to generate attenuated virus that would be suitable for vaccination, either as attenuated virus or as a DNA vaccine. All mutants with the exception of mut 163 were significantly attenuated as measured by the total lesion score. However, mut 163 was significantly attenuated as measured by thymus and spleen lesion scores.

It was notable that the most significant effects on attenuation were achieved by 25 mutation of the residues predicted to be involved directly in the PTPase function of the VP2, but that some attenuation was also achieved by mutating the acidic and basic regions at the carboxyl end of VP2.

In addition, mutation of the Kozac's sequence at the point of translational initiation 30 of the VP2 gene, such that more VP2 would be produced, resulted in a construct that was no longer capable of productive replication. Such a construct, while not useful as a basis for developing a live attenuated vaccine, can be used as a DNA vaccine.

These studies have also demonstrated that VP2 has a potent immunomodulatory effect. Mutant VP2 thus can be used to effect less potent changes in the immune system.

## II. Mutation of the Translational Initiation Signals of CAV VP2

These studies have demonstrated the general application of mutation of the gene for 5 VP2 in CAV and its homologues in other circoviruses for the generation of attenuated strains for use as live vaccines or DNA vaccines and for the generation of non-replicating genomic clones that can be used as DNA vaccines.

In addition, the present inventors have clearly demonstrated the role that VP2 plays in immunomodulation during CAV infections. It has been found that VP2 and its 10 homologues can be used to influence the function of the immune system.

There is some potential for using replication deficient mutants, pCAU283-3 and pCAU283+4 as DNA vaccines in chickens in that transient expression of VP2/VP3 may be sufficient to elicit immune response

## SUMMARY

15 The present inventors have found that directed mutagenesis is a feasible strategy for the production of an attenuated viral strain, firstly as the genome of CAV is amenable to manipulation due to its small size, and secondly as virus particles can be readily generated by transfection of genome alone. Directed mutations can be introduced into the genome in a cell and virus free system and precisely characterised prior to the production of virus.

20 This strategy is therefore highly efficient and employs optimal biosecurity. A limitation to the employment of a live attenuated vaccine is the low titre to which virus grows *in vitro* and the minor inconvenience due to the requirement for virus production in embryonated specific pathogen free (SPF) eggs. The development of a DNA vaccine eliminates the biosecurity risk of culture production and the limitations of low viral titres, and may prove 25 to be efficacious for *in ovo* inoculation. Alternative approaches to the live attenuated vaccine are inactivated vaccines or live vaccines attenuated through passage. Inoculation of chicks with co-expressed VP1 and VP2 generates a serum neutralising antibody response protective against challenge. Live attenuated viruses, however, typically have greater capacity for immunogenicity due to induction of both humoral and cell mediated 30 immunity. Strains which have been attenuated through passage are suboptimal as vaccine candidates as they retain low levels of pathogenicity. In addition, passaged attenuated strains rapidly revert to virulent forms with passaging in chicks. Therefore, there are

WO 02/102999

PCT/AU02/00787

70

significant advantages in the use of site directed mutagenesis on a recombinant genome for use as a DNA vaccine or for the derivation of live attenuated strains. Vaccine program design may incorporate the administration of DNA vaccines to embryonated eggs and of live attenuated vaccine to older birds.

- 5       The organisational features of the CAV genome both limit and enhance the possibilities for attenuation through mutagenesis whilst concurrently retaining infectivity and immunogenicity. CAV is extremely economical in its coding capacity. The genome is only 2.3 kb and encodes three overlapping ORFs, limiting the options available for mutagenesis. Mutations in one ORF must be designed so as not to disrupt overlapping
- 10      ORFs. The functions of all three viral proteins are critical to viral infectivity and therefore introduced mutations must ensure retention of protein function. The stability of attenuation can be enhanced through a multi-factorial approach. Reversion to virulence is expected to occur at a low frequency with reliance on simple point mutations. CAV has extreme sequence conservation in all characterised isolates across the coding regions
- 15      containing overlapping reading frames. This suggests that in the field situation, the capacity for spontaneous mutations to be tolerated by the virus is kept well below the expected rate of naturally occurring mutation associated with the error rate of the polymerase enzyme system. This is most probably a consequence of the restriction imposed on codon change in one frame due to concurrent changes in the overlapping frame
- 20      which may be deleterious. This argument also suggests that a strategy of passage attenuation will be extremely slow and may not produce the optimal attenuation that can be achieved through targeted mutagenesis. Naturally occurring mutations will only be tolerated at a measurable frequency in codons for which the overlapping reading frame has codon wobble. Site directed mutagenesis is therefore optimal as it does not rely on the
- 25      probability of low frequency mutational events and sites where the overlapping ORF has minimal codon wobble can be readily mutated through careful design. Mutations introduced by site directed mutagenesis *in vitro* that preserve the overlapping frame will have a reduced frequency of reversion due to the necessity for codon conservation in the overlapping frame. Attenuation requires a rationally designed strategy of carefully
- 30      constructed mutations using site-directed mutagenesis.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without

**WO 02/102999****PCT/AU02/00787**

71

departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

WO 02/102999

PCT/AU02/00787

72

## SEQUENCE LISTING

<110> The University of Melbourne  
<120> Circovirus vaccines  
<130> KYI:TYD:305017633  
5 <150> PR5674  
<151> 2001-06-14  
<160> 68  
<170> PatentIn version 3.1  
  
10 <210> 1  
<211> 2286  
<212> DNA  
<213> Artificial Sequence  
<220>  
15 <223> DNA sequence of pCAU269/7  
<400> 1  
  
ccccccctga accccccccc gggggggatt cccccccaga cccccccctt ataaagcact 60  
caataaacgc agctaattcg ttacccgcac aatcgcttc cgagtggta ctatccatc 120  
20 accattctag cctgtacaca aaaagtaaag atggacaaat cgctcactt cgctcgcgt 180  
tcgtcgaagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcgtgta 240  
caggggggta cgtcatccgt acaggggggg tacgtcacaa gaaggcgttc cctgtacagg 300  
gggtacgtaa catgttcagg ggggtacgtc acaaccatac aggagctgcc acgttgcgaa 360  
agtgacgttt cggaaatggg cggcgcaaga ctccctatat attgcgcga cataccggc 420  
25 ggcagttaggt atacgcgaaagg cggtccgggt ggtgcacgg aaacggcgga caaccggccg 480  
ctgggggcag tgaatcgccg cttagcccgag agggcAACCC tggcccgagc ggagccgcgc 540  
aggggcaagt aatttcaaat gaacgctcac caagaagata ctccaccagg accatcaacg 600  
gtgttcaggc caccaacaag ttacccggcc ttggaaaccc ctcactgcag agagatccgg 660  
attggtatcg ctggaattac agtcaactta tcgtctgtg gctgcgcgaa tgctcgcgtt 720  
30 cccacgctaa gatctgcaac tgccggacaaat tcagaaaaca ctggttcaa gaatgtgccg 780  
gacttgagga ccgtatcaacc caaggccccc tcgaagaagc gatctgcga cccctcccgag 840  
tacagggtaa gcgagctaa agaaagcttg attaccacta ctcccgccg accccgaacc 900  
gcaagaaggt gtataagact gtaagatggc aagacgagct cgcacaccga gaggccgatt 960  
ttaccccttc agaagaggac ggtggcacca ctcacgca ctgcacgaa gatataaatt 1020  
35 tcgacatcgaggagcaggatcgtag acgagctttt aggaaggcccttacacaaccc 1080  
ccggcccggtt acgtatagt tgaggctgcc aaaccccccag tccacgtatgc ctatccgcgtt 1140  
ccaaggagtc atcttctca ccgaaggact cattctacct aaaaacagca cagctgggg 1200  
ctatgcggac cacatgtacg gggcgagact cgcacaccgc tcaatgcgaa tggaaagatgtt 1260  
cctccatca tcaatgcgaa tgacatacgat gagcaagata ggaggccca tcggccgtga 1320  
40 gttgattgcg gacgggtcta aatcgcaacgc cgcggagaac tggccaaattt gctggctgcc 1380  
gctagataat aacgtgcctt ccgtatccacc atctgcgtgg tggagatggg cttaatgtat 1440  
gatgcagcca acggacccctt gcccggatcc taatccaccc aagcaaatga ccctgcgaa 1500  
catgggtcgg atgtttgggg gctggcatct gttccgacac attgaaaccc gcttcagct 1560  
ccttgcactt aagaatgagg gatccctcag ccccgccgac agtcttcctt cccaggagg 1620  
45 gtacccatcg cggccgcacgc atgttaagta cagcagcgcac caccagaacc ggtggcgaaa 1680  
aggcgagcaac ccgtatcgccgg gggggattgc ttacgcgacc ggtaaaatga gactcgacga 1740  
gcaacaatac ctcgtatgc ccccgccaccc cccgtatcc accactacca ctgcgcgaa 1800  
cagcgaatgc cgtatcgcatc atgcacgcgaa agcttgggtgg tcgtgggacacatataatgag 1860

WO 02/102999

PCT/AU02/00787

73

ctttgcaca ctcacagcac tcggtgctca atggctttt cctccaggc aacgtcagt 1920  
 ttcttagacgg tccttcaacc atcacaaggc ccgaggagcc ggggacccc agggccagag 1980  
 gtggcacacg ctggtgccgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 5 ggcacatcgag ctggacacga atttctcac gccttaactgta gcgcaaggca ctaataatc 2100  
 gcagcaatac aagttcggca cagcaacata cgccgtaaag gaaccgtaa tgaagagcga 2160  
 ttcatgggca gtggtgccgc tccagtccgt ctggcaactg ggtaacaggc aaaggccata 2220  
 cccgtgggac gtttaactggg ccaacagcac catgtactgg gggtcgcagc cctgaaaagg 2280  
 gggggg 2286

10 <210> 2  
 <211> 216  
 <212> PRT  
 <213> Artificial sequence  
 <220>  
 15 <223> protein sequence of VP2 of pCAU269/7  
 <400> 2

Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala			
1	5	10	15

20 Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
 20 25 30

Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile			
25	35	40	45

Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser		
50	55	60

30 Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
 65 70 75 80

Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn		
85	90	95

35 Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 100 105 110

Asp Arg Ser Thr Gln Ala Ser Leu Glu Ala Ile Leu Arg Pro Leu			
40	115	120	125

Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser		
130	135	140

45 Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 145 150 155 160

Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp	
---	--

WO 02/102999

PCT/AU02/00787

74

165 170 175

Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 180 185 190

5 Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 195 200 205

10 Thr Pro Ala Pro Val Arg Ile Val  
 210 215

&lt;210&gt; 3

&lt;211&gt; 2286

&lt;212&gt; DNA

15 &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; mut C 86 R of Chicken anaemia virus genome

&lt;400&gt; 3

20 ccccccgtga accccccctt ggggggatt ccccccaga ccccccctt ataaaggact 60  
 caataaacgc agctaattcg ttcacccgac aatcgctttc cgagtggta ctattccatc 120  
 accattctag cctgtacaca aaaagtaaag atggacaaat cgctcgactt cgctcgcat 180  
 tcgtcgaagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcgtgta 240  
 caggggggta cgtcatcgat acaggggggg tacgtcacaa gaaggcgatc ccgtacagg 300  
 25 gggtagttaa catgttcagg ggggtacgtc acaaccaatc aggagctgcc acgttgcgaa 360  
 agtgcacgtt cggaaaatggg cggcgcaaga ctccctatat attgcgcgc cataccggc 420  
 ggcagtaggt atacgcagg cggtcgggtt ggtgcacgg aaacggcgaa caaccggccg 480  
 ctggggcag tgaatcgccg cttagccgag agggcaacc tggcccccagc ggagccgcgc 540  
 agggcaagt aatttcaaat gaacgcgtcac caagaagata ctccaccagg accatcaacg 600  
 30 gtgttcaggc caccaacaag ttcaacggcc ttggaaaccc ctcaactgcg agagatccgg 660  
 attggatctcg ctggaattac agtcaactcta tcgctgtgt gctgcgcgaa cgctcgctt 720  
 cccacgctaa gatctgcac acggacaat tcagaaaaaca ctggttcaa gaatgtgcgg 780  
 gacttgagga ccgatcaacc caagcctccc tcgaagaagc gatctgcga cccctccgag 840  
 tacagggtaa gcgagctaaa agaaagctt attaccacta ctcccagccg accccgaacc 900  
 35 gcaagaagggt gtataagact gtaagatggc aagacgagct cgcagaccga gaggccgatt 960  
 ttacgccttc agaagaggac ggtggcacca cctcaagcga ctgcacgaa gatataattt 1020  
 tcgcacatcggtt aggagacagc ggtatcgtag acgagctttt aggaaggctt ttacaaccc 1080  
 cccggccgggtt acgtatagtg tgaggctgcc aaaccccccag tccacgtatc ctatccgctt 1140  
 ccaaggagtc atcttctca ccgaaggact cattctacctt aaaaacagca cagctgggg 1200  
 40 ctatgcggac cacatgtacg gggcgagact cgcacgatc tcagtgcacc tgaaagagtt 1260  
 cctcctagca tcaatgcacc tgacatacgat gagcaagata ggaggccccca tcgcccgtga 1320  
 gttgatttgcg acgggttca aatgcacgc cggggagaac tggccaaattt gctggctgcc 1380  
 gcttagataat aacgtgcctt ccgcacacc atctgcatttggatggg cttaatgtat 1440  
 gatgcggccca acggacttcc gccgggtttt taatcacccctt aagcaaatgc ccctgcaga 1500  
 45 catgggtcgg atgttgggg gctggcatctt gttccgacac attgaaaccc gctttcagct 1560  
 ccttgccact aagaatgagg gatccttcag cccctggcg agtcttcctt cccaggaga 1620  
 gtacctcacg cggcgacg atgttaagta cagcagcgac caccagaacc ggtggcgaaa 1680  
 aggcgagcaa ccgatgacgg gggggattgc ttacgcgacc ggtaaaatgc gactcgacga 1740

WO 02/102999

PCT/AU02/00787

75

gcaacaatac cctgctatgc cccgggaccc cccgatcatc accactacca ctgcgcagg 1800  
 cacgcaagtc cgctgcatga atagcacgca agcttgggg tcgtgggaca catatatgag 1860  
 ctttgcaca ctcacagcac tcgggtctca atggctttt cctccagggc aacgttcagt 1920  
 ttcttagacgg tccttcaacc atacaaggc ccgaggagcc ggggacccc aagggccagag 1980  
 5 gtggcacacg ctggtgccgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcacatcgag ctggcacacga atttttcac gctttacgta gcgcaggca ctaataaatc 2100  
 gcagcaatac aagtccggca cagcaacata cgcgttaag gaaccgtaa tgaagagcga 2160  
 ttcatgggca gtggtgccgc tccagtcgt ctggcaactg ggtaacaggc aaaggccata 2220  
 cccgtgggac gttaactggg ccaacagcac catgtactgg gggtcgcagc cctgaaaagg 2280  
 10 gggggg 2286  
  
 <210> 4  
 <211> 216  
 <212> PRT  
 15 <213> Artificial Sequence  
 <220>  
 <223> mut C 86 R of VP2 of Chicken anaemia virus  
 <400> 4  
  
 20 Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Ser Glu Ser Ala  
 1 5 10 15  
  
 Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
 20 25 30  
 25 Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
 35 40 45  
  
 Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
 30 50 55 60  
  
 Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
 65 70 75 80  
  
 35 Ala Val Trp Leu Arg Glu Arg Ser Arg Ser His Ala Lys Ile Cys Asn  
 85 90 95  
  
 Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 100 105 110  
 40 Asp Arg Ser Thr Gln Ala Ser Leu Glu Glu Ala Ile Leu Arg Pro Leu  
 115 120 125  
  
 Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
 45 130 135 140  
  
 Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 145 150 155 160

WO 02/102999

PCT/AU02/00787

76

Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
 165                170                175

Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 5                180                185                190

Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 195                200                205

10      Thr Pro Ala Pro Val Arg Ile Val  
 210                215

<210> 5  
 <211> 2286  
 15      <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> mut C 95 S of Chicken anaemia virus genome  
 <400> 5

20      cccccccttga accccccccctt gggggggatt ccccccaga ccccccctttt ataaaggactt 60  
 caataaacgc agctaatttc ttacccgcaac aatcgctttc cgagtggta ctattccatc 120  
 accattcttag cctgtacaca aaaagtaaag atggacgaaat cgctcgactt cgctcgcat 180  
 tcgtcgaagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcgtgta 240  
 caggggggttga cgtcatcgat acagggggggg tacgtcacaa gaaggcgatc ccgtacaggg 300

25      gggtagttaa catgttcagg ggggtacgtt cacaaccaatc aggagctgcc acgttgcgaa 360  
 agtgacgtttt cgaaaatggg cggcgcaaga ctccctatat attgcgcgcataaccggc 420  
 ggcagtaggtt atacgcagg cggtccgggtt ggatgcacgg aaacggcgaa caaccggccg 480  
 ctggggcag tgaatcgccg cttagccgag agggcaacc tggcccagc ggagccgcgc 540  
 agggcaagt aatttcaaat gaacgctcac caagaagata ctccaccagg accatcaacg 600

30      gtgttcaggc caccaacaag ttacggccg tttggaaaccc ctcaactgcag agagatccgg 660  
 attggtatcg ctggaattac agtcactcta tcgctgtgtt gtcgcgcgaa tgctcgctt 720  
 cccacgctaa gatcagcaac tgcggacaat tcagaaaaaca ctgggttcaa gaatgtccgg 780  
 gacttgagga ccgatcaacc caaggctccc tcgaagaagc gatctgcga cccctccgag 840  
 tacagggttaa gcgagctaaa agaaagctt attaccacta ctcccagccg accccgaacc 900

35      gcaagaaggtt gtataagact gtaagatggc aagacgagct cgcagaccga gaggccgattt 960  
 ttacgccttc agaagaggac ggtggcacca cctcaagcga ctgcacgaa gatataaattt 1020  
 tcgcacatcgaggaggacagc ggtatcgtag acgagctttt aggaaggccctt tcacaaccc 1080  
 cccggccgggtt acgtatgtt tgaggctgcc aaaccccaag tccacgatga ctatccgctt 1140  
 ccaaggagtc atcttcatacc caaggactt cattctaccc aaaaacagca cagctgggg 1200

40      ctatgcggac cacatgtacg gggcgagatc cgccaaatc tcagtgaacc tgaaagagttt 1260  
 cctcctagea tcaatgaacc tgacatacgat gagcaagata ggaggccca tcgcccgtga 1320  
 gttgattgcg gacgggttca aatcgcaagc cgcggagaac tggccaaattt gctggctgcc 1380  
 gcttagataat aacgtggccctt ccgcctacacc atctgcatttggatggg cttaatgtat 1440  
 gatgcggcca acggacttcc gccgggtttt taatcacccctt aagcaaatga cccctgcaga 1500

45      catgggtcggtt atgtttgggg gtcggcatctt gttccgacac attgaaaccc gctttcagctt 1560  
 ctttgccactt aagaatgagg gatccttcag ccccggtggcg agtcttcctt cccaggggaga 1620  
 gtacccatcg ccccgccgacg atgttaagta cagcagcgac caccagaacc ggtggcgaaa 1680  
 aggcgagcaa ccgatgacgg gggggatgc ttacgcgacc ggtaaaatga gactcgacga 1740

WO 02/102999

PCT/AU02/00787

77

gcaacaatac cctgctatgc cccggaccc cccgatcatc accactacca ctgcgcaagg 1800  
 cacgcaagtc cgctgcatga atagcacgca agcttggtgg tcgtgggaca catatatgag 1860  
 ctttcaaca ctcacagcac tcggtgctca atggtcttt cctccaggc aacgttcagt 1920  
 ttctagacgg tccitcaacc atcacaaggc ccgaggagcc ggggaccca agggccagag 1980  
 5 gtggcacacg ctggtgcgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcacatcagag ctggacacga atttctcac gcittacgta ggcacaggca ctaataaattc 2100  
 gcagcaatac aagttcgca cagcaacata cgcgctaaag gaacctgtaa tgaagagcga 2160  
 ttcatgggca gtggtgcgc tccagtccgt ctggcaactg ggtaacaggc aaaggccata 2220  
 cccgtgggac gtttaactggg ccaacagcac catgtactgg gggtcgcagc cctgaaaagg 2280  
 10 gggggg 2286

<210> 6  
 <211> 216  
 <212> PRT  
 15 <213> Artificial Sequence  
 <220>  
 <223> mut C 95 S of VP2 of Chicken anaemia virus  
 <400> 6

20 Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala  
 1 5 10 15

Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
 20 25 30

25 Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
 35 40 45

Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
 30 50 55 60

Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
 65 70 75 80

35 Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Ser Asn  
 85 90 95

Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 100 105 110

40 Asp Arg Ser Thr Gln Ala Ser Leu Glu Ala Ile Leu Arg Pro Leu  
 115 120 125

Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
 45 130 135 140

Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 145 150 155 160

WO 02/102999

PCT/AU02/00787

78

Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
 165            170            175

5    Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 180            185            190

Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 195            200            205

10    Thr Pro Ala Pro Val Arg Ile Val  
 210            215

<210> 7

15    <211> 2286

<212> DNA

<213> Artificial Sequence

<220>

<223> mut C 97 S of Chicken anaemia virus genome

20    <400> 7

cccccttga acccccccgt ggggggatt ccccccaga ccccccctt ataaagcact 60  
 caataaacgc agctaattcg ttcacccgac aatcgcttc cgagtggta ctattccatc 120  
 accattctag cctgtacaca aaaagtaaag atggacaaat cgctcgactt cgctcgcat 180  
 25    tcgtcgaagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcggtta 240  
 cagggggta cgtcatccgt acaggggggg tacgtcacaa gaaggcggttc ccgtacagg 300  
 gggtaatcgaa catgttcagg ggggtacgtc acaaccatac aggagctgcc acgttgcgaa 360  
 agtgcacgtt cggaaatggg cggcgcaaga ctccctatat attgcgcgca cataccggc 420  
 30    ggcagtaggt atacgcagg cggtccgggt ggtgcacgg aaacggcgga caaccggccg 480  
 ctgggggcag tgaatcgccg cttagccgg agggcaacc tggcccgcc ggagccgcgc 540  
 agggcaagt aatttcaaat gaacgctac caagaagata ctccaccagg accatcaacg 600  
 gtgtcaggc caccaacaag ttacacggcc ttggaaaccc ctcactgcag agagatccgg 660  
 attggatcg ctggaaattac agtcaactta tcgctgtgt gctgcgcga tgctcggtt 720  
 cccacgctaa gatctgcac acggacaaat tcagaaaaca ctggttcaa gaatgtgcgg 780  
 35    gacttgagga ccgatcaacc caagccccc tcgaagaagc gatccgcga cccctccgag 840  
 tacaggtaa gcgagctaaa agaaagctg attaccacta ctcccgccg accccgaacc 900  
 gcaagaaggt gtataagact gtaagatggc aagacgagct cgcagaccga gaggccatt 960  
 ttacgcccgc agaagaggac ggtggccacca ctcacgcga ctgcacgaa gatataaatt 1020  
 tcgacatcg aggagacgc ggtatcgtag acgagcttt aggaaggccct ttacacaaccc 1080  
 40    ccccccgggt acgtatgt tgaggctgcc aaaccccgag tccacgatga ctatccgtt 1140  
 ccaaggagtc atcttctca cccgaaaggact cattctacct aaaaacagca cagctgggg 1200  
 ctatgcggac cacatgtacg gggcgagact cgccaaagatc tcagtgaacc tggaaagagtt 1260  
 ctccttagca tcaatgaacc tgacatactg gagcaagata ggaggccccca tcgcccggta 1320  
 gttgattgcg gacgggtcta aatcgcaacg cccggagaac tggccaaatt gtcggctgcc 1380  
 45    gctagataat aacgtgcctt ccgcctacacc atctgcattt tggagatggg cttaatgtat 1440  
 gatgcagcca acggactctt gccggtttt taatcacctt aagcaaatga ccctgcaga 1500  
 catgggtcgg atgttgggg gtcggcatct ttccgcacac attgaaaccc gcttcagct 1560  
 cttggccact aagaatgagg gatcttcag cccctggcg agtctctt cccagggaga 1620

WO 02/102999

PCT/AU02/00787

79

	gtacctcagc cgccgcgacg atgttaaga cagcagcgac caccagaacc ggtggcgaaaa	1680
	aggcgagcaa ccgatgacgg gggggatgc ttacgcgacc ggtaaaaatga gactcgacga	1740
	gcaacaatac cctgctatgc ccccgaccc cccgatcatc accactacca ctgcgcagg	1800
	cacgcaagtc cgctgcgtga atagcacgcg agcttgggg tcgtgggaca catatatgag	1860
5	ctttgtcaaca ctcacagcac tcgggtctca atggctttt cctccagggc aacgttcagt	1920
	ttcttagacgg tccttcaacc atcacaaggc ccgaggagcc ggggacccc agggccagag	1980
	gtggcacacg ctgggtccgc tcggcacaga gaccataacc gacagctaca tgagagcacc	2040
	ggcatcagag ctggacacga atttcttcac gctttacgt a cgcgaaggca ctaataaaatc	2100
	gcagcaatac aagttcggca cagcaacata cgcgttaaag gaacccgtaa tgaagagcga	2160
10	ttcatgggca gtgggtgcgcg tccagtcgt ctggcaactg ggtaacaggc aaaggccata	2220
	cccggtggac gttaactggg ccaacagcac catgtactgg gggtcgcagc cctgaaaagg	2280
	gggggggg	2286

15            <210> 8  
          <211> 216  
          <212> PRT  
          <213> Artificial Sequence  
          <220>  
          <223> mut C 97 S of VP2 of Chicken anaemia virus  
20            sequence  
          <400> 8

	Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala			
1	5	10	15	
25				
	Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln			
	20	25	30	
30				
	Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile			
	35	40	45	
	Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser			
	50	55	60	
35				
	Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile			
	65	70	75	80
40				
	Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn			
	85	90	95	
45				
	Ser Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu			
	100	105	110	
	Asp Arg Ser Thr Gln Ala Ser Leu Glu Glu Ala Ile Leu Arg Pro Leu			
	115	120	125	
45				
	Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser			
	130	135	140	

WO 02/102999

PCT/AU02/00787

80

Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 145            150            155            160

5    Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
     165            170            175

Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 180            185            190

10    Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
       195            200            205

Thr Pro Ala Pro Val Arg Ile Val  
 15    210            215

<210> 9  
<211> 2286  
<212> DNA  
 20 <213> Artificial Sequence  
<220>  
<223> mut R 101 G of Chicken anaemia virus genome  
<400> 9

25 ccccccgtga accccccccctt gggggggatt ccccccaga cccccccttt ataaagcact 60  
 caataaacgc agctaattcg ttcacccgac aatcgcttc cgagtggta ctattccatc 120  
 accattctag cctgtacaca aaaagtaaag atggacaaat cgctcgactt cgctcgcat 180  
 tcgtcgaagg cggggggccg gaggcccccc gggtggccccc tccaaggagt ggagcgtgta 240  
 caggggggta cgtcatccgt acaggggggg tacgtcacaa gaaggcggtt ccgtacaggg 300  
 30 gggtagtcaa catgttcagg ggggtacgtc acaaccaatc aggagctgcc acgttgcgaa 360  
 agtgacgttt cggaaatggg cggcgcaaga ctccctatat attgcgcgcataaccggc 420  
 ggcagtaggt atacgcaagg cggccgggtt ggtgcacgg aaacggcgga caaccggccg 480  
 ctgggggca gtaatcggcg cttagccgg agggcaacc tggcccgac ggagccgcgc 540  
 agggcaagt aattcaaat gaacgctcac caagaagata ctccaccagg accatcaacg 600  
 35 gtgttcaggc caccaacaag ttacggccg tggaaaccc ctcaactgcag agagatccgg 660  
 attggtagtcg ctggaattac agtcactcta tcgctgttg gctgcgcgaa tgctcgctt 720  
 cccacgtaa gatctgcaac tggacaaat tggaaaaca ctgggttcaa gaatgtgcgg 780  
 gacttgagga cggatcaacc caaggctccc tcgaagaacg gatctgcga cccctccgag 840  
 tacaggtaa gcgagctaaa agaaagctt attaccacta ctcccagccg accccgaacc 900  
 40 gcaagaaggt gtataagact gtaagatggc aagacgagct cgcagaccga gaggccgatt 960  
 ttacgccttc agaagaggac ggtggcacca cctcaagcga ctgcacgaa gatataaatt 1020  
 tcgacatcg aggagacagc ggtatcgtag acgagcttt aggaaggcc ttacaaccc 1080  
 cccggccggt acgtatagt tgaggctgcc aaaccccaag tccacgtga ctatccgctt 1140  
 ccaaggagtc atcttctca cggaaaggact cattctacct aaaaacagca cagctgggg 1200  
 45 ctatgcggac cacatgtacg gggcgagact cgccaaagatc tcaatgttcaacc tggaaagatgtt 1260  
 cctccatca tcaatgttcaacc tgacatactg gagcaagata ggaggccca tcggccgtga 1320  
 gttgattgcg gacgggtctaa atcgtcaacc cggggagaac tggccaaatt gctggctgcc 1380  
 gctagataat aacgtccctt cccgtatcaacc atctgtatgg tggagatggg cttaatgtat 1440

WO 02/102999

PCT/AU02/00787

81

gatgcagcca acggactctt gccggtttt taatcacct aagcaaatga ccctgcaaga 1500  
 catgggtcggt atgtttgggg gctggcatct gttccgacac attgaaaccc gctttcagct 1560  
 ccttgccact aagaatgagg gatccttcag ccccgfgcg agtcttcct cccagggaga 1620  
 5 gtacctcacg cgccgcgacg atgtaagta cagcagcgcac caccagaaccc ggtggcgaaa 1680  
 aggccgagcaa ccgatgcagg gggggattgc ttacgcgacc ggtaaaaatga gactcgacga 1740  
 gcaacaatac cctgcatgc cccccggaccc cccgatcatc accactacca ctgcgcaagg 1800  
 cacgcaagtc cgctgcatacg atagcacca agcttggtgg tcgtgggaca catatatgag 1860  
 ctttgcacaca ctcacagcac tcggtgctca atggctttt cttccaggc aacgttcagt 1920  
 ttcttagacgg tcttcaacc atcacaaggc ccgaggagcc ggggacccc agggccagag 1980  
 10 gtggcacacg ctggtgccgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcacatcagag ctggacacga atttcttcac gctttacgt a ggcacaggca ctaataatc 2100  
 gcagcaatac aagttcggca cagaacata cgcgcataag gaaccctaa tgaagagcga 2160  
 ttcatgggca gtggtgccgc tccagtccgt ctggcaactg ggttaacagggc aaaggccata 2220  
 cccgtgggac gtttaactggg ccaacagcac catgtactgg gggtcgcagc cctgaaaagg 2280  
 15 gggggg 2286

<210> 10  
 <211> 216  
 <212> PRT  
 20 <213> Artificial Sequence  
 <220>  
 <223> mut R 101 G of VP2 of Chicken anaemia virus  
 <400> 10

25 Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala  
 1 5 10 15

Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
 20 25 30

30 Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
 35 40 45

Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
 35 50 55 60

Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
 65 70 75 80

40 Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn  
 85 90 95

Cys Gly Gln Phe Gly Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 100 105 110

45 Asp Arg Ser Thr Gln Ala Ser Leu Glu Ala Ile Leu Arg Pro Leu  
 115 120 125

WO 02/102999

PCT/AU02/00787

82

Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
 130            135            140

Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 5    145            150            155            160

Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
 165            170            175

10    Gly Gly Thr Thr Ser Ser Asp Phe Asp Asp Glu Asp Ile Asn Phe Asp Ile  
 180            185            190

Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 195            200            205

15    Thr Pro Ala Pro Val Arg Ile Val  
 210            215

<210> 11  
 20    <211> 2286  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> mut H 103 Y of Chicken anaemia virus genome  
 25    <400> 11

ccccccTTga accccccccctt gggggggatt ccccccaga ccccccTTt ataaaggactt 60  
 caataaaacgc agctaattcg ttacccgac aatcgTTTC cgagtggta ctattccatc 120  
 accattcttag cctgtacaca aaaagtaaag atggacgaat cgctcgactt cgctcgcgat 180  
 30    tcgtcgaagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcgtgt 240  
 caggggggtt cgtcatccgt acaggggggg tagtcacaa gaaggcggtt ccgtacaggg 300  
 gggtaatcagg ggggtacgtc acaaccaatc aggagctgcc acgttgcgaa 360  
 agtgacgttt cggaaaatggg cggcgcaaga ctccctatat attgcgcga cataccggtc 420  
 ggcagtaggt atacgcaagg cggtccgggt ggatgcacgg aaacggcgga caaccggccg 480  
 35    ctggggcag tgaatggcg citagccgag agggcaacc tggcccagc ggagccgcgc 540  
 agggcaagt aatttcaaattt gaacgcac caagaagata ctccaccagg accatcaacg 600  
 gtgttcaggc caccacaatg ttacacggcc ttggaaaccc ctcaactgcag agagatccgg 660  
 attggtatcg ctggattac agtcaatcta tcgctgtgt gctgcgcga tgctcggtt 720  
 cccacgctaa gatctgcaac tgcggacaat tcagaaaata ctggttcaa gaatgtgcgg 780  
 40    gacttgagga ccgatcaacc caagcctccc tcgaagaagc gatctgcga cccctccgag 840  
 tacaggtaa gcgagctaa agaaagctt attaccacta ctcccaagccg accccgaacc 900  
 gcaagaaggt gtataagact gtaagatggc aagacgagct cgcagaccga gaggccgatt 960  
 ttacgccttc agaagaggac ggtggcacca cctcaagcga ctgcacgaa gatataattt 1020  
 tcgacatcgaggagac ggtatcgtag acgagctttt aggaaggcc ttacacaaccc 1080  
 45    cccggccgggt acgtatagt tgaggctgcc aaaccccaag tccacatgtatc ctatccgctt 1140  
 ccaaggagtc atctttctca ccgaaggact cattctacct aaaaacagca cagctgggg 1200  
 ctatgcggac cacatgtacg gggcgagact cgccaaatc tcagtgaacc tgaaagagtt 1260  
 ctccctagca tcaatgaacc tgacatacg tgcatacgat ggcggccca tcgcccgtga 1320

WO 02/102999

PCT/AU02/00787

83

gttgattgcg gacgggtcta aatcgcaagc cgccggagaac tggccaaatt gctggctgcc 1380  
 gctagataat aacgtgcctt ccgcgtacacc atctgcatgg tggagatggg cttaatgat 1440  
 gatgcagcca acggactctt gcccggtttt taatcacccct aagcaaatga ccctgcaaga 1500  
 catgggtcgg atgtttgggg gctggcatct gtccgacac atgaaaccc gccttcagct 1560  
 5 ccttgccact aagaatgagg gatccitcag ccccggtggcg agtcttcctt cccagggaga 1620  
 gtacctcagc cgccgcgacg atgttaagta cagcagcgac caccagaacc gggtggcgaaa 1680  
 aggcgagcaa ccgcgtacgg gggggattgc ttacgcgacc ggttaaatga gactcgacga 1740  
 gcaacaatac cctgcgtatgc ccccgaccc cccgatcatc accactacca ctgcgcaagg 1800  
 cacgcaagtc cgctgcgtatga atagcagca agcttgggg tcgtgggaca catatatgag 1860  
 10 ctttgcaaca ctcacagcac tcgggtctca atggctttt cctccagggc aacgttcagt 1920  
 ttcttagacgg tccctcaacc atcacaaggc ccgaggagcc ggggacccca agggccagag 1980  
 gtggcacacg ctgggtccgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcacatcagag ctggacacga atttcttcac gctttacgta ggcacaggca ctaataaatac 2100  
 gcaacatac aagttcggca cagcaacata cgcgtaaag gaaccgtaa tgaagagcga 2160  
 15 ttcatggca gttactggg ccaacagcac catgtactgg gggtcgcgc cctgaaaagg 2220  
 cccgtgggac gttactggg ccaacagcac catgtactgg gggtcgcgc cctgaaaagg 2280  
 ggggggg 2286

<210> 12  
 20 <211> 216  
 <212> PRT  
 <213> Artificial Sequence  
 <220>  
 <223> mut H 103 Y of VP2 of Chicken anaemia virus  
 25 <400> 12

Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala  
 1 5 10 15

30 Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
 20 25 30

Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
 35 40 45

35 Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
 50 55 60

40 Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
 65 70 75 80

Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn  
 85 90 95

45 Cys Gly Gln Phe Arg Lys Tyr Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 100 105 110

WO 02/102999

PCT/AU02/00787

84

Asp Arg Ser Thr Gln Ala Ser Leu Glu Glu Ala Ile Leu Arg Pro Leu  
 115                120                125

Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
 5                130                135                140

Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 145                150                155                160

10 Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
 165                170                175

Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 180                185                190

15 Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 195                200                205

Thr Pro Ala Pro Val Arg Ile Val  
 20                210                215

<210> 13  
 <211> 2286  
 <212> DNA  
 25 <213> artificial sequence  
 <220>  
 <223> mut R 129 G of Chicken anaemia virus genome  
 <400> 13

30 ccccccgtga accccccccct gggggggatt ccccccaga ccccccgtt ataaagcact 60  
 caataaacgc agctaattcg ttcaccgac aatcgcttc cgagtggta ctattccatc 120  
 accattcttag cctgtacaca aaaagtaaag atggacgaat cgctcgactt cgctcgcgtat 180  
 tcgtcgaagg cggggggcccg gaggcccccc ggtggccccc tccaaggagt ggagcgtgtat 240  
 caggggggtta cgtcatccgt acaggggggg tacgtcacaa gaaggcgatc ccgtacaggg 300  
 35 gggtagtcaa catgttcagg ggggtacgtc acaaccaatc aggagctgcc acgttgcgaa 360  
 agtgacgttt cgaaaatggg cggcgcaga ctccttat attgcgcgc cataccggtc 420  
 ggcagtaggt atacgcaagg cggccgggtt ggatgcacgg aaacggcggaa caaccggccg 480  
 ctggggccag tgaatcgccgctt ctagccgat aggggcaacc tggcccgccg ggagccgcgc 540  
 aggggcaagt aatttcaaat gaacgctcac caagaagata ctccaccagg accatcaacg 600  
 40 gtgttcaggc caccaacaag ttacggccg ttggaaaccc ctcaactgcag agagatccgg 660  
 attggtagtgc ctggattac agtcaactcta tcgctgtgt gctgcgcgaa tgctcgcgtt 720  
 cccacgctaa gatctgcaac tgcggacaat tcagaaaaca ctggttcaa gaatgtggccg 780  
 gacttgagga ccgatcaacc caagccccc tcgaagaagc gatctgcga ccctcggag 840  
 tacaggtaa gcgagactaa agaaagcttg attaccacta ctcccgccg accccgaacc 900  
 45 gcaagaagggt gtataagact gtaagatggc aagacgagct cgcagaccga gaggccgatt 960  
 ttacgccttc agaagaggac ggtggccacca cctcaagcga ctgcacgaa gatataaattt 1020  
 tcgacatcgaggagacagc ggtatcgtag acgagctttt aggaaggccctt ttcacaaccc 1080  
 ccggcccggt acgtatagtg tgaggctgcc aaaccccgag tccacatgcgatgaaatccgcgtt 1140

WO 02/102999

PCT/AU02/00787

85

ccaaggagtc atcttctca ccgaaggact cattcacct aaaaacagca cagctggggg 1200  
 ctatcgccac cacatgtac gggcgagagt cgccaagatc tcagtgaacc taaaaagagtt 1260  
 ctccttagca tcaatgaacc tgacatacgat gagcaagata ggaggccccca tcggcggtga 1320  
 gtgtgattgcg gacgggtcta aatcgcaagc cgccggagaac tggccaaattt gctggcgcc 1380  
 5 gctagataat aacgtgccct ccgtacaccatctgcatgg tggagatggg cttaatgtat 1440  
 gatgcagcca acggactctt gcccggtttt taatcaccct aagcaaatga ccctgcaaga 1500  
 catgggtcgg atgtttgggg gctggcatct gttccgacac attgaacccc gctttcagct 1560  
 ctttgccact aagaatgagg gatccttcag ccccggtggcg agtcttctct cccagggaga 1620  
 gtacctcacg cgccgcgacg atgttaagta cagcagcgac caccagaacc ggtggcgaaa 1680  
 10 aggccgagcaa ccgtatgcggggatgc ttacgcgacc ggtaaaatga gactcgacga 1740  
 gcaacaataccctgctatgc ccccgacccccc gccgatcatc accactacca ctgcgcaagg 1800  
 cacgcaagtc cgctgcatga atagcacca agcttggtgg tctgtggaca catatatgag 1860  
 ctttgcacaactcacagcac tcggtgctca atggctttt cttccaggc aacgttcagt 1920  
 ttctagacgg tccctcaacc atcacaaggcccgaggagcc ggggacccca agggccagag 1980  
 15 gtggcacacg ctgggtccgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcacatcagag ctggacacga atttttcac gctttacgta ggcgcaaggca ctaataaattc 2100  
 gcagcaataac aagttcggca cagcaacata cgcgcataaag gaaccctaa tgaagagcga 2160  
 ttcatggca gtggcgcgc tccagtccgt ctggcaactg ggtaacaggc aaaggccata 2220  
 cccgtgggac gttaactggg ccaacagcac catgtactgg gggtcgcgc cctgaaaagg 2280  
 20 gggggg 2286

<210> 14  
 <211> 216  
 <212> PRT  
 25 <213> Artificial Sequence  
 <220>  
 <223> mut R129 G of VP2 of Chicken anaemia virus  
 <400> 14

30 Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala  
 1 5 10 15

Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
 20 25 30

35 Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
 35 40 45

Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
 40 50 55 60

Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
 65 70 75 80

45 Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn  
 85 90 95

WO 02/102999

PCT/AU02/00787

86

Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 100            105            110

Asp Arg Ser Thr Gln Ala Ser Leu Glu Glu Ala Ile Leu Arg Pro Leu  
 5            115            120            125

Gly Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
 130            135            140

10 Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 145            150            155            160

Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
 15            165            170            175

Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 180            185            190

20 Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 195            200            205

Thr Pro Ala Pro Val Arg Ile Val  
 210            215

25 <210> 15  
 <211> 2286  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 30 <223> mut Q 131 P of Chicken anaemia virus genome  
 <400> 15

cccccccttga accccccccctt gggggggatt ccccccaga ccccccctt ataaagcact 60  
 caataaacgc agctaattcg ttcacccgac aatcgcttc cgagtggta ctatccatc 120  
 35 accattctag cctgtacaca aaaagtaaag atggacgaat cgctcgactt cgctcgcat 180  
 tcgtcgaagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcgtgta 240  
 caggggggtta cgtcatccgt acaggggggg tacgtcacaa gaaggcggtc ccgtacaggg 300  
 gggtacgtaa catgttcaagg gggtacgta cacaaccatc aggacgtgcc acgttgcgaa 360  
 agtgacgttt cggaaaatggg cggcgcaaga ctccctatat attgcgcgca cataccggtc 420  
 40 ggcagtaggt atacgcaagg cggtccgggt ggatgcacgg aaacggcgga caaccggccg 480  
 ctggggcag tgaatcgccg cttagccgag agggcaacc tggcccgac ggagccgcgc 540  
 agggcaagt aatttcaaat gaacgctcac caagaagata ctccaccagg accatcaacg 600  
 gtgttcaggc caccaacaag ttacacggccg ttggaaaccc ctcactgcag agagatccgg 660  
 attggatcg ctggaattac agtcaactcta tcgctgtgtg gctgcgcgaa tgctcgcgtt 720  
 45 cccacgctaa gatctgcaac tgccggacaat tcagaaaaca ctggttcaaa gaatgtgcgg 780  
 gacttgagga ccgatcaacc caagcctccc tcgaagaagc gatcctgcga cccctccgag 840  
 taccggtaa gcgagctaaa agaaagcttg attaccacta ctcccgccg accccgaacc 900  
 gcaagaagggt gtataagact gtaagatggc aagacgagct cgcagaccga gaggccgatt 960

WO 02/102999

PCT/AU02/00787

87

ttacgccttc agaagaggac ggtggcacca cctcaagcga ctgcgaccaa gatataaatt 1020  
 tcgacatcg aggagacagc ggtatcttag acgagctttt aggaaggcct ttcacaaccc 1080  
 ccgcggccgt acgtatagt tgaggctgcc aaacccccag tccacatga ctatccgctt 1140  
 ccaaggagtc atcttctca ccgaaggact cattctactt aaaaacagca cagctgggg 1200  
 5 ctatcgccgac cacatgtacg gggcgagagt cgccaagatc tcagtgaacc taaaagagt 1260  
 ctccttagca tcaatgaacc tgacatacg tggcaagata ggaggccca tcgcccgtga 1320  
 gtgtgattgcg gacgggtcta aatcgcaagc cgcggagaac tggccaaatt gctggctgcc 1380  
 gctagataat aacgtccct ccgctacacc atctgcattt tggagatggg cttaatgat 1440  
 gatgcagcca acggactctt gccgggtttt taatcacctt aagcaaatga ccctgcaaga 1500  
 10 catgggtcgg atgttgggg gctggcatct gtccgacac atgaaaccc gcittcagct 1560  
 ccttgccact aagaatgagg gatccttcacg cccctgtggcg agtcttcctt cccaggggaga 1620  
 gtacctacg cggccgcacg atgttaagta cagcagcgac caccagaacc ggtggcgaaa 1680  
 aggcgagcaa ccgatgacgg gggggattgc ttacgcgacc ggtaaaatga gactcgacga 1740  
 gcaacaatac cctgctatgc cccggaccc cccgatcatc accactacca ctgcgcaagg 1800  
 15 cacgcaagtc cgctgcatac atagcactca agcttggtgg tcgtgggaca catatatgag 1860  
 cttagacaca ctcacagcac tcgggtctca atggctttt cctccaggcc aacgttcag 1920  
 ttcttagacgg tccttcaacc atcacaaggc ccgaggagcc ggggacccca agggccagag 1980  
 gtggcacacg ctgggtccgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcacatcagag ctggacacga atttcttcac gctttacgta ggcacaggca ctaataaattc 2100  
 20 gcacaaatac aagttcggca cagcaacata cgcgtaaag gaacctgtaa tgaagagcga 2160  
 ttcatggca gtggtgccgc tccagtcgt ctggcaactg ggtacaggc aaaggccata 2220  
 cccgtgggac gttaaactggg ccaacagcac catgtactgg gggtegcagc cctgaaaagg 2280  
 ggggg 2286

25 &lt;210&gt; 16

&lt;211&gt; 216

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

30 <223> mut Q 131 P of VP2 of Chicken anaemia virus  
<400> 16

Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala

1 5 10 15

35

Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
20 25 30

40

Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
35 40 45Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
50 55 60

45

Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
65 70 75 80

WO 02/102999

PCT/AU02/00787

88

Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn  
 85            90            95

Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 5            100            105            110

Asp Arg Ser Thr Gln Ala Ser Leu Glu Glu Ala Ile Leu Arg Pro Leu  
 115            120            125

10 Arg Val Pro Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
 130            135            140

Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 145            150            155            160

15 Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
 165            170            175

Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 20            180            185            190

Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 195            200            205

25 Thr Pro Ala Pro Val Arg Ile Val  
 210            215

<210> 17  
 <211> 2286  
 30 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> mut R/K/K 150/151/152 G/A/A of Chicken anaemia virus genome  
 <400> 17

35 ccccccgtga accccccccct gggggggatt ccccccaga ccccccctt ataaagcact 60  
 caataaacgc agctaattcg ttacccgcac aatcgcttc cgagtggta ctattccatc 120  
 accattctag cctgtacaca aaaagtaaag atggacgaat cgctcgactt cgctcgcat 180  
 tcgtcgaagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcgtgta 240  
 40 cagggggta cgtcatccgt acaggggggg tacgtcacaa gaaggcggtc ccgtacagg 300  
 gggtagtcaa catgttcagg ggggtacgtc acaaccaatc aggagctgcc acgttgcgaa 360  
 agtgacgtt cgaaaatggg cggcgcaga cttccctatat attgcgcgca cataccggc 420  
 ggcagtaggt atacgcaagg cggtccgggt ggatgcacgg aaacggcggaa caaccggccg 480  
 ctggggcag tgaatcggcg cttagccgag agggcaacc tggcccgcc ggagccgcgc 540  
 45 agggcaagt aatttcaaat gaacgtcac caagaagata ctccaccagg accatcaacg 600  
 gtgttcaggc caccaacaag ttacggccg ttggaaaccc ctcactgcag agagatccgg 660  
 attggtatcg ctggattac agtactcta tcgctgtgt gctgcgcgaa tgctcgctt 720  
 cccacgctaa gatctgcaac tgcggacaat tcagaaaaca ctggttcaa gaatgtgccc 780

WO 02/102999

PCT/AU02/00787

89

gacttgagga ccgatcaacc caaggctccc tcgaagaagc gatccctgcga cccctccgag 840  
 tacagggtaa gcgagactaa agaaagctt attaccacta ctccccggc accccgaacg 900  
 gcgccggcggt gtataagact gtaagatggc aagacgagct cgccagaccga gaggccgatt 960  
 ttacgccc ttaaagaggac ggtggcacca cctcaagcga cttcgacgaa gatataaatt 1020  
 5 tcgacatcg aggagacagc ggtatcgtag acgagctttt aggaaggcc ttcacaaccc 1080  
 ccggcccggt acgtatagtg tgaggctgcc aaacccccc tccacatga ctatccgctt 1140  
 ccaaggagtc atcttctca ccgaaggact cattctacct aaaaacagca cagctgggg 1200  
 ctatgcggac cacatgtacg gggcgagagt cgccaagatc tcagtgaacc tgaaagagtt 1260  
 cctcctagca tcaatgaacc tgacatacg tggcaagata ggaggccca tcgcccgtga 1320  
 10 gttgattgcg gacgggtcta aatcgcaagc cgcggagaac tggccaaatt gctggctgcc 1380  
 gctagataat aacgtgccct ccgcctacacc atctgcatttgg tggagatggg ctttaatgtat 1440  
 gatgcagcca acggactctt gccgggtttt taatcacctt aagcaaatga ccctgcaaga 1500  
 catgggtcgg atgtttgggg gctggcatct gtccgacac attgaaaccc gctttcagct 1560  
 ccttgcact aagaatgagg gatccctcag cccctggcg agtcttctt cccaggggaga 1620  
 15 gtacctcacg cgcgcgacg atgttaagta cagcagcgac caccagaacc gttggcgaaa 1680  
 agggcagcaa ccgcgcacgg gggggattgc ttacgcgacc ggtttaaatga gactcgacga 1740  
 gcaacaatac ctcgcctatgc cccggaccc cccgcatacc accactacca ctgcgcaagg 1800  
 cacgcaagtc cgtgcacatgca atagcacgca agcttgggg tcgtgggaca catatatgag 1860  
 ctgttgcaca ctcacagcac tcgggtctca atggctttt cttccaggcc aacgttcagt 1920  
 20 ttcttagacgg tccttcaacc atcacaaggc ccgaggagcc gggggccca agggccagag 1980  
 gtggcacacg ctgggtccgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcacatcagag ctggcacacgaa atttcttcac gctttacgtt ggcacaggca ctaataaatac 2100  
 gcaacatac aagttcggca cagcaacata cgcgttaaag gaacccgtaa tgaagagcga 2160  
 ttcatgggcac gtgggtccgc tccagtcgt ctggcaactg ggttacaggc aaaggccata 2220  
 25 cccgtgggac gttactggg ccaacagcac catgtactgg gggtcgcagc cctgaaaagg 2280  
 gggggg 2286

&lt;210&gt; 18

&lt;211&gt; 216

30 &lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; mut R/K/K of VP2 of Chicken anaemia virus

&lt;400&gt; 18

35 Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Ser Glu Ser Ala  
 1 5 10 15

Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
 40 20 25 30

Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
 35 40 45

45 Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
 50 55 60

WO 02/102999

PCT/AU02/00787

90

Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
 65            70            75            80

Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn  
 5                85            90            95

Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 100            105            110

10 Asp Arg Ser Thr Gln Ala Ser Leu Glu Glu Ala Ile Leu Arg Pro Leu  
 115            120            125

Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
 130            135            140

15 Gln Pro Thr Pro Asn Gly Ala Ala Val Tyr Lys Thr Val Arg Trp Gln  
 145            150            155            160

Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
 20                165            170            175

Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 180            185            190

25 Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 195            200            205

Thr Pro Ala Pro Val Arg Ile Val  
 210            215

30 <210> 19  
 <211> 2286  
 <212> DNA  
 <213> Artificial Sequence

35 <220>  
 <223> mut D/E 161/162 G/G of Chicken anaemia virus genome  
 <400> 19

ccccccttga accccccccct gggggggatt cccccccaga ccccccttt ataaagcact 60  
 40 caataaacgc agctaattcg ttcacccgac aatcgcttc cgagtggta ctattccatc 120  
 accattcttag cctgtacaca aaaagtaaag atggacgaaat cgctcgaact cgctcgcgt 180  
 tcgtcgaagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcgtgta 240  
 caggggggta cgtcatccgt acaggggggg tacgtcacaa gaaggcggtc ccgtacaggg 300  
 gggtaatcgaa catgttcagg gggtaatgc acaaccaatc aggacgtgcc acgttgcgaa 360  
 45 agtgacgtt cggaaatggg cggcgcaaga ctccctatat attgcgcgc cataccggc 420  
 ggcagtaggt atacgcaagg cggtccgggt ggatgcacgg aaacggcgga caaccggccg 480  
 ctggggcag tgaatggcg cttagccgag agggcaacc tggcccgac ggagccgcgc 540  
 agggcaagt aatttcaaat gaacgctcac caagaagata ctccaccagg accatcaacg 600

WO 02/102999

PCT/AU02/00787

91

gtgtcaggc caccacaac 660  
 attggatcg ctggattac agtcactta tcgctgtgt gctgcgcaa tgctcgctt 720  
 cccacgctaa gatctcaac tgcggacaat tcagaaaaca ctggttcaa gaatgtgcg 780  
 gacttgagga ccgatcaacc caagccccc tcgaagaagc gatccctgca cccctccgag 840  
 5 tacagggtaa gcgagctaa agaaagcttg attaccata ctcccgcc accccgaacc 900  
 gcaagaagggt gtataagact gtaagatggc aaggccccct cgccgaccga gaggccgatt 960  
 ttacgccttc agaagaggac ggtggcacca cctcaagcga ctgcacgaa gatataaatt 1020  
 tcgcacatcgg aggagacagc ggtatcgtag acgagctttt aggaaggctt ttcacaaccc 1080  
 10 cccggccgt acgtatgt tgaggctgcc aaacccca tccacgatga ctatccgtt 1140  
 ccaaggagtc atcttcctca ccgaaggact cattctacct aaaaacagca cagctgggg 1200  
 ctatgcggac cacatgtacg gggcgagagt cgccaaagatc tcagtgaacc tgaaagagtt 1260  
 cctcctagca tcaatgaacc tgacatacg gagcaagata ggaggccccca tcggcggta 1320  
 gttgattgcg gacgggtcta aatgcgaacg cgccggaaac tggccaaatt gctggctgcc 1380  
 gctagataat aacgtccct ccgtacacc atctgcatgg tggagatggg cttaatgat 1440  
 15 gatgcagcca acggactcct gcccgtttt taatcacct aagcaaatga cccctgcaaga 1500  
 catgggtcgg atgtttgggg gctggcatct gttccgacac attgaaaccc gctttcagct 1560  
 ccttgcact aagaatgagg gatcctcag cccctggcg agtcttcctcccaggaga 1620  
 gtacctcacg cgccgcgacg atgttaagta cagcagcgac caccagaacc ggtggcggaa 1680  
 20 aggcgagcaa ccgtatgcg gggggattgc ttacgcgacc ggtttaaatga gactcgcgac 1740  
 gcaacaatac cctgtatgc cccggaccc cccgatcatc accactacca ctgcgcaagg 1800  
 cagcgaagtc cgctgcatac atagcgcac agcttgtgg tcgtggacatacatatgag 1860  
 ctgtcaaca ctcacagcac tcggatctca atggctttt cttccaggc aacgttcagt 1920  
 ttcttagacgg tccttcaacc atcacaaggc ccgaggagcc ggggacccca agggccagag 1980  
 25 gggcacaacg ctggatccgc tcggacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcatacagcg ctggacacga atttctcac gctttacgt ggcgcaaggca ctaataaatac 2100  
 gcaatac aagtgcgca cagcaacata cgccgtaaag gaaccgtaa tgaagagcga 2160  
 ttcatggca gtggatccgc tccagttcgatc ctggcaatcg ggttacaggc aaaggccata 2220  
 cccgtggac gtttaactggg ccaacagcac catgtactgg gggatcgacg cctggaaaagg 2280  
 ggggg 2286  
 30 <210> 20  
 <211> 216  
 <212> PRT  
 <213> Artificial Sequence  
 35 <220>  
 <223> mut D/E 161/162 G/G of VP2 of Chicken anaemia virus  
 <400> 20  
 Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala  
 40 1 5 10 15  
 Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
 20 25 30  
 45 Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
 35 40 45

WO 02/102999

PCT/AU02/00787

92

Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
 50            55            60

Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
 5     65        70        75        80

Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn  
 85            90            95

10    Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 100          105          110

Asp Arg Ser Thr Gln Ala Ser Leu Glu Glu Ala Ile Leu Arg Pro Leu  
 115          120          125

15    Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
 130          135          140

20    Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 145          150          155          160

Gly Gly Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
 165          170          175

25    Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 180          185          190

Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 195          200          205

30    Thr Pro Ala Pro Val Arg Ile Val  
 210          215

<210> 21  
 35    <211> 2286  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> mut L 163 P of Chicken anaemia virus genome  
 40    <400> 21

ccccccttga acccccccgtt gggggggatt ccccccaga ccccccgtt ataaagcact 60  
 caataaacgc agctaattcg ttacccgcac aatcgcttc cgagtggta ctattccatc 120  
 accattcttag cctgtacaca aaaagtaaaag atggacgaaat cgctcgactt cgctcgcat 180  
 45    tgcgtcaagg cggggggcgtt gaggcccccc ggtggccccc tccaaggagt ggagcggtta 240  
 caggggggtt cgtcatccgtt acaggggggg tacgtcacaa gaaggcggtt ccgtacaggg 300  
 gggtacgtaa catgttcagg ggggtacgtt acaaccaatc aggagctgcc acgttgccaa 360  
 atgtacgtttt cggaaatggg cggcgtcaaga ctccctatat attgccgcataccgggtt 420

WO 02/102999

PCT/AU02/00787

93

ggcagtaggt atacgcaagg cggccgggt ggatgcacgg aaacggcgga caaccggccg 480  
 ctggggcag tgaatcgccg cttagccgag agggcaacc tggcccccagc ggagccgcgc 540  
 agggcaagt aatttcaaat gaacgctcac caagaagata ctccaccagg accatcaacg 600  
 gtgtcaggg caccaacaag ttacggcc tggaaaccc ctactcgag agagatccgg 660  
 5 attggtatcg ctggattac agtcactcta tcgctgttg gctgcgcgaa tgctcgctt 720  
 cccacgctaa gatctcaac tgcggacaat tcagaaaaca ctggttcaa gaatgtccg 780  
 gacttgagga ccgatcaacc caagccccc tcgaagaagc gatctcgca cccctccgag 840  
 tacagggtaa gcgagctaaa agaaaagctt attaccacta ctcccagccg accccgaacc 900  
 gcaagaaggt gtataagact gtaagatggc aagacgagcc cgccgacccgaa gaggccgatt 960  
 10 ttacgccttc agaagaggac ggtggcacca cctcaagcga ctgcacgaa gatataaatt 1020  
 tcgacatcg aggagacagc ggtatcgtag acgagctttt aggaaggccctt tcacaaccc 1080  
 cccggccggt acgtatgt tgaggctgcc aaaccccccag tccacgtatgat ctatccgtt 1140  
 ccaaggagtc atcttctca ccgaaggact cattctacct aaaaacagca cagctgggg 1200  
 ctatcgccgac cacatgtacg gggcgagagt cgccaaagatc tcagtgaacc taaaagagtt 1260  
 15 cctcctagca tcaatgaacc tgacatacgt gagcaagata ggaggccca tcgcccgtga 1320  
 gttgattgcg gacgggtcta aatcgcaagc cgccggagaac tggccaaatt gctggctgcc 1380  
 gctagataat aacgtgcctt ccgtacacc atctgcattt tggagatggg cttaatgat 1440  
 gatcgagcca acggactctt gccgggtttt taatcacccctt aagcaaatga cccctgcaaga 1500  
 catgggtcgg atgttgggg gctggcatctt gttccgacac attgaaaccc gctttcagct 1560  
 20 ccttgcctact aagaatgagg gatccttcag ccccggtggcg agtcttcctt cccagggaga 1620  
 gtacctcagc cgccgcgacg atgttaatgatc cagcagccgac caccagaacc ggtggcgaaa 1680  
 aggcgagcaa ccgtatgcgg gggggattgc ttacgcgacc ggtaaaatgatc gactcgacga 1740  
 gcaacaatac cctgtatgc ccccgaccc cccgatcatc accactacca ctgcgcaagg 1800  
 cacgcaagtc cgctgcatac atagcactca agcttgtgg tcgtggacca catatatgag 1860  
 25 ctttgcacca ctcacagcac tcggctca atggctttt ctcaggccg aacgttcagt 1920  
 ttctagacgg tccitcaacc atcacaaggc ccgaggagcc ggggacccca agggccagag 1980  
 gtggcacacg ctggccgc tggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcacatcggatc ctggacacga atttcttcac gctttacgtt ggcacaggca ctaataatc 2100  
 gcaacaatac aagttcggca cagcaacata cgcgttaaaag gaaccgtaa tgaagagcga 2160  
 30 ttcatgggca gtggtgcgcg tccagtttctt ctggcaactg ggttaacaggc aaaggccata 2220  
 cccgtggac gtttaactggg ccaacagcac catgtactgg gggtcgcagc cctgaaaagg 2280  
 gggggg 2286

&lt;210&gt; 22

35 &lt;211&gt; 216

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; mut L 163 P of VP2 of Chicken anaemia virus

40 &lt;400&gt; 22

Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala  
 1 5 10 15

45 Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
 20 25 30

WO 02/102999

PCT/AU02/00787

94

Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
 35            40            45

Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
 5        50        55        60

Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
 65        70        75        80

10 Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn  
 85        90        95

Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 100      105      110

15 Asp Arg Ser Thr Gln Ala Ser Leu Glu Ala Ile Leu Arg Pro Leu  
 115      120      125

Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
 20        130      135      140

Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 145      150      155      160

25 Asp Glu Pro Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
 165      170      175

Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 180      185      190

30 Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 195      200      205

Thr Pro Ala Pro Val Arg Ile Val  
 35        210      215

<210> 23  
 <211> 2286  
 <212> DNA  
 40 <213> Artificial Sequence  
 <220>  
 <223> mut D 169 G of Chicken anaemia virus genome  
 <400> 23

45 ccccccttga acccccccattt gggggggattt ccccccaga ccccccattt ataaaagcactt 60  
 caataaacgc agctaattcg ttacccgcac aatcgctttc cgagtggta ctattccatc 120  
 accattcttag cctgtacaca aaaagtaaag atggacaaat cgctcgactt cgctcgcat 180  
 tcgtcgaagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcggtta 240

WO 02/102999

PCT/AU02/00787

95

caggggggta cgcatccgt acaggggggg tacgtcacaa gaaggcgltc ccgtacaggg 300  
 ggttacgtaa catgttcagg ggggtacgtc acaaccaatc aggagctgcc acgttgcgaa 360  
 agtacgttt cggaaatggg cggcgcaaga ctccctatat attgcgcga cataccggtc 420  
 ggcagttaggt atacgcaagg cggtccgggt ggtatgcacgg aaacggcgaa caaccggccg 480  
 5 ctggggcag tgaatcgccg citagccag aggcccacc tggtcccgcc ggagccgcgc 540  
 aggggcaagt aatttcaaat gaacgctac caagaagata ctccaccagg accatcaacg 600  
 gtgttcaggc caccaacaag itcacggcc ttggaaaccc ctactgcag agagatccgg 660  
 attggatcgtc ctggaaattac agtcaactta tcgtgttg gctgcgcga tgctgcgtt 720  
 cccacgtaa gatctcaac tgcggacaat tcagaaaaca ctgggttcaa gaatgtgcgg 780  
 10 gacttgagga ccgatcaacc caagccccc tcgaagaagc gatccgcga cccctccgag 840  
 tacagggtaa gcgagctaaa agaaaaggctt attaccacta ctcccgcc accccgaacc 900  
 gcaagaaggt gtataagact gtaagatggc aagacgacgt cgcagaccga gaggccgggt 960  
 ttacgcccitc agaagaggac ggtggcacca cctcaagcga ctgcacgaa gatataaatt 1020  
 tcgacatcgg aggagacagc ggtatcgtag acgagctttt aggaaggcc ttacaaccc 1080  
 15 ccccccgggt acgtatgt tgaggctgc aaaccccgat tccacgatca ctatccgtt 1140  
 ccaaggagtc atcttctca ccgaaggact cattctacct aaaaacagca cagctgggg 1200  
 ctatgcggac cacatgtacg gggcgagagt cgccaagatc tcagtgaacc taaaagagtt 1260  
 cctcctagca tcaatgaacc tgacatacgt gagcaagata ggaggcccc tcggccgiga 1320  
 gttgattgctgacggggtcta aatcgcacgc cgccggagaac tggccaaatt gctggctgcc 1380  
 20 gctagataat aacgtgccct ccgtacacc atctgcattt tggagatggg cttaatgt 1440  
 gatgcagcca acggactctt gcccggtttt taatcacctt aagcaaatga ccctgcaga 1500  
 catgggtcgg atgttgggg gctggcatctt gttccgacac attgaaaccc gctttagt 1560  
 ccttgccact aagaatgagg gatccttcag cccctggcg agtcttcctt cccaggggaga 1620  
 gtacctcacg cgccgcacg atgtaagta cagcagcgac caccagaacc ggtggcgaaa 1680  
 25 aggcgagcaa ccgtatgcgg gggggattgc ttacgcgacc gttaaaatga gactcgacga 1740  
 gcaacaatac cctgtatgc ccccgaccc cccgatcatc accactacca ctgcgcagg 1800  
 cacgcacgtc cgtgcataatgcacgc a gcttgggtgg tcgtggaca catatatgag 1860  
 ctgtcaaca ctcacagcac tcggatctca atggctttt cttccaggcc aacgttcagt 1920  
 ttctagacgg tccttcaacc atcacaaggc ccggaggacc ggggaccacc agggccagag 1980  
 30 gtggcacacgc ctggatccgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcacatcgatc ctggacacgc atttctcac gctttagtgc ggcacaggca ctaataaattc 2100  
 gcaacatac aagttcgca cagcaacata cgcgcataag gaacccgtaa tgaagagcga 2160  
 ttcatggca gtggatccgc tccagtcgt ctggcaactg gtaacaggc aaaggccata 2220  
 cccgtggac gtaactggg ccaacagcac catgtactgg gggatccgcgc cctgaaaagg 2280  
 35 gggggg 2286

<210> 24  
 <211> 216  
 <212> PRT  
 40 <213> Artificial Sequence  
 <220>  
 <223> mut D 169 G of VP2 of Chicken anaemia virus  
 <400> 24

45 Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala  
 1 5 10 15

WO 02/102999

PCT/AU02/00787

96

Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
 20            25            30

Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
 5            35            40            45

Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
 50            55            60

10 Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
 65            70            75            80

Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn  
 85            90            95

15 Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
 100            105            110

Asp Arg Ser Thr Gln Ala Ser Leu Glu Ala Ile Leu Arg Pro Leu  
 20            115            120            125

Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
 130            135            140

25 Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
 145            150            155            160

Asp Glu Leu Ala Asp Arg Glu Ala Gly Phe Thr Pro Ser Glu Glu Asp  
 165            170            175

30 Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
 180            185            190

Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
 35            195            200            205

Thr Pro Ala Pro Val Arg Ile Val  
 210            215

40 <210> 25  
 <211> 2286  
 <212> DNA  
 <213> Artificial Sequence  
 <220>

45 <223> mut K 102 E of Chicken anaemia virus genome  
 <400> 25

ccccccctga accccccccc gggggggatt cccccccaga cccccccctt ataaagcact 60

WO 02/102999

PCT/AU02/00787

97

caataaacgc agctaattcg ttcacccgac aatcgcttc cgagtggta ctattccatc 120  
 accattctag cctgtacaca aaaagtaaag atggacgaat cgctcgactt cgctcgcat 180  
 tcgtcgagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcggtta 240  
 caggggggta cgtcaiccgta acaggggggg tacgtcacaa gaaggcggtc cggacaggg 300  
 5 gggtagtacgtaa catgttcagg ggggtacgtc acaaccaatc aggagctgcc acgttgcgaa 360  
 agtgacgtt cggaaaatggg cggcgaaga ctccctatat attgcgcgca cataccggtc 420  
 ggcagtaggt atacgcaagg cggtccgggt ggatgcacgg aaacggcgga caaccggccg 480  
 ctggggcag tgaatcgccg cttagccgag agggcaacc tggcccgcc ggagccgcg 540  
 agggcaagt aattcaaat gaacgctcac caagaagata ctccaccagg accatcaacg 600  
 10 gtgttcaggc caccaacaag ttacacggccg ttggaaaccc ctcaactgcag agagatccgg 660  
 atttgttatcg ctggaaattac agtcactcta tcgcgtgtgt gctgcgcgaa tgctcgctt 720  
 cccacgctaa gatctgcac tgcggacaat tcagagaaca ctggttcaa gaatgtgcgg 780  
 gacttgagga ccgatcaacc caagcctccc tcgaagaagc gatctgcga cccctccgag 840  
 tacagggtaa gcgagctaa agaaagctg attaccacta ctcccgccg accccgaacc 900  
 15 gcaagaagggt gtataagact gtaagatggc aagacgagct cgcagaccga gaggccgatt 960  
 ttacgccttc agaagaggac ggtggcacca cctcaagcga ctgcgacgaa gatataaatt 1020  
 tcgacatcg aggagacagc ggtatcgtag acgactttt aggaaggcct ttacacaaccc 1080  
 ccggcccggt acgtatagtg tgaggctccaa acggcccttccacatgta ctatccgctt 1140  
 ccaaggagtc atcttcitca ccgaaggact cattctacact aaaaacagca cagctggggg 1200  
 20 ctatgcggac cacatgtacg gggcgagagt cgccaagatc tcagtgaaacc tgaaagagtt 1260  
 cctccctagca tcaaigaacc tgacatacg gagaagata ggaggccca tcgcgggtga 1320  
 gtgtgattgcg gacgggtcta aatcgcaagc cgcggagaac tggccaaatt gctggctgcc 1380  
 gctagataat aacgtgcctt ccgctacacc atctgcatgg tggagatggg cttaatgtat 1440  
 gatgcagccca acggactctt gcccgggtttt taatcaccct aagcaaatacgcc 1500  
 25 catgggtcgg atgttgggg gctggcatct gttccgacac attgaaaccc gcttcagct 1560  
 ccttgcact aagaatgagg gatccitcag cccctgtcgcc agtcttcctt cccaggggaga 1620  
 gtacctcactc cgccgcgacg atgttaagta cagcagcgac caccagaacc ggtggcgaaa 1680  
 aggcgagcaa ccgatgcacgg gggggatgc ttacgcgacc ggtaaaatga gactcgacga 1740  
 gcaacaatac cctctatgc ccccgaccc cccgatcatc accactacca ctgcgaagg 1800  
 30 cacgcaagtc cgctgcata atagcacca agcttggtgg tcgtggaca catatatgag 1860  
 tttagcaaca ctcacagcac tcgggtctca atggctttt cctccaggc aacgttcagt 1920  
 ttcttagacgg tccttcaacc atcacaaggc ccgaggagcc ggggacccca agggccagag 1980  
 gtggcacacg ctgggtccgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 ggcacatcagag ctggacacga atttcttcac gctttacgta ggcacaggca ctaataaattc 2100  
 35 gcagcaatac aagttcgccca cagcaacata cgcgtaaag gaaccgtaa tgaagagcga 2160  
 ttcatgggca gtgggtcgccg tccagtcgt ctggcaactg ggtaacaggc aaaggccata 2220  
 cccgtgggac gttaactggg ccaacagcac catgtactgg gggtcgcagc cctgaaaagg 2280  
 gggggg 2286  
 <210> 26  
 40 <211> 216  
 <212> PRT  
 <213> Artificial Sequence  
 <220>  
 <223> mut K 102 E of VP2 of Chicken anaemia virus  
 45 <400> 26

Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala

1 5 10 15

WO 02/102999

PCT/AU02/00787

98

Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
20 25 30

5 Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
35 40 45

Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
50 55 60

10 Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
65 70 75 80

Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn  
15 85 90 95

Cys Gly Gln Phe Arg Glu His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
100 105 110

20 Asp Arg Ser Thr Gln Ala Ser Leu Glu Glu Ala Ile Leu Arg Pro Leu  
115 120 125

Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
130 135 140

25 Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
145 150 155 160

Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
30 165 170 175

Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp Ile  
180 185 190

35 Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
195 200 205

Thr Pro Ala Pro Val Arg Ile Val  
210 215

40 <210> 27  
<211> 2286  
<212> DNA  
<213> Artificial Sequence

45 <220>  
<223> mut E 186 G of Chicken anaemia virus genome  
<400> 27

WO 02/102999

PCT/AU02/00787

99

cccccctiga acccccccctt gggggggatt ccccccaga ccccccctt ataaagcact 60  
 caataaacgc agctaattcg ttacccgcac aatcgcttc cgagtgtta ctattccatc 120  
 accattctag cctgtacaca aaaagtaaag atggacgaat cgctcgactt cgctcgcgat 180  
 tcgtcgaagg cggggggccg gaggcccccc ggtggccccc tccaaggagt ggagcgtgta 240  
 5 caggggggta cgtcatccgt acaggggggg tacgtacaaa gaaggcgltc ccgtacagg 300  
 gggtagtta catgtcagg ggggtacgtc acaaccaatc aggagctgcc acgtgcgaa 360  
 agtgacgtt cggaaatggg cggcgcaga cttccatat attgcgcga cataccggc 420  
 ggcagtaggt atacgcagg cggicgggtt ggatgcacgg aaacggcgga caaccggccg 480  
 ctggggcag tgaatcggcg cttagccgag agggcaacc tggggcccagc ggagccgcgc 540  
 10 aggggcaagt aatttcaaat gaacgctcac caagaagata ctccaccagg accatcaacg 600  
 gtgtcaggg caccaacaag ttacggccg ttggaaaccc ctactgcag agagatccgg 660  
 attggatcg ctggattac agtcaactta tcgctgtgt gctgcgcgaa tgctcgcgtt 720  
 cccacgctaa gatctgcac tgcggacaat tcagaaaaca tcggttcaa gaatgtgcgg 780  
 gacttgagga ccgatcaacc caagccccc tcgaagaagc gatctcgca cccctccgag 840  
 15 tacagggtaa gcgagctaaa agaaaagctt attaccacta ctcccagccg accccgaacc 900  
 gcaagaagggt gtataagact gtaagatggc aagacgagct cgcagaccga gaggccgatt 960  
 ttacgccttc agaagaggac ggtggcacca cctcaagcga ctgcgacggatataaatt 1020  
 tcgacatcg aggagacagc ggtatcgtag acgagctttt aggaaggcc ttcacaaccc 1080  
 cccggccggt acgtatgt tgaggctccaa acggccatc tccacatgatc ctatccgtt 1140  
 20 ccaaggagtc atcttctca ccgaaggact cattctacct aaaaacagca cagctgggg 1200  
 ctatcgccgac cacatgtacg gggcgagact cgcgaagatc tcagtgaacc tgaaagagtt 1260  
 cctcctagca tcaatgaacc tgacatacg tgcggacaat ggaggccca tcggcggtga 1320  
 gttgattgctg gacgggtcta aatcgcaagc cgccggaaac tggccaaatt gctggctgcc 1380  
 gctagataat aacgtccctt ccgtacacc atctgcattt tggagatggg cttaatgat 1440  
 25 gatgcggcca acggactcct gcccggttt taatcacccct aagcaaatga cccctgcaga 1500  
 catgggtcgg atgtttgggg gctggcatct gttccgacac attgaaaccc gctttcagct 1560  
 ccttgcactt aagaatgagg gatccttcag ccccggtggcg agtcttcctt cccaggggaga 1620  
 gtacccatcg cgccgcgacg atgttaatcg cagcagcgac caccagaacc ggtggcgaaa 1680  
 aggccgacaa ccgtatcg gggggatgc ttacgcgacc ggtaaaatga gactcgacga 1740  
 30 gcaacaatac cctgcgtatgc ccccgaccc cccgatcatc accactacca ctgcgcaagg 1800  
 cacgcgaagtc cgctgcata gatgcacca agcttgggtt tcgtggacca catatatgag 1860  
 ctttgcaaca ctacagcac tcggtgctca atggctttt cttccaggc aacgttcagt 1920  
 ttctagacgg tccttcaacc atcacaaggc ccggaggagcc gggggccca agggccagag 1980  
 gtggcacacg ctggcgccgc tcggcacaga gaccataacc gacagctaca tgagagcacc 2040  
 35 ggcacatcgatcg ctggacacga atttcctac gcttacgtt ggcacaggca ctaataatc 2100  
 gcaacatac aagtgcggca cagcaacata cgcgcataaag gaaccgtaa tgaagagcga 2160  
 ttcatggca gtggtgccgc tccagtcgtt ctggcaactg ggtacacaggc aaaggccata 2220  
 cccgtggac gttaaactggg ccaacacgc catgtactgg gggtcgcagc cctgaaaagg 2280  
 gggggg 2286  
 40 <210> 28  
 <211> 216  
 <212> PRT  
 <213> Artificial Sequence  
 45 <220>  
 <223> mut E 186 G of VP2 of Chicken anaemia virus  
 <400> 28

WO 02/102999

PCT/AU02/00787

100

Met His Gly Asn Gly Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser Ala  
1 5 10 15

Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly Gln  
5 20 25 30

Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr Ile  
35 40 45

10 Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro Ser  
50 55 60

Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Ser His Ser Ile  
65 70 75 80

15 Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys Asn  
85 90 95

Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu Glu  
20 100 105 110

Asp Arg Ser Thr Gln Ala Ser Leu Glu Ala Ile Leu Arg Pro Leu  
115 120 125

25 Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr Ser  
130 135 140

Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp Gln  
145 150 155 160

30 Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu Asp  
165 170 175

Gly Gly Thr Thr Ser Ser Asp Phe Asp Gly Asp Ile Asn Phe Asp Ile  
35 180 185 190

Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe Thr  
195 200 205

40 Thr Pro Ala Pro Val Arg Ile Val  
210 215

<210> 29  
<211> 30  
45 <212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut C 86 R +oligo

WO 02/102999

PCT/AU02/00787

101

&lt;400&gt; 29

ctgcgcgaac gtcgcgttc ccacgctaag 30

5 <210> 30  
<211> 30  
<212> DNA  
<213> Artificial Sequence  
<220>

10 <223> mut C 86 R -oligo  
<400> 30  
aacgcgagcg ttcgcgcagc cacacagcga 30

15 <210> 31  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut C95 S +oligo

20 <400> 31  
cgctaagatc agcaactgcg 20

25 <210> 32  
<211> 22  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut C 95 S -oligo  
<400> 32

30 cgcagttgct gatcttagcg tg 22

35 <210> 33  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut C 97 S +oligo  
<400> 33

atctgcaaca gcggacaatt c 21

40 <210> 34  
<211> 24  
<212> DNA  
<213> Artificial Sequence  
<220>

45 <223> mut C 97 S -oligo  
<400> 34  
attgtccgct gttgcagatc ttag 24

WO 02/102999

PCT/AU02/00787

102

<210> 35  
<211> 25  
<212> DNA  
5 <213> Artificial Sequence  
<220>  
<223> mut R 101 G +oligo  
<400> 35  
ctgcggacaa ttccggaaaac actgg 25

10 <210> 36  
<211> 24  
<212> DNA  
<213> Artificial Sequence  
15 <220>  
<223> mut R 101 G -oligo  
<400> 36  
cagtgtttc cgaattgtcc gcag 24

20 <210> 37  
<211> 32  
<212> DNA  
<213> Artificial Sequence  
<220>  
25 <223> mut H 103 Y +oligo  
<400> 37  
cagaaaatac tggtttcaag aatgtgccgg ac 32

30 <210> 38  
<211> 29  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut H 103 Y -oligo  
35 <400> 38  
gaaaccagta ttttctgaat tgtccgcag 29

40 <210> 39  
<211> 23  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut R 129 G +oligo  
<400> 39  
45 ctgcggacccc tcggaggata ggg 23

<210> 40  
<211> 29

WO 02/102999

PCT/AU02/00787

103

<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut R 129 G -oligo  
5 <400> 40  
ccctgtactc cgaggggtcg caggatcgc 29

<210> 41  
<211> 26  
10 <212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut Q 131 P +oligo  
<400> 41  
15 cgagtaccgg gtaagcgagc taaaag 26

<210> 42  
<211> 21  
<212> DNA  
20 <213> Artificial Sequence  
<220>  
<223> mut Q 131 P -oligo  
<400> 42  
25 cgcttacccg gtactcggag g 21

<210> 43  
<211> 24  
<212> DNA  
<213> Artificial Sequence  
30 <220>  
<223> mut R/K/K 150/151/152 G/A/A +oligo  
<400> 43  
ccgaacggcg cggcggtgtaa 24  
<210> 44

<211> 25  
<212> DNA  
<213> Artificial Sequence  
<220>  
35 <223> mut R/K/K 150/151/152 G/A/A -oligo  
<400> 44  
atacaccggcc gcgccgttcg gggtc 25

<210> 45  
<211> 27  
40 <212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut D/E 161/162 G/G +oligo

WO 02/102999

PCT/AU02/00787

104

<400> 45  
taagatggca aggcgggctc gcagacc 27

5 <210> 46  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut D/E 161/162 G/G

10 <400> 46  
tgcgagcccg ccttgccalc 20

15 <210> 47  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut L 163 P +oligo

20 <400> 47  
gacgagccccg cagaccgaga g 21

25 <210> 48  
<211> 24  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut L 163 P -oligo

30 <400> 48  
ggccctctcggtctgcggctcgctc 24

35 <210> 49  
<211> 24  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut D 169 G +oligo

40 <400> 49  
gagaggccgg ttttacgccttcag 24

45 <210> 50  
<211> 22  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut D 169 G -oligo

50 <400> 50  
gcgtaaaaacc ggccctctcggtct 22

WO 02/102999

PCT/AU02/00787

105

<210> 51  
<211> 29  
<212> DNA  
<213> Artificial Sequence  
5 <220>  
<223> mut K 102 E +oligo  
<400> 51  
ctgcggacaa ttcagagaac actggttc 29

10 <210> 52  
<211> 29  
<212> DNA  
<213> Artificial Sequence  
<220>  
15 <223> mut K 102 E -oligo  
<400> 52  
gaaaccaggatg ttctctgaat tgtccgcag 29

20 <210> 53  
<211> 26  
<212> DNA  
<213> Artificial Sequence  
<220>  
25 <223> mut E 186 G +oligo  
<400> 53  
gcgacttcga cggagatata aatttc 26

30 <210> 54  
<211> 22  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> mut E 186 G -oligo  
<400> 54

35 tttatatctc cgtcgaagtc gc 22  
<210> 55  
<211> 25  
<212> DNA  
<213> Artificial Sequence  
40 <220>  
<223> CAV.1 primer  
<400> 55  
ctatcgaatt ccgagtgggtt actat 25

45 <210> 56  
<211> 20  
<212> DNA  
<213> Artificial Sequence

WO 02/102999

PCT/AU02/00787

106

<220>  
<223> CAV.10 primer  
<400> 56  
tgctcacgta tgtcagggtc 20  
5 <210> 57  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
10 <220>  
<223> CAV.2 primer  
<400> 57  
gcggagccgc gcaggggcaa 20  
15 <210> 58  
<211> 26  
<212> DNA  
<213> Artificial Sequence  
<220>  
20 <223> CAV 19 oligo  
<400> 58  
cggtccggga ggatgcacgg aaacgg 26  
25 <210> 59  
<211> 25  
<212> DNA  
<213> Artificial Sequence  
<220>  
30 <223> CAV 20 oligo  
<400> 59  
gtgcatcctc ccgaccgcct tgcgt 25  
35 <210> 60  
<211> 26  
<212> DNA  
<213> Artificial Sequence  
<220>  
40 <223> CAV 21 oligo  
<400> 60  
cggtccgggt ggatggacgg aaacgg 26  
45 <210> 61  
<211> 26  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> CAV 22 oligo  
<400> 61

WO 02/102999

PCT/AU02/00787

107

gtccatccac ccggaccgcc ttgcgt 26  
<210> 62  
<211> 25  
5 <212> DNA  
<213> Artificial Sequence  
<220>  
<223> CAV 1 oligo  
<400> 62  
10 ctatcgatt ccgagttgggtt actat 25  
<210> 63  
<211> 30  
<212> DNA  
15 <213> Artificial Sequence  
<220>  
<223> CAV 11 oligo  
<400> 63  
agctcgtctt gccatcttac agtcttatac 30  
20 <210> 64  
<211> 9  
<212> PRT  
<213> Chicken anaemia virus- signature motif CAV VP2 PTP  
25 <400> 64  
Ile Cys Asn Cys Gly Gln Phe Arg Lys  
1 5  
<210> 65  
30 <211> 34  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> CAV.1 primer  
35 <400> 65  
cggtcggat ccatgcacgg aaacggcgga caac 34  
<210> 66  
<211> 33  
40 <212> DNA  
<213> Artificial Sequence  
<220>  
<223> CAV.2 primer  
<400> 66  
45 ggtttggaat tctcacacta tacgtaccgg ggc 33  
<210> 67  
<211> 31

WO 02/102999

PCT/AU02/00787

108

<212> DNA  
<213> Artificial Sequence  
<220>  
<223> TLMV.1 primer  
5 <400> 67  
ttggatccat gagcagctt ctaacaccat c 31

<210> 68  
<211> 33  
10 <212> DNA  
<213> Artificial Sequence  
<220>  
<223> TLMV.2 primer  
<400> 68  
15 ggcgaattct taccatcggt ctcttcgaa atc 33

WO 02/102999

PCT/AU02/00787

109

**Claims:**

1. An isolated attenuated circovirus having a mutation in viral nucleic acid encoding viral protein 2 (VP2).
- 5 2. An isolated attenuated circovirus according to claim 1, wherein the circovirus being derived or obtained from Chicken anaemia virus (CAV), a TT virus (TTV) or other similar virus expressing a VP2 protein.
- 10 3. An isolated attenuated circovirus according to claim 2, wherein the circovirus being derived or obtained from Chicken anaemia virus (CAV).
4. An isolated attenuated circovirus according to any one of claims 1 to 3, wherein the mutation is present in a region of nucleic acid encoding the signature motif of VP2.
- 15 5. An isolated attenuated circovirus according to claim 4, wherein the mutation alters viral PTPase activity, PTPase motifs, acidic alpha helical regions or basic beta sheet regions.
6. An isolated attenuated circovirus according to claim 3, wherein the mutation is present in the region of nucleic residues 80 to 110, 128 to 143, 151 to 158 and 160 to 170 in CAV VP2.
- 20 7. An isolated attenuated circovirus according to claim 6, wherein the sites targeted for mutagenesis within CAV VP2 are selected from the group consisting of 86, 95, 97, 101, 103 and 169.
- 25 8. An isolated attenuated circovirus according to claim 6, wherein the mutations are selected from the group consisting of mut C86 R, mut C 95 S, mut C 97 S, mut R 101 G, mut K 102 E, mut H 103 Y, mut R 129 G, mut Q 131 P, mut R/K/K 150/151/152 G/A/A, mut D/E 161/162 G/G, mut L 163 P, mut D 169 G, mut E 186 G, and combinations thereof.
- 30 9. An isolated attenuated circovirus according to claim 8 comprising mut D 169 G.

WO 02/102999

PCT/AU02/00787

110

10. An isolated attenuated circovirus according to any one of claims 1 to 9 having a nucleic acid sequence selected from the group consisting of sequence no's 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27.
11. A circovirus vaccine composition comprising an attenuated circovirus having a mutation in viral nucleic acid encoding viral protein 2 (VP2) together with an acceptable carrier or diluent.  
5
12. A circovirus vaccine composition according to claim 11, wherein the circovirus being derived or obtained from Chicken anaemia virus (CAV), a TT virus (TTV) or other similar virus expressing a VP2 protein.  
10
13. A circovirus vaccine composition according to claim 12, wherein the circovirus being derived or obtained from Chicken anaemia virus (CAV).  
15
14. A circovirus vaccine composition according to any one of claims 11 to 13, wherein the mutation is present in a region of nucleic acid encoding the signature motif of VP2.  
20
15. A circovirus vaccine composition according to claim 14, wherein the mutation alters viral PTPase activity, PTPase motifs, acidic alpha helical regions or basic beta sheet regions.  
25
16. A circovirus vaccine composition according to claim 13, wherein the mutation is present in the region of nucleic residues 80 to 110, 128 to 143, 151 to 158 and 160 to 170 in CAV VP2.  
25
17. A circovirus vaccine composition according to claim 16, wherein the sites targeted for mutagenesis within CAV VP2 are selected from the group consisting of 86, 95, 97, 101, 103 and 169.  
30
18. A circovirus vaccine composition according to claim 16, wherein the mutations are selected from the group consisting of mut C86 R, mut C 95 S, mut C 97 S, mut R 101 G, mut K 102 E, mut H 103 Y, mut R 129 G, mut Q 131 P, mut R/K/K 150/151/152 G/A/A,

WO 02/102999

PCT/AU02/00787

111

mut D/E 161/162 G/G, mut L 163 P, mut D 169 G, mut E 186 G, and combinations thereof.

19. A circovirus vaccine composition according to claim 18 comprising mut D 169 G.
- 5 20. A circovirus vaccine composition according to any one of claims 11 to 19 comprising a nucleic acid sequence selected from the group consisting of sequence no's 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27.
  
- 10 21. A method for imparting immunity to circovirus infection in an animal comprising administering to the animal an effective amount of circovirus vaccine according to any one of claims 11 to 20.
  
- 15 22. A method for imparting immunity according to claim 21 wherein the animal is a bird.
  
- 15 23. A method for imparting immunity according to claim 22 wherein the bird is a chicken.
  
- 20 24. A method for imparting immunity according to any one of claims 21 to 23 wherein the vaccine is administered parenterally, intramuscularly, subcutaneously, orally, intranasally, or *in ovo* route.
  
- 25 25. A method for imparting immunity according to claim 24 wherein the animal is a bird and the route of administration of the vaccine is by mucosal administration, aerosol administration or via drinking water.
  
- 25 26. A method for imparting immunity according to claim 25 wherein the bird is a chicken.
  
- 30 27. A method for imparting immunity according to any one of claims 21 to 26 wherein the vaccine is administered in a dosage range from 1 to 100 million TCID<sub>50</sub>.

WO 02/102999

PCT/AU02/00787

112

28. A method for imparting immunity according to claim 27 wherein the vaccine is administered in a dosage range of about 1000 TCID<sub>50</sub>.
29. An isolated nucleic acid molecule derived or obtained from a circovirus genome, the  
5 nucleic acid molecule including at least a portion of a coding region for viral protein 2  
(VP2) having a mutation therein.
30. An isolated nucleic acid molecule according to claim 29, wherein the circovirus  
being derived or obtained from Chicken anaemia virus (CAV), a TT virus (TTV) or other  
10 similar virus expressing a VP2 protein.
31. An isolated nucleic acid molecule according to claim 30, wherein the circovirus  
being derived or obtained from Chicken anaemia virus (CAV).
- 15 32. An isolated nucleic acid molecule according to any one of claims 29 to 31, wherein  
the mutation is present in a region of nucleic acid encoding the signature motif of VP2.
- 20 33. An isolated nucleic acid molecule according to claim 32, wherein the mutation alters  
viral PTPase activity, PTPase motifs, acidic alpha helical regions or basic beta sheet  
regions.
- 25 34. An isolated nucleic acid molecule according to claim 31, wherein the mutation is  
present in the region of nucleic residues 80 to 110, 128 to 143, 151 to 158 and 160 to 170  
in CAV VP2.
- 30 35. An isolated nucleic acid molecule according to claim 34, wherein the sites targeted  
for mutagenesis within CAV VP2 are selected from the group consisting of 86, 95, 97,  
101, 103 and 169.
36. An isolated nucleic acid molecule according to claim 34, wherein the mutations are  
selected from the group consisting of mut C86 R, mut C 95 S, mut C 97 S, mut R 101 G,  
mut K 102 E, mut H 103 Y, mut R 129 G, mut Q 131 P, mut R/K/K 150/151/152 G/A/A,

WO 02/102999

PCT/AU02/00787

113

mut D/E 161/162 G/G, mut L 163 P, mut D 169 G, mut E 186 G, and combinations thereof.

37. An isolated nucleic acid molecule according to claim 36 comprising mut D 169 G.

5

38. An isolated nucleic acid molecule according to any of one claims 29 to 37 comprising a sequence selected from the group consisting of sequence no's 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27.

10 39. A vaccine composition comprising an isolated nucleic acid molecule according to any one of claims 29 to 38 together with an acceptable carrier or diluent.

15 40. A method of conferring immunity in an animal against a circovirus infection, the method comprising administering to the animal a vaccine composition according to claim 39.

41. A method of conferring immunity according to claim 40 wherein the circovirus infection is a CAV infection.

20 42. A method of conferring immunity according to claim 41 wherein the animal is a bird.

43. A method of conferring immunity according to claim 42 wherein the bird is a chicken.

25 44. Use of an isolated attenuated circovirus according to any one of claims 1 to 10 in the manufacture of a vaccine for conferring immunity in an animal against a circovirus infection.

30 45. Use of an isolated nucleic acid molecule according to any one of claims 29 to 38 in the manufacture of a vaccine for conferring immunity in an animal against a circovirus infection.

WO 02/102999

PCT/AU02/00787

114

46. A method of producing a circovirus vaccine comprising:

(a) inoculating an isolated nucleic acid molecule derived or obtained from a circovirus genome into the yolk sac of an embryonated egg, wherein the nucleic acid molecule includes at least a portion of a coding region for viral protein 2 (VP2) having a mutation

5 therein;

(b) allowing circovirus to replicate from the isolated nucleic acid; and

(c) harvesting the circovirus from the egg.

47. A method according to claim 46, wherein the isolated nucleic acid molecule being derived or obtained from Chicken anaemia virus (CAV), a TT virus (TTV) or other similar virus expressing a VP2 protein.

48. A method according to claim 47, wherein the isolated nucleic acid molecule being derived or obtained from Chicken anaemia virus (CAV).

15

49. A method according to any one of claims 46 to 48, wherein the mutation is present in a region of nucleic acid encoding the signature motif of VP2.

50. A method according to claim 49, wherein the mutation alters viral PTPase activity, 20 PTPase motifs, acidic alpha helical regions or basic beta sheet regions.

51. A method according to claim 48, wherein the mutation is present in the region of nucleic residues 80 to 110, 128 to 143, 151 to 158 and 160 to 170 in CAV VP2.

25 52. A method according to claim 51, wherein the sites targeted for mutagenesis within CAV VP2 are selected from the group consisting of 86, 95, 97, 101, 103 and 169.

53. A method according to claim 51, wherein the mutations are selected from the group consisting of mut C86 R, mut C 95 S, mut C 97 S, mut R 101 G, mut K 102 E, mut H 103 30 Y, mut R 129 G, mut Q 131 P, mut R/K/K 150/151/152 G/A/A, mut D/E 161/162 G/G, mut L 163 P, mut D 169 G, mut E 186 G, and combinations thereof.

**WO 02/102999****PCT/AU02/00787**

115

54. A method according to claim 53 comprising mut D 169 G.

55. A method according to any one of claims 46 to 54 having a nucleic acid sequence selected from the group consisting of sequence no's 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23,


5 25, and 27.

WO 02/102999

PCT/AU02/00787

1/20

Figure 1:




WO 02/102999

PCT/AU02/00787

2/20

Figure 2: Transfection of mut C86 R into MSB1 cells.




WO 02/102999

PCT/AU02/00787

3/20

Figure 3: Transfection of mut C 95 S into MSB1 cells.




WO 02/102999

PCT/AU02/00787

4/20

Figure 4: Transfection of mut C 97 S into MSB1 cells.




WO 02/102999

PCT/AU02/00787

5/20

Figure 5: Transfection of mut R 101 G into MSB1 cells.




WO 02/102999

PCT/AU02/00787

6/20

Figure 6: Transfection of mut H103 Y into MSB1 cells.




WO 02/102999

PCT/AU02/00787

7/20

Figure 7: Transfection of mut R129 G into MSB1 cells.




WO 02/102999

PCT/AU02/00787

8/20

Figure 8: Transfection of mut N 131 P into MSB1 cells.




WO 02/102999

PCT/AU02/00787

9/20

Figure 9: Transfection of mut R/K/K 150/151/152 G/A/A into MSB1 cells.




WO 02/102999

PCT/AU02/00787

10/20

Figure 10: Transfection of mut D/E 161/162 G/G into MSB1 cells.




WO 02/102999

PCT/AU02/00787

11/20

Figure 11: Transfection of mut L 163 P into MSB1 cells.




WO 02/102999

PCT/AU02/00787

12/20

Figure 12: Transfection of mut D169 G into MSB1 cells.



WO 02/102999

PCT/AU02/00787

13/20




Figure 13. R-PTPase homologues aligned to the CAV VP2 amino acid sequence using the ECLUSTALW software (WebANGIS) and displayed graphically using the Seqvu software (Garvin Institute). Row 1: chicken protein-tyrosine phosphatase alpha (Z32749), residues 302-306, homology score 30%. Row 2: human R-PTPase alpha (PP18433), residues 301-353, homology score 32%. Row 3: rat R-PTPase alpha (Q03348), residues 295-347, homology score 32%. Row 4: mouse R-PTPase alpha (P18052), residues 328-380, homology score 32%. Row 5: human R-PTPase alpha (17011300A). Row 6: human placental protein-tyrosine phosphatase (CAA38065), residues 292-345, homology score 32%. Row 7: CAV VP2.

WO 02/102999

PCT/AU02/00787

14/20





Figure 14. Alignment of CAV VP2 amino acid sequence and SANBAN TTV sequence using the ECLUSTALW software (WebANGIS) and displayed graphically using the Seqvu software (Garvin Institute). The Genbank accession numbers for the TT viruses are shown.

WO 02/102999

PCT/AU02/00787

15/20

**Figure 15.** Electrophoresis of glutathione-S-transferase (GST) fusion proteins on a 12.5% polyacrylamide gel and visualisation with Coomassie blue staining. Lane 1, Broad range molecular weight standards (Biorad); lane 2, 2.6 µg CAV VP2-GST fusion; lane 3, 3.0 µg GST.




WO 02/102999

PCT/AU02/00787

16/20

Figure 16. Western blot probed with a mouse polyclonal antiserum raised against the COOH-terminal region of VP2. Lane 1, Broad range molecular weight standards (Biorad) ; lane 2, 3.0 µg GST; lane 3, 2.6 µg CAV VP2-GST fusion.



WO 02/102999

PCT/AU02/00787

17/20

Figure 17. Western blot probed with a rabbit polyclonal antiserum raised against GST. Lane 1, molecular weight standards; lane 2, 3.0 $\mu$ g GST; lane 3, 2.6  $\mu$ g chicken anaemia virus VP2-GST fusion.



WO 02/102999

PCT/AU02/00787

18/20




Figure 18. Time course study of phosphate release from ENDY(Pi)INASL as catalysed by VP2-GST or a GST control preparation. Reactions were carried out with 15 nmol substrate. Activity [V] was measured in nmol of phosphate released for each timepoint.

WO 02/102999

PCT/AU02/00787

19/20




Figure 19. PTPase activity of VP2-GST and GST control proteins in the PTP assay. Reactions were carried out with 10 nmol substrate and for 1min. Initial activity [ $V_0$ ] was measured in nmol phosphate released for each substrate value. The standard error of the mean for each substrate value tested was less than 0.101.

WO 02/102999

PCT/AU02/00787

20/20




Figure 20. TLMV VP2 PTPase activity relative to CAV VP2 activity.

INTERNATIONAL SEARCH REPORT		International application No. PCT/AU02/00787																				
<b>A. CLASSIFICATION OF SUBJECT MATTER</b>																						
Int. Cl.?: C12N 7/04, 15/34																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
<b>B. FIELDS SEARCHED</b>																						
Minimum documentation searched (classification system followed by classification symbols)																						
<b>IPC (WPIDS) AND CHEMICAL ABSTRACTS</b>																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																						
SEE BELOW																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																						
WPIDS, CA, MEDLINE, AGRICOLA. Keywords: circovir?, chicken anemia/anaemia virus, vp2, vp(2), vp-2 ...																						
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X	The Journal of Veterinary Medical Science, vol. 58(7), 1996, Farkas et al., "Cloning and Sequencing of the Genome of Chicken Anaemia Virus (CAV) TK-5803 Strain and Comparison with Other CAV Strains", pages 681-4. Abstract, line 6.	1-45																				
X	Archives of Virology, vol. 146(4), 2001, Scott et al., "Characterisation of a chicken anaemia virus variant population that resists neutralisation with a group-specific monoclonal antibody", pages 713-28. Page 717 and Table 5.	1-45																				
X	Australian Veterinary Journal, vol. 78, no. 9, 2000, Brown et al., "Full-length infectious clone of a pathogenic Australian isolate of chicken anaemia virus", pages 637-40. Figure 1B and page 639, 2 <sup>nd</sup> column, line 1.	1-45																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C		<input checked="" type="checkbox"/> See patent family annex																				
<p>* Special categories of cited documents:</p> <table> <tbody> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier application or patent but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&amp;"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </tbody> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 7 August 2002	Date of mailing of the international search report 19 AUG 2002																					
Name and mailing address of the ISA/AU <b>AUSTRALIAN PATENT OFFICE</b> PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized officer <b>Christopher Luton</b> Telephone No: (02) 6283 2256																					

INTERNATIONAL SEARCH REPORT		International application No. PCT/AU02/00787
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5981502 B (Noteborn et al.) 9 November 1999. Column 7, lines 51-53.	1-45
X	WO 96/03507 A (MALLINCKRODT VETERINARY, INC.) 8 February 1996. Page 12, lines 12-24 and Figure 4.	1-45
X	WO 96/01116 A (CORNELL RESEARCH FOUNDATION, INC.) 18 January 1996. Page 4, lines 2-21 and page 7, line 20.	1-45
X	WO 95/03414 A (AESCUAAP B.V.) 2 February 1995. Page 6, line 34 to page 7, line 2.	1-45
A	WO 96/40931 A (AESCUAAP B.V.) 19 December 1996. Page 23, lines 10-16; page 26, lines 17-19 and 27.	1-45
A	EP 0483911 A2 (AKZO N.V.) 6 May 1992. Page 8, lines 15-32 and claim 14.	1-45

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU02/00787

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report			Patent Family Member				
WO	9004020	AU	44088/89	CA	2000094	EP	437516
		PT	91924	US	5424197		
EP	362732	AU	42639/89	CA	1340448	DE	3834157
		DK	4943/89	FI	894721	JP	2171190
		PT	91903	US	6025153		
US	5981502	AU	86580/91	CA	2091181	EP	548234
		EP	905246	HR	940668	HU	65974
		MX	9101042	NL	9002008	SI	9111508
		US	5922600	US	5932476	US	5958424
		US	6071520	US	6162461	US	6217870
		US	6238669	US	6319693	WO	9204446
		ZA	9107065	US	5491073	AU	75473/94
		CA	2167578	EP	784685	NL	9301272
		US	5952002	WO	9503414	ZA	9405275
		AU	59136/96	CA	2221495	EP	830604
		NZ	309171	WO	9641191		
WO	9603507	AU	29890/95	ZA	9506150		
WO	9601116	AU	29611/95	EP	769952	US	5789567
		US	5965139				
WO	9503414	AU	75473/94	CA	2167578	EP	784685
		NL	9301272	US	5922600	US	5952002
		US	5981502	US	6071520	US	6162461
		US	6217870	ZA	9405275	AU	86580/91
		CA	2091181	EP	548234	EP	905246
		HR	940668	HU	65974	MX	9101042
		NL	9002008	SI	9111508	US	5932476
		US	5958424	US	6238669	US	6319693
		WO	9204446	ZA	9107065	US	5491073
		AU	59136/96	CA	2221495	EP	830604
		NZ	309171	WO	9641191		
WO	9640931	US	5932476	AU	59137/96	CA	2221570
		CN	1194001	EP	832242	NZ	309172

INTERNATIONAL SEARCH REPORT					International application No.
Information on patent family members					PCT/AU02/00787
AU	86580/91	CA	2091181	EP	548234
EP	905246	HR	940668	HU	65974
MX	9101042	NL	9002008	SI	9111508
US	5922600	US	5958424	US	5981502
US	6071520	US	6162461	US	6217870
US	6238669	US	6319693	WO	9204446
ZA	9107065	US	5491073	AU	75473/94
CA	2167578	EP	784685	NL	9301272
US	5952002	WO	9503414	ZA	9405275
AU	59136/96	CA	2221495	EP	830604
NZ	309171	WO	9641191		
EP	483911	AU	86888/91	CA	2054542
		HU	62325	JP	5086088
		ZA	9108426	US	5554525
END OF ANNEX					